Latest studies
Every paper our editors flag with a plain-language note and an evidence rating. Filter by evidence, species, or design to find what actually applies to you.
- Study · SemaglutideMixed
Hunger pain and its reduction; qualitative insight from people with schizophrenia on semaglutide.
Qualitative interview work rarely surfaces in peptide coverage, but it is unusually informative about the appetite-suppression accounts that dominate community discussion of GLP-1 agonists. The dual finding matters: the same appetite reduction was described as liberating by most participants and destabilizing by some, which supports assessing eating patterns before initiation. Eleven interviews from a single trial cohort is descriptive evidence only, and should be regarded as context rather than as an outcome result.
International journal of qualitative studies on health and well-beingn=——Dec 31, 2026 - Study · SemaglutideWeak / none
Design, synthesis, and stability evaluation of semaglutide-derived lactam-stapled peptide scaffolds for GLP-1R targeting.
Early-stage medicinal chemistry: stability was measured, function was only modelled. Improved serum and proteolytic stability relative to semaglutide is a real result, but without receptor-activation or in vivo data it says nothing about potency or duration of effect. Relevant as a window into where next-generation GLP-1 peptide design is heading.
Journal of enzyme inhibition and medicinal chemistryn=—In vitroDec 1, 2026 - Study · SemaglutideMixed
Comparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study.
A small (n=53) non-randomized observational comparison, so the findings are hypothesis-generating rather than definitive. Semaglutide was associated with one-year weight loss but higher two-year weight regain (55.6%) than the structured lifestyle arm. Group sizes were uneven and outcomes were not adjusted for confounders, so read the comparative results with caution.
Journal of obstetrics and gynaecologyn=—HumanDec 1, 2026 - Study · SemaglutideWeak / none
A qualitative study exploring experiences about using semaglutide for weight loss in a rural setting in Denmark - 'she is probably on the meds'.
This qualitative study explored how nine adults in a rural Danish municipality experienced using semaglutide for weight loss, through semi-structured interviews analysed by systematic text condensation. Researchers identified themes of community stigma (use perceived as 'cheating' or an 'easy way out'), increased everyday energy, a sense that the medicine is a short-term aid rather than a permanent fix amid worries about weight regain, and ongoing weighing of long-term side-effect fears against the burden of obesity. This is a small, context-specific qualitative account, nine people in one rural setting, so it is not generalisable and reports no clinical outcomes. Its value is in lived experience and the social dimension of semaglutide use, which aligns with the community-synthesis angle. Read it as texture on how people relate to the drug, not as efficacy or safety evidence.
Scandinavian journal of primary health caren=——Dec 1, 2026 - Study · SemaglutideMixed
GLP-1 receptor agonists in stroke prevention: a narrative review on emerging therapeutic frontiers.
This narrative review synthesises cardiovascular-outcome trials, meta-analyses and mechanistic studies on GLP-1 receptor agonists, including semaglutide, and their role in reducing stroke risk in type 2 diabetes. The authors describe anti-inflammatory, antioxidant, neuroprotective and endothelial mechanisms, and report relative risk reductions for stroke ranging 15-39% across trials for long-acting agents, with short-acting exendin-based agents showing limited cerebrovascular benefit. As a narrative (non-systematic) review, it is a useful map of the field but carries selection and interpretation bias, and it aggregates several agents rather than isolating semaglutide. The evidence it summarises is genuinely mixed, trial results are inconsistent and data in non-diabetic populations are thin. Read this as orientation to the stroke-risk conversation around GLP-1 agents, not as a pooled estimate, and note the authors' call for stroke-specific trials.
Annals of medicinen=——Dec 1, 2026 - Study · TirzepatideWeak / none
Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.
This US cost-effectiveness simulation compared tirzepatide against semaglutide (both at maximum tolerated dose) for obesity or overweight, using head-to-head SURMOUNT-5 trial data as its clinical engine. Researchers reported the model estimated tirzepatide to be both less costly (about $41,688 saved per patient, societal perspective) and more effective on modelled outcomes (0.506 QALYs gained), projecting fewer future cases of type 2 diabetes and cardiovascular disease. This is an economic model, not new clinical evidence: outputs depend on SURMOUNT-5's weight-loss advantage for tirzepatide plus many pricing and progression assumptions, and the sensitivity analyses matter for interpretation. It usefully frames a real decision, the two leading agents head to head, but the QALY and cost figures are projections, not observed outcomes, and the disclosed sponsorship context of such models warrants a careful read.
Journal of medical economicsn=——Dec 1, 2026 - Study · CagrilintideSupported
Co-agonism of GLP-1R and CTR/AMYR in the lateral dorsal tegmental nucleus produces additive effects on homeostatic and motivated feeding.
Careful mechanistic work using direct intra-brain drug delivery in rodents — a level of anatomical precision human studies cannot reach, but also a route of administration with no clinical parallel. It supplies a plausible neural substrate for why cagrilintide-semaglutide co-agonism outperforms monotherapy without saying anything about systemic dosing in people. Solid basic science from an established feeding-neuroscience group, appropriately framed by its authors.
Physiology & behaviorn=—AnimalNov 1, 2026 - Study · RetatrutideMixed
Development and validation of a multiplexed LC-HRMS method for nine GLP-1 receptor agonists and its pharmaceutical application.
This is an analytical chemistry paper, not a clinical study, so it says nothing about efficacy or safety. Its practical significance is quality verification: a validated, high-accuracy method covering approved and pipeline GLP-1 agonists in one run is directly useful for authenticating products in a market where counterfeit and compounded GLP-1 formulations are a live concern. The validation metrics reported are solid for the class, though independent replication in other labs is the usual next step. Relevant to readers who follow product-testing and vendor-credibility questions rather than clinical outcomes.
Journal of chromatography. An=——Oct 11, 2026 - Study · TirzepatideMixed
Differential Biliary Adverse Event Signals Among Glp-1 Receptor Agonists: A FAERS Disproportionality Analysis.
FAERS disproportionality analyses can rank reporting patterns, not measure true incidence — reporting is voluntary and confounded by publicity, prescribing volume, and indication. Several of the between-agent differences here are small, with PRRs near 1.0, and rarer outcomes lost significance in sensitivity analyses. The consistent class-wide biliary signal is the durable takeaway, in line with known trial data on gallstone risk; the agent-to-agent rankings should be held loosely.
Digestive diseases and sciencesn=——Oct 1, 2026 - Study · SemaglutideMixed
Effects of semaglutide and empagliflozin on markers of endothelial function in persons with type 2 diabetes: A post hoc analysis of a randomized clinical trial.
This is a post-hoc analysis of a registered randomized trial, so the endothelial markers were not the primary endpoint and the study was likely underpowered for them, as the authors acknowledge. The results cut both ways: E-Selectin moved in a favorable direction on semaglutide while VCAM-1 moved unfavorably, and the reactive hyperaemic index improved only against baseline, not placebo. With 120 participants split across four arms, this is best read as mechanistic signal-generation rather than an answer to how semaglutide lowers cardiovascular risk. The heterogeneous marker responses are the genuinely interesting finding.
Journal of diabetes and its complicationsn=—HumanOct 1, 2026 - Study · SemaglutideSupported
Impact of GLP-1 receptor agonists on cardiovascular outcomes in patients with peripheral artery disease without diabetes: A propensity score-matched analysis.
The effect sizes here are striking — arguably too striking, which is itself a caution: a 60% mortality reduction exceeds anything seen in randomized GLP-1 trials, suggesting residual confounding and healthy-user bias despite propensity matching. TriNetX gives scale but limited clinical granularity on disease severity and adherence. The direction of effect is consistent with STRIDE and the diabetic-PAD literature; the magnitude should await randomized confirmation in nondiabetic PAD.
Journal of investigative medicine : the official publication of the American Federation for Clinical Researchn=—HumanOct 1, 2026 - Study · SemaglutideSupported
Semaglutide improves markers of cardiovascular risk in people with HIV.
This is a secondary analysis of SLIM LIVER, a single-arm phase 2b trial, so there is no placebo group and only 36 selected responders were profiled — findings are mechanistic and hypothesis-generating. It is nonetheless the first lipidomic and lipoprotein/glycoprotein profiling reported during semaglutide therapy in any population. The disconnect between biomarker improvement and weight change is the interesting thread, dovetailing with cardiovascular-outcome trial analyses suggesting semaglutide's heart benefits are not fully explained by weight loss.
AIDS (London, England)n=——Oct 1, 2026 - Study · TirzepatideSupported
What obgyns need to know about GLP-1 receptor agonists.
A single-author narrative review, but one addressing questions with real practical stakes for reproductive-aged women, who make up a large share of GLP-1 users. The contraception interaction with tirzepatide and the preconception-discontinuation guidance are drawn from manufacturer labeling and emerging cohort data rather than dedicated trials. The call for pregnancy registries is well placed — the human exposure data remain thin.
Current opinion in obstetrics & gynecologyn=——Oct 1, 2026 - Study · SemaglutideMixed
Implications of Glucagon-Like Peptide-1 Receptor Agonists in Otolaryngology - Head and Neck Surgery: A Review.
A specialty-focused narrative review that usefully collects effects scattered across the head and neck literature, both favorable and concerning. The evidence quality behind each claim varies widely — the sleep apnea benefit rests on randomized trial data, while the sinusitis, olfaction, and hearing threads are early and speculative. The balanced handling of the thyroid cancer question, where animal signals have not been confirmed in population studies, is appropriately cautious.
The Annals of otology, rhinology, and laryngologyn=——Oct 1, 2026 - Study · SemaglutideSupported
Esophageal Motility Patterns Are Not Impacted By Glucagon-Like Peptide-1 Receptor Agonist Use.
A useful negative finding: GLP-1 drugs clearly slow the stomach, but this single-center case-control comparison found no measurable effect on the esophagus itself. The sample is small and the overall motility comparison landed at P=0.07, close enough to the threshold that a larger study could shift the picture. For now it supports letting patients stay on their GLP-1 through esophageal testing.
Journal of clinical gastroenterologyn=—HumanOct 1, 2026 - Study · SemaglutideSupported
Impact of semaglutide on liver fibrosis score in people with HIV: findings from the CNICS cohort.
A large multi-site cohort in a population — people with HIV — largely absent from the semaglutide liver trials, which is what makes this notable. The pre/post design without a comparator group leaves room for regression to the mean, and FIB-4 is a blood-based estimate of fibrosis rather than biopsy or imaging. Still, the dose-response-like pattern by baseline fibrosis severity is consistent with the general-population evidence, including the phase 3 MASH data.
AIDS (London, England)n=—HumanOct 1, 2026 - Study · SemaglutideWeak / none
Acute glucagon-like peptide-1 receptor agonist, semaglutide, attenuates cue-, drug-, and stress-induced fentanyl seeking in male Sprague-Dawley rats.
A well-controlled preclinical study that extends the GLP-1-and-addiction literature from exenatide and liraglutide to semaglutide, and from alcohol to opioids. The reinstatement model is the standard animal proxy for relapse, but it remains a proxy — acute dosing in male rats says nothing about chronic use or human outcomes. Human trials of semaglutide in substance use disorders are the necessary next step, and several are underway.
Behavioural pharmacologyn=—AnimalOct 1, 2026 - Study · SemaglutideSupported
Use of Glucagon-Like Peptide 1 Receptor Agonists and the Associated Risk of Hospitalisation in Bipolar Disorder, From a Nationwide Cohort, 2009-2024.
This is a methodologically serious registry study: the within-individual design compares each person to themselves across time, which strips out stable confounders like genetics and baseline severity. The fact that the association appeared for semaglutide but not liraglutide or dulaglutide argues against a simple class effect and against pure healthy-user bias, though time-varying confounding can't be excluded. As the authors note, only a randomized trial can settle whether semaglutide itself is doing the work.
Acta psychiatrica Scandinavican=—HumanOct 1, 2026 - Study · TirzepatideSupported
Comparative Efficacy of Tirzepatide Versus Semaglutide for Weight Loss in Adults With Overweight or Obesity: A Systematic Review and Meta-Analysis of Head-to-Head Studies.
The pooled sample is large and the effect direction is consistent across subgroups by study design and diabetes status, but only some of the ten included studies are randomised - observational comparisons of these two drugs are vulnerable to who gets prescribed what. The serious-adverse-event finding (RR 1.83) deserves attention precisely because it runs against the otherwise similar tolerability profile, and it comes from event counts that meta-analyses handle less reliably than continuous outcomes. Readers should regard the 4-point weight difference as an average, not a prediction for any individual.
Clinical obesityn=—HumanOct 1, 2026 - Study · SemaglutideMixed
Burden and Risk of Depression in Patients Receiving Semaglutide: A Systematic Review and Meta-Analysis.
This is the broadest pooled look yet at the semaglutide mental-health question, and its answer lines up with earlier regulatory reviews by the FDA and EMA: no statistically significant psychiatric signal. The point estimates do lean above 1.0, and heterogeneity is extreme (I-squared above 90 percent), so the confidence intervals are wide and the certainty of evidence is low. The authors' own framing — reassuring but not conclusive — is the right one, and we should mirror that restraint. A useful data point for readers weighing the persistent anecdotal reports against the aggregate evidence.
Clinical obesityn=—HumanOct 1, 2026 - Study · TirzepatideWeak / none
Glucagon-like receptor-1 agonists and impotence: A meta-analysis.
Two hundred thirty-seven men across seven heterogeneous studies is a thin base for pooled hormone estimates, and the confidence interval on total testosterone (MD 73.04, CI 16.91 to 129.17) is wide enough to span clinically trivial and clinically meaningful. The analysis is class-level, so semaglutide and tirzepatide appear as search terms rather than as separately estimated arms — nothing here supports an agent-specific effect. Weight loss itself raises testosterone in men with obesity, and the design cannot separate that from any direct drug effect. Directionally reassuring against the post-marketing impotence reports, but no more than that.
World journal of methodologyn=—HumanSep 20, 2026 - Study · RetatrutideSupported
Comparative effects of semaglutide tirzepatide and retatrutide on renal fibrosis in UUO and aged mice.
A genuinely useful comparative design — same models, same readouts, three agents — and the pathway dissection (PI3K-AKT for semaglutide, PI3K-AKT plus PPAR for tirzepatide, PI3K-AKT plus NF-kB for retatrutide) gives mechanism rather than just an endpoint. The limits are the usual ones: mouse ureteral-obstruction and ageing models are aggressive surrogates for human chronic kidney disease, and a single dose level per agent cannot establish that retatrutide is more potent in people. The authors frame it as hypothesis-generating, which is the right register. Retatrutide remains investigational and unapproved.
iSciencen=—AnimalSep 18, 2026 - Study · SemaglutideMixed
Carbon Emission Impact of Semaglutide in People with Obesity in the UK Using a Disease Modelling Approach.
A Markov cohort model, not an empirical measurement — results hinge on assumptions drawn from the STEP and SELECT trials and on how emissions are attributed to healthcare resource use. Author affiliations suggest manufacturer involvement, which is worth weighing for an environmental-benefit framing. The finding that longer survival can raise lifetime emissions in the cardiovascular-disease population is an honest wrinkle that adds credibility to the modeling.
PharmacoEconomicsn=——Sep 10, 2026 - Study · TirzepatideSupported
Semaglutide and Tirzepatide for the treatment of MASH: What Works, What's Coming, and What's Missing.
A narrative review, so it synthesizes rather than adds evidence, but its anchors are solid: interim phase 3 data behind semaglutide's accelerated MASH approval and consistent phase 2 fibrosis signals for tirzepatide. The open questions it flags — durability, long-term liver outcomes, safety over years — are the right ones. Senior author Tacke is a leading name in hepatology, which lends weight to the framing.
Digestionn=——Sep 9, 2026 - Study · TirzepatideWeak / none
Anesthetic Safety and Perioperative Outcomes in GLP-1 Receptor Agonist-Treated Patients Undergoing Lipoabdominoplasty.
A reassuring data point on the perioperative question that has dominated anesthesiology guidance since 2023, but a limited one: retrospective, single-protocol, and the authors themselves stress it was not powered for equivalence or for rare events such as aspiration. Absence of a detected signal in 98 exposed patients is not proof of safety. Useful context for patients planning body-contouring surgery after GLP-1 weight loss, not a basis to relax pre-operative precautions.
Aesthetic plastic surgeryn=—HumanSep 9, 2026 - Study · TirzepatideMixed
Current and forthcoming pharmacotherapies for adolescent obesity: Evidence-based review.
A minireview with a stated but not fully systematic search, so the 16.1 percent BMI figure should be read as drawn from the adolescent semaglutide trial programme rather than independently pooled here. The honest part is the gap it names: adolescent evidence for tirzepatide and for the cagrilintide-semaglutide combination is close to absent, and long-term safety data in a growing population do not yet exist. The equity and cost discussion is the practical constraint clinicians will recognise. Adolescent dosing is a prescriber decision, not a reported-protocol question.
World journal of clinical pediatricsn=——Sep 9, 2026 - Study · SemaglutideMixed
A Biweekly GLP-1R Agonist Designed With Drug-Free Intervals for Enhanced Efficacy, Receptor Homeostasis and Gastrointestinal Tolerability.
Entirely preclinical — rodents plus a primate pilot — and the head-to-head framing against semaglutide deserves the usual caution about dose-matching across different dosing schedules. The 'GLP-1R recovery' concept, letting the receptor recycle during drug-free windows while continuous semaglutide exposure drives internalization, is a genuinely interesting design hypothesis with possible tolerability implications. Years from human data, if it gets there at all.
Diabetes, obesity & metabolismn=—AnimalSep 8, 2026 - Study · SemaglutideWeak / none
HIF-1 exerts a double-edged sword regulatory role in hippocampal neuronal PANoptosis of Alzheimer's disease through HK2/VDAC1/NLRP3 axis and RIPK3 signal.
This is bench science in a mouse model, several steps removed from any clinical claim about Alzheimer's disease. The mechanistic detail — semaglutide acting through a GLP-1R-AMPK route to shift HIF-1's dual role — adds to a substantial preclinical literature on GLP-1 receptor agonists in neurodegeneration. Human trial evidence for semaglutide in Alzheimer's remains unsettled, so mechanistic findings like this should be read as target biology, not efficacy data.
Pharmacological researchn=—AnimalSep 6, 2026 - Study · SemaglutideWeak / none
Improvement of post-COVID-19 vaccination dysautonomia with GLP-1 receptor agonist.
A single-patient case report, so this is hypothesis-generating at best. The use of objective measures — a 24-hour heart rate recording and validated symptom questionnaires — strengthens the observation, but with no control there is no way to separate a drug effect from natural recovery over time. The authors, who specialize in dysautonomia, explicitly call for randomized placebo-controlled trials rather than drawing conclusions from one case.
Immunopharmacology and immunotoxicologyn=—HumanSep 6, 2026 - Study · TirzepatideWeak / none
Adjunctive Treatments for Patients with Type 1 Diabetes Using Automated Insulin Delivery Systems. A Narrative Review.
This narrative review draws on a thin evidence base — the authors themselves describe the underlying data as limited, mixing small randomized and observational studies. Off-label GLP-1 use in type 1 diabetes is a live clinical question, and the early signal here is directionally encouraging on weight, insulin dose, and time in range. Larger and longer trials are needed before the safety picture, especially around ketoacidosis, can be considered settled.
Diabetes technology & therapeuticsn=——Sep 4, 2026 - Study · SemaglutideSupported
Oral Incretin-Based Therapies for Weight Management.
A narrative review tracking the shift from injectables to oral incretin formulations, a shift with obvious implications for access and adherence. The efficacy figures quoted match the phase 3 record, and the authors flag a real safety watchpoint: drug-induced liver injury seen with first-generation small-molecule agents. No new data, but a solid map of a fast-moving pipeline.
Current atherosclerosis reportsn=——Sep 4, 2026 - Study · SemaglutideSupported
Emerging role of GLP-1 mono, dual, and triple agonists in the management of MASH-related fibrosis.
A timely expert review from a group that includes Rohit Loomba, one of the most cited investigators in fatty liver disease, anchored to trials with histology-assessed endpoints — the strongest evidence standard in this field. As a review it contributes synthesis rather than new data, and it is candid about open questions on therapy duration, tolerability, and variable response. Useful context following semaglutide's MASH approval.
Cell reports. Medicinen=——Sep 4, 2026 - Study · TirzepatideSupported
Recent Advances in Glucagon-Like Peptide-1 Receptor and Melanocortin-4 Receptor Agonists for the Treatment of Obesity and Type 2 Diabetes.
A broad literature review that favors breadth over depth, pairing the mainstream incretin class with the smaller melanocortin-4 field best known for setmelanotide in genetic obesity. It offers no systematic search methodology or pooled analysis, so it is best read as a mechanism-and-landscape primer. The efficacy characterizations are consistent with the published trial record.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolismen=——Sep 4, 2026 - Study · SemaglutideMixed
Beyond Weight Loss: Disentangling the Direct Effects of Semaglutide vs Equivalent Calorie Restriction on Reproductive Systems of Male and Female Rats.
The pair-fed control design is the notable strength here — it separates what semaglutide does directly from what any equivalent weight loss would do, a distinction most GLP-1 studies skip. The sex-specific split is the headline: androgen preservation in males reads as favorable, while the drug-specific reduction in female gonadal hormones is a signal worth watching, not yet an alarm. This is a four-week rat study in a diet-induced obesity model; rodent reproductive endocrinology maps imperfectly onto humans, and no fertility outcomes were measured in offspring terms. It lands amid growing clinical interest in GLP-1s and fertility, and gives that conversation some mechanistic footing.
Molecular metabolismn=—AnimalSep 3, 2026 - Study · TirzepatideSupported
Glucagon-like Peptide-1 Receptor Agonist-Associated Injection Site and Dermatologic Reactions.
A useful cross-agent comparison of a side-effect category that gets less attention than nausea and GI complaints, with real numbers behind it. The FAERS data carry the usual caveats: reports are voluntary, lack denominators, and reporting rates are skewed by drug age, media coverage, and formulation differences — so the between-drug percentages rank report proportions, not true incidence. The authors themselves call for prospective studies to pin down actual risk rates. Still, for injection-site reactions specifically, the practical takeaway — common, usually mild, rarely a reason to stop — is well supported.
Clinics in dermatologyn=——Sep 3, 2026 - Study · SemaglutideMixed
Semaglutide Bioavailability: Limitations, Formulation Innovation and Future Opportunities.
A useful, unglamorous review of the central problem in oral peptide delivery. The counterintuitive point is that despite large swings in individual absorption, steady-state exposure stays relatively stable because semaglutide's roughly week-long half-life and extensive albumin binding smooth day-to-day differences. Nothing here changes clinical practice, but it clarifies why the fasting-and-limited-water dosing instructions are load-bearing rather than advisory. The formulation candidates discussed remain preclinical or early-stage.
Pharmaceutical researchn=——Sep 3, 2026 - Study · TirzepatideMixed
Postmarketing Safety Signals and Medication-Use Risks of GLP-1-Based Therapies in Diabetes and Obesity: A Multi-Source Pharmacovigilance and Regulatory Evidence-Mapping Study.
This is a signal-prioritisation exercise, not a risk estimate, and the authors say so explicitly: spontaneous-reporting data cannot yield incidence, causality or comparative risk. The notable pattern is how much of the reported burden is medication-use error rather than classic pharmacology, with incorrect dose administered, extra dose administered and off-label use among the most common terms. Tirzepatide's share reflects uptake and reporting behaviour as much as anything intrinsic to the molecule. Read it as a map of where postmarketing attention is concentrated.
Diabetes, obesity & metabolismn=——Sep 3, 2026 - Study · TirzepatideSupported
Integrating the liver into the cardiovascular-kidney-metabolic syndrome: pathophysiology and therapeutic implications.
The most actionable point is diagnostic rather than pharmacological: the authors want noninvasive fibrosis scoring used routinely in high-risk kidney-disease cohorts. On drugs, they read the recent trial set as evidence that incretin agents act across the whole cardiovascular-renal-hepatic-metabolic spectrum rather than on a single organ. Nomenclature is explicitly unsettled here, so the acronym itself should be regarded as provisional.
Current opinion in nephrology and hypertensionn=——Sep 2, 2026 - Study · SemaglutideSupported
Late-life semaglutide treatment slows ageing and extends lifespan in female mice.
This is the strongest published case so far that GLP-1 receptor activation behaves as a calorie-restriction mimetic, with lifespan extension and modulation of conserved genetic regulators of ageing. The design is what gives it weight: dosing began late in life, and matched calorie restriction ran as a live comparator rather than a citation. The usual limits apply, since this is one mouse strain, female animals only, and no human lifespan data exists. Its main value is a mechanistic frame for the pleiotropic effects clinicians keep reporting.
Naturen=—AnimalSep 2, 2026 - Study · SemaglutideSupported
Impact of surfactants on the stability of therapeutic peptides under interfacial stress.
A laboratory formulation study, not a clinical one, but it speaks directly to a question peptide readers care about: what actually happens to a peptide solution under agitation stress. The methods are appropriate — size-exclusion chromatography, circular dichroism, and NMR converging on the same mechanistic story — though liraglutide is the primary model and semaglutide only an exploratory comparison, so the semaglutide finding is a single-condition observation rather than a characterised profile. The relative robustness of semaglutide's oligomers is consistent with its commercial formulation. Nothing here should be extrapolated to reconstituted or repackaged material, which faces different stresses entirely.
Journal of pharmaceutical sciencesn=—In vitroSep 2, 2026 - Study · SemaglutideMixed
Cardiometabolic outcomes of once-weekly IcoSema in adults with type 2 diabetes: systematic review and meta-analysis of the COMBINE trials.
The signal readers should take from this is the weight and blood-pressure differential against insulin intensification, which is consistent with what the semaglutide component would be expected to contribute. Two caveats limit how far it travels: the HbA1c pooling carries I-squared of 98 percent, meaning the two trials disagreed sharply enough that the pooled figure is close to uninterpretable, and every cardiovascular claim rests on surrogate markers plus an explicitly illustrative modelling exercise. Only two trials met inclusion, and the authors themselves call for dedicated outcome trials before any cardiovascular benefit is regarded as established.
Cardiovascular diabetology. Endocrinology reportsn=—HumanSep 2, 2026 - Study · TirzepatideMixed
Multi-Database Pharmacovigilance Analysis of Gastroesophageal Reflux Disease Associated with GLP-1 Receptor Agonists: A Cross-National Signal Validation Study.
The strength here is replication: the same directional signal appears in Western and Asian reporting systems, using an active comparator rather than the whole database, which blunts some of the usual disproportionality artefacts. The weakness is inherent to the method — spontaneous reporting captures what gets reported, not incidence, and the JADER counts (19 versus 16 cases) are far too small to carry the reported 4.76-fold estimate on their own. For readers tracking GLP-1 tolerability, reflux belongs on the list of gastrointestinal effects to watch alongside nausea and delayed gastric emptying, particularly at higher doses and in older users.
Gut and livern=——Sep 2, 2026 - Study · TirzepatideSupported
The Evolution of Medications for Obesity Management.
A narrative review rather than a systematic one, so study selection reflects the authors' judgment and no pooled estimates are offered. Its value is as a readable synthesis of how the field moved past a history of market withdrawals to the current incretin class, with headline efficacy figures that align with the pivotal trials. Useful orientation; no new data.
JGH open : an open access journal of gastroenterology and hepatologyn=——Sep 1, 2026 - Study · RetatrutideSupported
Pharmacological management of obesity: Current landscape and emerging therapies.
A serviceable landscape review rather than new data. Its value is the pipeline framing: the cagrilintide-semaglutide combination and retatrutide are positioned as the agents expected to narrow the efficacy gap with bariatric surgery, while oral and longer-acting formulations are the adherence play. The regional guideline detail is a reminder that staging conventions and access differ considerably by market. Claims about approaching surgical efficacy rest on trial weight-loss percentages, not on head-to-head outcome data.
Indian journal of pharmacologyn=——Sep 1, 2026 - Study · SemaglutideSupported
Current therapeutic landscape and future treatment perspectives of MASH.
Semaglutide's approval anchors the incretin arm of a field that until recently had nothing licensed at all. The review's substantive contribution is the phenotype argument: liver-centric subsets with fast fibrogenesis may respond differently from cardiometabolic subsets driven by insulin resistance, which would help explain heterogeneity across trials. Combination regimens and biomarker-guided selection are framed as the direction of travel, not established practice.
Naturen=——Sep 1, 2026 - Study · SemaglutideWeak / none
GLP-1 receptor agonist exposure and non-arteritic anterior ischaemic optic neuropathy: an illustrative case.
What makes this case notable is the patient profile rather than the event itself: NAION is more typically seen in older patients with vascular risk factors, and this woman had neither diabetes nor hypertension. The workup was thorough and appropriately excluded the main alternatives, but a single report with a short exposure window can only generate hypotheses — the authors say so explicitly. It sits alongside a growing body of pharmacovigilance and cohort signals on GLP-1 agonists and optic neuropathy, and the practical takeaway for readers is that sudden painless vision loss warrants prompt assessment rather than watchful waiting.
Clinical & experimental optometryn=—HumanSep 1, 2026 - Study · SemaglutideMixed
Higher semaglutide dose is associated with lower neuropsychiatric event incidence independent of weight loss.
The dose-response and landmark design are the interesting parts: separating exposure and outcome windows makes reverse causation less likely than in a simple cross-sectional comparison, and the finding that most associations tracked dose rather than weight loss argues against weight change being the whole story. It remains an observational database analysis, so confounding by adherence is the obvious rival explanation — people who tolerate and escalate to higher doses are generally healthier and better engaged with care than those who stall at low doses, and propensity matching on baseline covariates does not fix that. The accompanying transcriptomic work found only low-level, regionally restricted GLP1R signal in nervous tissue, which the authors correctly present as hypothesis-generating rather than mechanism. Read it as a reason for prospective study, not as an established neuropsychiatric benefit.
npj metabolic health and diseasen=—HumanSep 1, 2026 - Study · SemaglutideMixed
Incretin-Based Therapies as Cardiometabolic Interventions: Outcome Hierarchy, Receptor-Network Pharmacology and Phenotype-Based Clinical Positioning.
The useful contribution is the framing rather than any new data: mechanistic plausibility is not outcome evidence, and this review is explicit about which agents have crossed that line and which have not. As a narrative review with structured literature identification, it carries no pooled estimates and no formal risk-of-bias appraisal, so it should be read as expert synthesis. The lean-mass and discontinuation caveats are the parts most directly relevant to readers following the incretin class outside of a clinic.
Diabetes, obesity & metabolismn=——Sep 1, 2026 - Study · TirzepatideWeak / none
Tirzepatide non-response with subsequent semaglutide response in class 2 obesity.
A single case, so it establishes that a tirzepatide non-responder can respond to semaglutide - not how often that happens or why. The proposed GIP receptor mechanism is inference from the literature rather than anything measured in this patient, and the authors themselves flag that the HOMA-IR threshold idea needs prospective testing. Useful as a counterweight to the assumption that the dual agonist is universally the stronger choice, which the head-to-head trial data supports only on average.
JCEM case reportsn=—HumanSep 1, 2026 - Study · TirzepatideSupported
Weight Regain Trajectories After Discontinuation of Semaglutide or Tirzepatide: A Reconstructed Aggregate-Data Bayesian Longitudinal Meta-Analysis.
A Bayesian re-analysis of aggregate timepoint data rather than individual participant records, which limits how finely predictors can be examined - the signals for initial weight loss magnitude and for behavioural support both had credible intervals crossing zero. The authors are explicit that anything past 52 weeks is a linear extrapolation, so the 15-month return-to-baseline figure is a model output, not an observation. Even with those caveats, the direction and speed of regain are consistent with what individual discontinuation trials have reported.
Endocrinology, diabetes & metabolismn=—HumanSep 1, 2026 - Study · RetatrutideSupported
Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes : An Updated Systematic Review.
An Annals of Internal Medicine update with declared funding of none, adding 14 new randomised trials and roughly 11,000 participants to the prior version - about as authoritative a synthesis as this field currently has. The key limitation is stated plainly by the authors: heterogeneity ruled out pooled quantitative synthesis, so the percentage figures come from individual trials rather than a single meta-analytic estimate and should not be lined up as a strict ranking. Safety reporting across trials was inconsistent, which matters most for the newest multiagonists where exposure is still short.
Annals of internal medicinen=——Sep 1, 2026 - Study · SemaglutideWeak / none
Body Composition and Lifestyle Interventions in Pharmacological Treatment of Acquired Hypothalamic Obesity: A Systematic Review of Randomized Controlled Trials.
Seven small randomized trials, combined descriptively because they were too heterogeneous to pool, with GRADE certainty rated low for anthropometric, metabolic and behavioral outcomes. The semaglutide result is directionally consistent but rests on a handful of participants in a rare condition, and the reviewers flag that lean-mass assessment was inadequate across the whole literature. Read it as an early signal for a population with few options, not as evidence of comparative superiority over the other agents reviewed.
Obesity (Silver Spring, Md.)n=——Sep 1, 2026 - Study · SemaglutideMixed
Weight Loss-Independent Mechanisms of Kidney Protection With Glucagon-Like Peptide 1 Receptor Agonists and Implications for Clinical Practice.
A hypothesis piece in a leading nephrology journal, not new data, but the argument matters: FLOW and related trials showed kidney benefit that correlated poorly with the magnitude of weight loss, and direct receptor-mediated, anti-inflammatory, and hemodynamic mechanisms are plausible. The clinical implication — kidney protection as a goal independent of weight response — would reshape how the class is deployed in CKD. The authors are candid that this remains unconfirmed; mediation analyses and mechanism-focused trials are the needed follow-through.
American journal of kidney diseases : the official journal of the National Kidney Foundationn=——Sep 1, 2026 - Study · TirzepatideMixed
Patient Experiences and Safety Concerns Regarding GLP-1 Receptor Agonists for Obesity: A Cross-Sectional Survey in Jeddah, Saudi Arabia.
A single-city survey with descriptive statistics, so it says nothing about how well these drugs actually work — but it is a useful window into how patients experience them. The standout patterns: longer duration of use tracked with higher perceived safety, and tirzepatide users stayed on therapy longer than semaglutide users. The affordability and information-gap findings echo what we see in community discussions well beyond Saudi Arabia. File under real-world use, not efficacy.
Saudi medical journaln=——Sep 1, 2026 - Study · SemaglutideSupported
Efficacy and safety of semaglutide injection in Indian patients with type 2 diabetes mellitus inadequately controlled on metformin: A phase 3, randomized, active-controlled, multicenter, non-inferiority trial (WIN-IND study).
This is a properly registered, randomized non-inferiority trial of a biosimilar-style semaglutide, and the numbers line up: an HbA1c difference of 0.16 points with a confidence interval inside the pre-set margin, and no new safety signals over 24 weeks. The open-label design and modest size are limitations, but the primary endpoint is objective. The broader story is supply: semaglutide's patent position in India is eroding, and credible domestic versions will reshape pricing there. Worth publishing as a marker of that shift.
Metabolism openn=—HumanSep 1, 2026 - Study · TirzepatideSupported
Impact of GLP-1 receptor agonists on cardiovascular outcomes in heart failure with preserved ejection fraction (HFpEF): systematic review and meta-analysis.
HFpEF has long resisted drug therapy, so a pooled 27 percent reduction in the composite of death or heart-failure hospitalization is a meaningful signal for the GLP-1 class — five of the six included studies used semaglutide, one tirzepatide. The effect is driven by hospitalizations rather than mortality, and 4,043 patients across six heterogeneous studies is still a modest evidence base. With zero statistical heterogeneity and low risk of bias in the RCTs, though, the direction of the finding looks solid.
Clinical research in cardiology : official journal of the German Cardiac Societyn=—HumanSep 1, 2026 - Study · SemaglutideSupported
Nationwide Real-World Retrospective Study of Oral Semaglutide Use in Adults Living With Type 2 Diabetes in Finland.
Nationwide register studies like this are how trial results get stress-tested against everyday practice, and here the oral formulation broadly held up: glycaemic, weight, lipid, and liver-enzyme improvements all moved in the expected direction. Two caveats deserve equal billing. Discontinuation was high, with nearly half off the drug by one year, and the endpoint samples shrink sharply from the full cohort, which can flatter the averages among those who persisted.
Diabetes, obesity & metabolismn=—HumanSep 1, 2026 - Study · SemaglutideSupported
Weight Changes With Lower Doses of Semaglutide in Clinical Practice: Findings From the Chinese HARMONY Cohort.
The headline here is dose: these results came from 0.5 to 1.0 mg weekly, well below the 2.4 mg used in the STEP obesity trials, yet the 24-week losses are respectable. That will interest readers following the low-dose question, though this is an observational cohort of just over 100 completers, with no comparator arm and lifestyle counselling running alongside. The subgroup signal, blunted response with diabetes or intrapancreatic fat, echoes patterns seen in larger datasets and is worth watching.
Diabetes, obesity & metabolismn=—HumanSep 1, 2026 - Study · SemaglutideMixed
GLP-1 receptor agonists in multiple sclerosis: a systematic review of preclinical and clinical evidence.
The gap between the animal literature and the human literature is the whole story here. Animal models show a consistent anti-inflammatory effect, while the two human cohorts — 109 patients between them — show metabolic changes and no measurable effect on disability or relapse. The pharmacovigilance reporting ratios are a weak instrument and should not be read as protective. The useful takeaway is that no randomized trial exists yet, and the authors say so plainly.
Multiple sclerosis and related disordersn=——Sep 1, 2026 - Study · SemaglutideMixed
The Effect of Semaglutide on Quality of Life in Adults With Overweight or Obesity: A Brief Systematic Review and Meta-Analysis.
A sobering counterpoint to the weight-loss headlines: across the STEP program, semaglutide's average effect on patient-reported physical function was statistically real but below the threshold for a change patients would actually feel. Effects were smaller still in participants with type 2 diabetes. The authors' framing is careful — the drug improves these outcomes, but expectations about quality-of-life gains should be calibrated. All included trials come from the manufacturer's own development program, which limits the evidence base's independence.
Diabetes, obesity & metabolismn=—HumanSep 1, 2026 - Study · SemaglutideSupported
Electrospun Nanofiber Oral Thin Film Platform for Sublingual Peptide Delivery: A Promising Alternative to Conventional Semaglutide Formulations.
Delivery, not efficacy, is the story here: an electrospun nanofiber film that carries semaglutide across the sublingual mucosa, sidestepping both the needle and the finicky absorption of the current oral tablet. In minipigs, the film edged out the Rybelsus-style dosing on weight-gain attenuation and biomarker response. It is a 40-animal, 8-week study in non-obese pigs, so this is a materials-science proof of concept rather than a clinical result — but a plausible route worth tracking given how much of the GLP-1 conversation now revolves around formulation.
Diabetes, obesity & metabolismn=—AnimalSep 1, 2026 - Study · SemaglutideSupported
Cardiovascular Outcomes in a SELECT-Like Obesity Cohort: Real-World Insights From the Swedish AROS Database.
This registry study does not test semaglutide directly; it maps how a real-world SELECT-like population actually fares, and the answer is worse than the trial suggested — older, more prior strokes, higher event rates despite extensive preventive medication. That higher baseline risk translates into an estimated number-needed-to-medicate of 35 to avert one major cardiovascular event, a favorable figure for population-level impact. A useful bridge between trial efficacy and real-world applicability, with the standard limits of applying a trial's relative effect to an observational cohort.
Diabetes, obesity & metabolismn=—HumanSep 1, 2026 - Study · SemaglutideSupported
Pharmacotherapy for Children and Adolescents With Overweight or Obesity: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
In this network meta-analysis of pediatric obesity pharmacotherapy, semaglutide tops the efficacy rankings but shares the podium with phentermine-topiramate, which the authors favor on tolerability grounds. The evidence base is thinner than in adults — 41 trials but under 4,000 participants total — and indirect comparisons carry the usual caveats. Worth noting as the pediatric evidence for GLP-1 agents continues to accumulate; long-term data in this age group remain the open question.
Diabetes, obesity & metabolismn=—HumanSep 1, 2026 - Study · TirzepatideWeak / none
Compounded Semaglutide and Tirzepatide Products Use Unique Formulations but Efficacy and Safety Largely Unknown.
This is the clearest inventory yet of what "unique formulation" actually means in practice once the shortage exemption closed, and the answer is mostly additives with no stated rationale. The authors find little justification for the vitamin, amino acid, or stool-softener combinations, allow a pharmacological rationale for ondansetron while noting no evidence for giving it subcutaneously, and flag that sublingual and dissolving-tablet routes have not been shown to outperform the approved oral tablet. Fewer than one in five products documented a beyond-use date, which is a basic stability disclosure.
The Annals of pharmacotherapyn=——Sep 1, 2026 - Study · SemaglutideWeak / none
Sexual Safety Signals of Common Antidiabetic Drugs: Insights From FAERS Disproportionality Analysis.
Spontaneous-reporting databases capture what clinicians and patients choose to file, not what actually happens in a population, so a reporting odds ratio near 1.5 on roughly 50 reports is a weak observation by design. Confounding by indication is severe here: diabetes itself is a leading cause of erectile dysfunction, and no denominator or comorbidity adjustment is possible in this data. The authors are appropriately explicit that this establishes no causal link and is hypothesis-generating only.
Andrologyn=——Sep 1, 2026 - Study · SemaglutideMixed
Cost-Effectiveness of Access to Obesity Care and Treatments for Adolescents.
The striking number is not the cost-effectiveness ratio but the collapse from 57% to 3% of averted obesity cases once realistic access frictions are modelled. That gap says the binding constraint is not drug efficacy but whether adolescents reach a prescriber at all. This is a simulation built on parameter estimates and 2025 pricing, so the absolute figures will shift as prices move, and the authors note the results are sensitive to assumed efficacy and discontinuation rates.
Childhood obesity (Print)n=——Sep 1, 2026 - Study · SemaglutideSupported
Effects of Oral Semaglutide on Dietary Intake and Body Composition in Japanese People With Type 2 Diabetes: A Prospective Observational Study in Clinical Practice.
What makes this small study interesting is the food-group detail rather than the headline weight numbers. Participants ate less across the board without changing their macronutrient ratios, and the drop in salt intake appears to be a downstream consequence of eating less overall rather than a deliberate dietary change. Twenty-five people, no control group, and self-reported dietary questionnaires all argue for caution, but the pattern lines up with appetite-suppression mechanisms described elsewhere.
Endocrinology, diabetes & metabolismn=—HumanSep 1, 2026 - Study · TirzepatideSupported
Weight Loss-Dependent Changes in Body Composition and Bone Health in People With Obesity and Type 1 Diabetes Treated With Liraglutide, Semaglutide, or Tirzepatide.
The signal worth noting here is what did not change: total bone mineral density held steady across a year of incretin-driven weight loss in a population with type 1 diabetes, a group already carrying elevated fracture risk. Lean mass did decline in proportion to total weight lost, which is consistent with the wider incretin literature and reinforces why resistance training and protein intake keep coming up in clinical discussion. This is an observational cohort of 70 people with no control arm, so read the results as reassuring rather than definitive.
Diabetes/metabolism research and reviewsn=—HumanSep 1, 2026 - Study · SemaglutideWeak / none
Semaglutide exerts anti-pulmonary fibrosis effects by inhibiting cellular senescence through activation of the Sirt1/HSF1/HSPs pathway.
A mechanistic preclinical study reporting that semaglutide reduced pulmonary fibrosis and cellular senescence in bleomycin-treated mice and in cell models, with effects mediated through the Sirt1/HSF1/HSP pathway. The work is well-designed at the bench level, using gene silencing to probe mechanism, but findings are confined to animal and in vitro systems and have not been tested in humans. It offers a plausible biological signal worth following, framed strictly as early research.
Biochemical pharmacologyn=—AnimalSep 1, 2026 - Study · SemaglutideMixed
Changes in food cravings, dietary quality, body composition, and dietary intake during GLP-1 receptor agonist therapy: The CRAVE study.
A small prospective cohort (n=28) tracking body composition and diet during semaglutide or tirzepatide therapy, notable for flagging estimated muscle-mass loss and unchanged diet quality. The sample is tiny with attrition, muscle mass was estimated by bioimpedance, and the authors themselves label the findings exploratory. Still a useful, honest signal on the nutrition and lean-mass gaps that can accompany pharmacologic weight loss.
Obesity pillarsn=—HumanSep 1, 2026 - Study · SemaglutideMixed
Direct effects of glucagon-like Peptide-1 receptor agonists on mitochondrial function in human-derived in vitro models: A systematic review and meta-analysis.
The first meta-analysis of GLP-1 receptor agonists' direct mitochondrial effects in human-derived cell models reports improved bioenergetics and reduced mitochondrial reactive oxygen species, with no clear effect on membrane potential. The authors are candid that overall certainty is very low, driven by heterogeneity, imprecision, and publication bias, and that relevance to whole-body physiology is unproven. Semaglutide appears as a class exemplar rather than the sole agent, so read this as an early mechanistic hint, not established benefit.
Metabolism openn=—HumanSep 1, 2026 - Study · SemaglutideWeak / none
Semaglutide, at a dose that produces modest weight loss, induces mild suppression of bone remodeling in healthy control rats and those with chronic kidney disease.
In male rats with progressive chronic kidney disease and healthy littermates, escalating-dose semaglutide over 28 days was assessed for effects on bone. Researchers reported that at doses causing mild weight loss, semaglutide modestly lowered trabecular bone remodeling (mineralising surfaces and bone-formation rate trended about 20% lower) with little interaction with CKD status; muscle mass was also lower in treated animals. These are preclinical findings in rodents, mechanistic signals, not clinical proof, and the 28-day window is short. Bone and muscle effects of GLP-1 agonists during rapid weight loss are a live question, and this adds a cautionary rodent data point suggesting remodeling can dip. Human data would be needed before drawing skeletal conclusions; readers should not extrapolate fracture risk from a 28-day rat study.
Bonen=—AnimalSep 1, 2026 - Study · SemaglutideWeak / none
Micronutrient risk with GLP-1 receptor and dual incretin agonists in obesity: Mechanistic pathways, clinical signals, and a monitoring framework.
This narrative clinical review examines whether GLP-1 and dual GIP/GLP-1 receptor agonists, the drug class that includes semaglutide and tirzepatide, raise the risk of micronutrient deficiencies during long-term weight-loss treatment. Drawing on dietary studies, cohorts, and pharmacovigilance reports rather than trials, the authors argue that reduced food intake, less dietary variety, gastrointestinal intolerance, delayed gastric emptying, and rapid weight loss can converge on vulnerabilities in iron, vitamin B12, vitamin D, calcium, magnesium, zinc, and others. They stress that most abnormalities reported so far are subclinical or indirect, with clinically meaningful effects likely confined to higher-risk individuals. The abstract does not name specific agents, so this is class-level context. For semaglutide and tirzepatide readers, the practical value is a monitoring framework, not evidence of a defined deficiency rate.
Obesity pillarsn=——Sep 1, 2026 - Study · SemaglutideWeak / none
Obstetrical and medical outcomes following GLP-1 receptor agonist exposure in pregnancy: a case series.
A 16-patient case series describing outcomes when women with overweight or obesity conceived unintentionally while using subcutaneous semaglutide and continued it into part of the first trimester. Researchers reported no major fetal anomalies among the singleton pregnancies, but the design is the point: an uncontrolled case series of this size cannot establish safety, and the absence of malformations in 16 pregnancies is only weakly reassuring given how small the number is. Notable observations include a preeclampsia rate of 18.8%, one medically indicated preterm birth at 35 weeks, and that most patients needed metformin and insulin for diabetes control after stopping semaglutide. GLP-1 receptor agonists are not established for use in pregnancy, and manufacturer labelling advises discontinuation; this report does not change that. It is best read as an early, honest description of inadvertent exposures that adds a few data points to a thin literature, with the authors themselves calling for formal safety studies. Not evidence of safety, and not guidance.
Case reports in women's healthn=—HumanSep 1, 2026 - Study · SemaglutideSupported
Glycaemic Changes After Semaglutide Discontinuation in Adults With Type 1 Diabetes Using Automated Insulin Delivery: Analysis of the ADJUST-T1D Extension Study.
This is an extension phase of the randomised ADJUST-T1D trial, so the comparison groups carry over real randomisation - a strength for a discontinuation question that is usually studied observationally. The sample is very small (16 who stopped semaglutide versus 22 on placebo), and the differences, while statistically adjusted, sit close to the significance threshold. Type 1 diabetes remains an off-label setting for this drug class, which makes durability data like this worth tracking even at this scale.
Diabetes, obesity & metabolismn=—HumanAug 31, 2026 - Study · SemaglutideWeak / none
Intranasal delivery of Semaglutide using a thermoresponsive PNPHO nanocarrier: formulation development, characterization and biological evaluation.
This is early formulation science - physicochemical characterisation, cell-layer permeation and rodent pharmacodynamics - not a clinical study, and the efficacy comparisons are against free drug in the same experimental systems. A needle-free nasal route is a genuinely interesting direction given how much of this market runs on weekly injections, but the gap between a rodent glucose-tolerance curve and a human bioavailability figure is large. Several authors list affiliations that suggest industry involvement in the delivery platform; no funding statement is visible in the abstract.
International journal of pharmaceuticsn=—AnimalAug 30, 2026 - Study · SemaglutideWeak / none
Intrathecal semaglutide attenuates burn injury-induced pain in mice through a spinal GLP-1R-linked enkephalin/δ-opioid receptor pathway.
A careful mechanistic study using immunoblotting, immunofluorescence and RNAscope to build a coherent chain from receptor location to behavioural effect, with the female-mouse check that too many rodent pain studies omit. The route matters: intrathecal dosing into the spinal fluid bears no relationship to how semaglutide is used in people, so nothing here transfers to subcutaneous dosing. Read this as basic pharmacology on a spinal GLP-1 to enkephalin pathway, not as evidence about pain in humans.
Neuropharmacologyn=—AnimalAug 30, 2026 - Study · SemaglutideSupported
Effects of subcutaneous semaglutide on weight loss and inflammatory markers in adults with overweight or obesity without diabetes: a systematic review and meta-analysis.
This is a consolidation rather than a surprise: the pooled effect sizes track closely with the individual STEP trials, and the genuine addition is the CRP result, which suggests inflammatory markers move alongside weight. The limits are the familiar ones for this literature — trial durations of 68 weeks or less, placebo rather than active comparators, and a serious-adverse-event confidence interval (0.76 to 1.65) wide enough to say little about rarer harms. The authors note the newer 7.2 mg STEP UP data sit outside the pooled estimate, so the headline figure should be read as reflecting mainly 2.4 mg dosing.
International journal of obesity (2005)n=—HumanAug 29, 2026 - Study · SemaglutideSupported
Semaglutide in Japanese participants with metabolic dysfunction-associated steatohepatitis: a subgroup analysis of the ESSENCE trial.
The headline steatohepatitis-resolution effect in the Japanese subgroup is large and its confidence interval excludes zero, tracking the direction of the full ESSENCE interim result. The fibrosis-improvement endpoint is the weaker signal here: the 7-point difference has a confidence interval crossing zero, which is what one would expect from a subgroup of 78 versus 38 participants and should not be read as evidence of no effect. Readers should regard this as a consistency check on the parent trial rather than independent confirmation, and note that ESSENCE is industry-sponsored, still ongoing to 240 weeks, and that this analysis was not powered for subgroup inference.
Journal of gastroenterologyn=—HumanAug 28, 2026 - Study · SemaglutideSupported
IDE-mediated GLP-1 degradation as the basis for designing long-acting and CNS-stable GLP-1 receptor agonists.
A mechanistic study in Science Advances, run in mice and in tissue secretomes, that identifies a previously undescribed route of GLP-1 breakdown and then uses it as a design target. The compound tested is a D-amino-acid variant, not the semaglutide available to patients, so the results speak to future drug design rather than to how current dosing behaves in people. The findings are internally consistent, including an enzyme-knockdown control and direct brain injection, but they remain entirely preclinical.
Science advancesn=—AnimalAug 28, 2026 - Study · TirzepatideMixed
From adiposity to multisystem morbidity: the case for weight loss as disease modification.
The useful contribution here is the honest map of where the randomised evidence exists and where it does not: the incretin trial programme has produced hard outcome data for a handful of conditions and left most of the multisystem burden of obesity under-investigated. This is a narrative review rather than a quantitative synthesis, so the causal claims rest on the authors' triangulation judgement, and reviews by senior trialists in this field commonly carry industry advisory relationships worth checking in the declarations. Readers should note the framing distinction the paper draws between weight loss as a marker and weight loss as the mechanism of benefit, which the authors flag as still unresolved and dependent on mediation analyses yet to be done.
The lancet. Diabetes & endocrinologyn=——Aug 27, 2026 - Study · SemaglutideSupported
Effects of Semaglutide versus Bariatric Surgery on Noninvasive Markers of Hepatic Steatosis and Fibrosis in Obesity with MASLD.
Single-center, prospective observational cohort with roughly 30 patients per arm, so groups were not randomized and baseline liver stiffness differed between them. The average semaglutide dose was about 1.0 mg weekly, below the 2.4 mg obesity dose, which makes the comparable stiffness reduction versus surgery more striking but also harder to generalize. Outcomes are non-invasive FibroScan and blood-score surrogates rather than biopsy or clinical endpoints. The authors themselves frame the weight-independent liver effect as hypothesis-generating.
The Journal of clinical endocrinology and metabolismn=—HumanAug 27, 2026 - Study · TirzepatideMixed
Glucagon-Like Peptide 1 Receptor Agonists, Mortality, and Cardiovascular Outcomes in Serious Mental Illness.
A target-trial emulation in JAMA Psychiatry using a new-user, active-comparator design, which is the right choice for observational data of this kind, and a direction consistent with randomized cardiovascular results for semaglutide. The one-year mortality gap, close to a halving, is larger than any randomized trial has produced and points to residual confounding in who is started on which drug rather than a clean pharmacological effect. The semaglutide and tirzepatide findings sit in exploratory subgroups, not the prespecified primary outcome, and the authors themselves call for randomized confirmation.
JAMA psychiatryn=—HumanAug 26, 2026 - Study · TirzepatideMixed
Nonscarring Alopecia in Adults Treated With GLP-1s: A Propensity Score Matched TriNetX Cohort Study.
A retrospective propensity-matched TriNetX cohort: strong on sample size, weak on controlling who gets prescribed these drugs and who gets a dermatology code entered. The null result for alopecia areata is a useful negative control, and the lower follow-up BMI among those with hair loss fits the authors' reading that rapid weight loss itself accounts for much of the effect. Coding-based outcomes and unmeasured confounding mean this shows an association rather than a drug-specific mechanism, and telogen effluvium is typically self-limited.
The Laryngoscopen=—HumanAug 26, 2026 - Study · SemaglutideMixed
Glucagon-Like Peptide-1 Receptor Agonist Use and Risks of Hospitalization and Mortality in Patients with End-Stage Kidney Disease.
This is the first sizeable look at GLP-1 receptor agonists in incident dialysis patients, a population excluded from the randomised outcome trials, so the question is worth asking. The exposure is class-level, defined as a prescription within the first 30 days of dialysis rather than semaglutide specifically, and the groups differed sharply at baseline (98% versus 73% with diagnosed diabetes, higher BMI, more pre-dialysis nephrology care), so selection by better underlying condition and better access to care is hard to rule out even after matching. Single-organisation EHR data with adherence after the index prescription unverified. Regard the effect sizes as hypothesis-generating pending a randomised trial in this group.
Clinical journal of the American Society of Nephrology : CJASNn=—HumanAug 25, 2026 - Study · SemaglutideSupported
Longitudinal Changes in Body Composition, Adaptive Thermogenesis and Muscle Strength in Patients with Obesity Treated with Semaglutide.
The interesting nuance is the split between absolute and relative muscle measures: lean mass fell in the semaglutide arm while the standardised muscle index and relative grip strength improved, which argues against reading absolute lean-mass loss as functional decline on its own. Design limits are real, though: single centre, retrospective, non-randomised, 83 patients in total, with body composition by bioelectrical impedance rather than DXA or MRI, so group differences are adjusted rather than eliminated. The adaptive-thermogenesis result also rests on a predictive equation derived from this same small cohort, which caps how far it generalises.
Obesity factsn=—HumanAug 25, 2026 - Study · SemaglutideMixed
Cardiorenal Mortality and Safety Outcomes of GLP-1 Receptor Agonists in Type 2 Diabetes With BMI Below 27 kg/m2: A Target Trial Emulation.
The exposure is the GLP-1 receptor agonist class excluding tirzepatide, so this is class-level evidence rather than a semaglutide-specific result. The authors are candid that the mortality gap versus DPP-4 inhibitors is implausibly large and likely reflects residual confounding, and its disappearance against SGLT2 inhibitors, an active comparator with its own survival benefit, supports that reading. The consistently lower coded heart-failure risk across all three comparisons is the finding most likely to survive scrutiny. Observational design, 24-month maximum follow-up, coded outcomes only.
Diabetes, obesity & metabolismn=—HumanAug 25, 2026 - Study · SemaglutideSupported
A microencapsulation strategy for intranasal semaglutide delivery.
A formulation feasibility study rather than a clinical one, with endpoints limited to encapsulation efficiency, storage stability and transport across cultured nasal cells. Those results are internally consistent and encouraging for the delivery route, but nothing here speaks to blood levels, bioavailability or weight outcomes in a living subject. Nasal peptide delivery has repeatedly failed at exactly the step this paper does not test, so read the results as a materials-science signal only.
Journal of microencapsulationn=—In vitroAug 25, 2026 - Study · SemaglutideMixed
GLP-1 receptor agonists and outcomes after cervical spine fusion: a systematic review, meta-analysis, and evidence map of real-world evidence.
The headline here is the disagreement, not a direction. With an overall I-squared of 97 percent and estimates running from OR 0.52 to OR 4.79 depending on procedure and database, the pooled number is not interpretable and the authors sensibly decline to draw a class-wide conclusion. All twelve inputs are retrospective claims-database cohorts with overlapping populations, so confounding by indication and double-counting are live concerns even with the prespecified de-duplication. The semaglutide posterior-fusion signal is worth watching but is a single cohort and hypothesis-generating only.
European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Societyn=—HumanAug 24, 2026 - Study · SemaglutideMixed
Exploring The Role of GLP-1 Receptor Agonists and DPP4 Inhibitors in the Treatment of Opioid Use Disorder: A Scoping Review.
The signal is consistent in direction but almost entirely preclinical and retrospective, which is exactly the pattern that dissolves under randomisation. Observational cohorts of people prescribed semaglutide differ systematically from those who are not, and the authors say as much in calling for controlled trials. Worth logging as an early lead: three ongoing randomised trials will decide this, and the single existing RCT is not yet peer-reviewed. No claim about clinical benefit is supportable today.
Journal of dual diagnosisn=——Aug 24, 2026 - Study · SemaglutideSupported
Dual-transporter-targeted oral nanomicelles of semaglutide enable enhanced intestinal absorption and metabolic reprogramming in obesity and diabetes.
A well-characterised drug-delivery paper: particle size, incorporation efficiency and the transporter mechanism (ASBT and GLUT2, plus endocytosis) are all documented, and the oral-to-subcutaneous comparison is run in the same model. The ceiling is that relative oral bioavailability was still only 4.62 percent, and everything here is Caco-2 monolayers and high-fat-diet mice — no human data. Doses in mg/kg in mice do not map onto human dosing. Read it as formulation progress, not as evidence about any product available now.
Journal of controlled release : official journal of the Controlled Release Societyn=—AnimalAug 24, 2026 - Study · SemaglutideMixed
Psychiatric and eye disorders associated with use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs).
Disproportionality analysis of spontaneous reports detects reporting patterns, not risk — EudraVigilance has no denominator, and semaglutide's media profile alone can inflate its report counts relative to dulaglutide. The suicidal-ideation confidence intervals are very wide (ROR 6.49, CI 1.57 to 26.81), which signals sparse counts. The authors are appropriately hedged and align with the regulators' position that no causal link is established. Useful as a vigilance signal for people with existing ophthalmic or neuropsychiatric vulnerability, and nothing more than that.
Naunyn-Schmiedeberg's archives of pharmacologyn=——Aug 22, 2026 - Study · SemaglutideMixed
GLP-1 and dual GIP/GLP-1 receptor agonists' psychopharmacology and putative neuropsychiatric associated effects: a Bradford Hill-informed, systematic, evaluation.
This is a structured causal-inference review rather than new trial data, and its main value is discipline: it sorts a noisy pharmacovigilance literature through the Bradford Hill criteria instead of tallying case reports. The authors land where most regulators have — plausible mechanisms, insufficient proof of causation — which is a meaningfully calmer read than headlines about GLP-1s and suicidality. As a review, it cannot resolve confounding by indication; obesity and diabetes themselves carry psychiatric comorbidity. Worth reading as a map of open questions, not a safety verdict.
Current psychiatry reportsn=——Aug 21, 2026 - Study · SemaglutideWeak / none
Glucagon-like peptide-1 receptor agonists in idiopathic intracranial hypertension: A systematic review and meta-analysis.
The direction of effect is consistent across outcomes and time points, which is notable, but this pooled estimate leans heavily on observational cohorts with moderate-to-serious confounding risk and substantial heterogeneity on several endpoints. Weight loss alone lowers intracranial pressure, so disentangling a drug-specific effect from the metabolic one is the central unresolved question. The abstract also pools the GLP-1 class without naming agents — earlier IIH work centered on exenatide, so readers should not assume semaglutide-specific data. Hypothesis-generating, as the authors say; the randomized trials it calls for are the real test.
Headachen=—HumanAug 20, 2026 - Study · SemaglutideSupported
Oral semaglutide vs DPP-4 inhibitors in reducing risk of cognitive impairment in elderly patients with HFpEF and obesity.
A striking effect size in a high-risk population, and it lands the same week as a 13,000-patient EHR cohort pointing the same direction on semaglutide and cognition — the convergence is the story. Caution is still warranted: 246 patients, no randomization, and matching on age, sex, and BMI leaves room for confounding, since patients prescribed semaglutide may differ systematically from those given DPP-4 inhibitors. The very high background rate of cognitive impairment also suggests a frail cohort where small biases can loom large. A signal worth tracking into randomized territory.
Internal and emergency medicinen=—HumanAug 20, 2026 - Study · SemaglutideSupported
Semaglutide Alleviates LPS-Induced Cognitive Disorder via O-GlcNAcylation of AKT-mTOR Signaling Pathway Components.
A mechanistic mouse study that goes beyond the usual 'GLP-1 drug reduces neuroinflammation' observation, mapping a specific O-GlcNAcylation-AKT-mTOR-gephyrin axis with inhibitor and gene-silencing controls — reasonably rigorous causal dissection for this literature. The model, intracerebroventricular LPS, is an imperfect stand-in for perioperative neurocognitive disorder, and mouse doses rarely translate cleanly. Interesting mechanism, but keep it filed under preclinical until human perioperative data exist.
Neuromolecular medicinen=—AnimalAug 20, 2026 - Study · TirzepatideMixed
Trends in utilization of glucagon-like peptide‑1 receptor agonists, sodium-glucose cotransporter‑2 inhibitors, and metabolic bariatric surgery in U.S. Adults with diabetes and obesity.
This is market-structure data rather than an efficacy study, and it quantifies two things the field discusses anecdotally: the near-total shift of metabolic care toward incretin drugs, and how leaky real-world use is — roughly half of initiators discontinue within a year. Tirzepatide leading on adherence and persistence is a competitive signal worth watching. Limitations are those of claims data: no reasons for discontinuation, no cash-pay or compounded use captured, and a privately insured population that may not generalize.
Diabetes research and clinical practicen=—HumanAug 20, 2026 - Study · SemaglutideSupported
Cognitive signs and symptoms in people with a psychiatric diagnosis on semaglutide: a retrospective cohort study of 13 007 patients in the USA.
A large, well-conducted EHR cohort from an Oxford-affiliated group, using active-comparator designs and the parametric g-formula to reduce obvious biases. Semaglutide beat no-treatment, glipizide, and empagliflozin on a composite cognitive score, though the gap versus sitagliptin did not reach significance — a useful check on overinterpretation. The outcome is a clinician-rated composite from routine notes, not formal neuropsychological testing, and residual confounding by health-seeking behavior is plausible. This adds to a growing cognitive-benefit signal for semaglutide that now needs a randomized trial.
BMJ mental healthn=—HumanAug 20, 2026 - Study · TirzepatideSupported
Major Adverse Liver Outcomes With Tirzepatide and Injectable Semaglutide in Adults With Overweight or Obesity and Type 2 Diabetes.
This is observational target-trial emulation, not a randomized head-to-head, so residual confounding remains possible despite propensity matching. The sitagliptin benchmark is the useful detail: it shows the design had enough resolution to separate incretin users from a weaker comparator, and against that backdrop tirzepatide and semaglutide were indistinguishable on hard liver endpoints. Read the extra BMI reduction with tirzepatide as decoupled from liver outcomes over this window rather than as a signal of hepatic advantage. Seventeen months is short for cirrhosis progression, so the comparison stays open.
Obesity (Silver Spring, Md.)n=—HumanAug 19, 2026 - Study · SemaglutideSupported
Effect of Semaglutide on the Inflammatory Biomarker High-Sensitivity CRP in Patients With Established Cardiovascular Disease and Overweight or Obesity in SELECT: A Prespecified Secondary Analysis.
As a prespecified analysis of a very large randomized trial, this sits near the top of the evidence hierarchy for the GLP-1 class. The timing signal is the substantive finding: inflammation markers fell early and independently of weight change, statin use, and LDL levels, which weakens a weight-loss-only account of the cardiovascular results. It remains a biomarker association, and the authors are careful to say inflammation may have contributed only in part to the event reduction.
Circulationn=—HumanAug 18, 2026 - Study · TirzepatideMixed
Prospective changes in sleep quality and depressive symptom burden following initiation of GLP-1-based therapies in patients with obesity: a real-world study.
This is a small single-arm observational cohort with no comparison group, so regression to the mean and expectation effects cannot be excluded. The interesting detail is that response tracked baseline symptom severity rather than percentage weight loss, which argues against a purely weight-mediated explanation for the mood and sleep changes. Read the results as hypothesis-generating, and weigh them against the larger randomized mood-safety datasets rather than in place of them.
Journal of endocrinological investigationn=—HumanAug 18, 2026 - Study · SemaglutideSupported
Semaglutide for primary prevention of major adverse cardiac and cerebrovascular events in patients with type 2 diabetes and comorbid rheumatoid arthritis: a target-trial emulation.
Target-trial emulation is the more disciplined end of observational design, with a new-user framework and propensity matching, but it is still not randomization and residual confounding by prescribing preference is plausible. The composite result rests almost entirely on incident heart failure, with no differences in death, myocardial infarction, or stroke, so it should be read narrowly. The lower rate of DMARD escalation is the novel observation here and is worth watching in a population that has been largely absent from the cardiovascular outcome trials.
European heart journal. Cardiovascular pharmacotherapyn=—HumanAug 17, 2026 - Study · SemaglutideMixed
Efficacy of Luseogliflozin Added to Semaglutide in Patients With Metabolic Dysfunction-Associated Steatohepatitis and Type 2 Diabetes Mellitus: A Randomised, Open-Label Trial.
A negative trial on its primary analysis, and worth reporting as such: with 60 participants and an open-label design, it was underpowered to resolve histological differences of the size observed. The consistent direction across all three histology endpoints plus the biomarker improvements makes this a reasonable signal for a larger study rather than a null result. Note also that semaglutide was dosed at antidiabetic rather than obesity-trial levels, which limits comparison with the MASH-specific programme.
Diabetes, obesity & metabolismn=—HumanAug 17, 2026 - Study · CagrilintideSupported
Maximizing weight loss with cagrisema: a systematic review and GRADE-assessed meta-analysis of randomized controlled trials.
This is the strongest available synthesis on the amylin-plus-incretin combination, and it uses RoB 2 and GRADE rather than pooling uncritically. The head-to-head comparisons against both monotherapies are the load-bearing part: the additive effect is large and consistent across trials, while glycaemic outcomes were heterogeneous. Durability past the trial windows and long-term tolerability remain open, and the authors say so.
Naunyn-Schmiedeberg's archives of pharmacologyn=—HumanAug 17, 2026 - Study · SemaglutideMixed
Review Article: Fibrosis Reversal in Metabolic Dysfunction-Associated Steatohepatitis-The Promise of Emerging Therapeutics.
A narrative review rather than a pooled analysis, so the numbers are drawn from individual trials and not statistically combined. Its most useful line for peptide readers is the caveat the authors put on their own optimism: the link between histological improvement and reduced long-term clinical events remains unproven. Worth carrying as landscape context for where semaglutide now sits in liver-disease management, not as new efficacy evidence.
Alimentary pharmacology & therapeuticsn=——Aug 17, 2026 - Study · TirzepatideWeak / none
Depressed mood and suicidal thoughts reporting with GLP-1 receptor agonists in type 2 diabetes: A WHO VigiBase study.
This disproportionality analysis of the WHO VigiBase (2010-2024) examined reports of depressed mood and suicidal thoughts with GLP-1 receptor agonists in type 2 diabetes. Researchers reported signals for semaglutide, liraglutide and tirzepatide (adjusted reporting odds ratios of 2.13, 1.52 and 1.07 for depressed mood; 6.76, 2.43 and 3.39 for suicidal thoughts), with no signal for suicide attempts or completed suicide and low absolute reporting frequencies. Crucially, this is a spontaneous-reporting method: it detects reporting patterns, not incidence, and cannot establish causation, and concomitant antidepressant use and comorbid depression were more common in the GLP-1 group, pointing to underlying vulnerability or reporting effects. The authors themselves frame this as supporting monitoring in vulnerable patients rather than a uniform drug effect. Read it as a pharmacovigilance flag, not evidence that these peptides cause mood harm.
Journal of affective disordersn=——Aug 15, 2026 - Study · SemaglutideSupported
Once-weekly IcoSema versus once-daily insulin glargine U100 in type 2 diabetes management (COMBINE 4): an open-label, multicentre, treat-to-target, randomised, phase 3b trial.
COMBINE 4 is a well-powered phase 3b randomized trial, and the results land where the mechanism predicts: pairing semaglutide with a once-weekly basal insulin outperformed daily glargine on glucose control, weight, and hypoglycemia risk. The open-label design and Novo Nordisk funding call for the usual careful reading, but the effect sizes — nearly a full percentage point more HbA1c reduction and a 4.6 kg weight difference — are hard to dismiss. For our readers, the signal is semaglutide's continued expansion into once-weekly combination regimens for insulin-naive type 2 diabetes.
The lancet. Diabetes & endocrinologyn=—HumanAug 13, 2026 - Study · TirzepatideWeak / none
Association of Glucagon-Like Peptide-1 Receptor Analogues and Laryngeal Symptoms in Obese Adults.
A genuinely new side-effect signal from a very large matched records database, and one that fits plausibly with known GLP-1 effects on reflux and delayed gastric emptying. The design is retrospective and diagnosis-code-based, so confounding and detection bias — people on these drugs see doctors more often — could account for some of the effect. The tirzepatide null result is intriguing but should not be over-read; it may reflect the shorter time this drug has been on the market. One to note for readers tracking the fuller side-effect picture as these medications scale to tens of millions of users.
The Laryngoscopen=—HumanAug 12, 2026 - Study · TirzepatideSupported
From Pathobiology to Prescribing in Obesity-Driven HFpEF: A Systematic Review and Practical Therapeutic Framework.
This is a synthesis rather than new trial data, but it is a useful marker of where cardiology consensus is heading: incretin peptides are being written into the core HFpEF playbook, not the margins. The semaglutide claims rest on the STEP-HFpEF program and the tirzepatide claims on SUMMIT, both dedicated randomized trials, so the framework stands on reasonably firm ground. The proposed sequencing itself is the authors' judgment and has not been tested head-to-head. Worth covering as a signal of how quickly these agents have moved into mainstream heart-failure thinking.
Current problems in cardiologyn=——Aug 12, 2026 - Study · SemaglutideSupported
Semaglutide/Acarbose combination protects against diabetic nephropathy in rats; a novel insight into modulation of Nrf-2/HO-1& TGF-β/Smad pathways.
A mechanistic rat study with the usual limits: chemically induced disease, four weeks of dosing, and outcomes measured as biomarkers and histology rather than clinical events. The signal is a plausible additive interaction on the Nrf-2/HO-1 and TGF-beta/Smad pathways, not evidence that transfers directly to people. Notable mainly as an early hypothesis for combination regimens in diabetic kidney disease.
International immunopharmacologyn=—AnimalAug 11, 2026 - Study · SemaglutideSupported
EQ-5D Health Utility Gains with Once-Weekly Semaglutide 2.4 mg in People with MASH and F2/F3 Fibrosis: An Analysis of ESSENCE.
A small absolute gain, and the purpose of the analysis is economic rather than clinical: it supplies the utility inputs health-technology assessors need for cost-effectiveness models. The authors are appropriately cautious, since utilities were mapped from SF-36 scores rather than measured directly, using a UK tariff. Useful as supporting quality-of-life evidence in the semaglutide-MASH file rather than a headline efficacy finding.
JHEP reports : innovation in hepatologyn=—HumanAug 11, 2026 - Study · SemaglutideMixed
Semaglutide vs Metabolic and Bariatric Surgery and Cardiovascular Outcomes in Obesity.
A large propensity-matched real-world comparison, and the direction holds across every subgroup and sensitivity analysis the authors ran. The caveats are the usual ones for retrospective cohorts: residual confounding, no randomisation, and semaglutide exposure inferred from refill records rather than measured. Read the results as comparative context for surgical versus pharmacologic paths in obesity care, not as evidence that semaglutide itself raises cardiovascular risk.
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologistsn=—HumanAug 11, 2026 - Study · SemaglutideSupported
AgRP neurons are required for the weight-lowering effects of GLP-1 receptor agonists in female mice.
This inverts a standing assumption about how incretins act centrally: the hunger-promoting neurons appear to be recruited rather than silenced, and the full weight effect depends on them. The sex-dependence is notable given the work was done in female mice and the authors report the requirement varies with sex and diet. Mouse circuit neuroscience does not transfer directly to human dosing, but it points at why long-term response may be shaped by adaptive rather than purely suppressive mechanisms.
Proceedings of the National Academy of Sciences of the United States of American=—AnimalAug 11, 2026 - Study · SemaglutideMixed
Semaglutide as a potential neuroprotective agent for neurological and neurodegenerative disorders: Mechanisms, preclinical evidence, and translational challenges and opportunities.
A timely synthesis of where semaglutide's neuroprotection story stands after the EVOKE setback. The picture is genuinely mixed: preclinical models and observational dementia-risk data point one way, while the phase 3 trials in early Alzheimer's missed their primary cognitive endpoints even as p-tau and inflammation biomarkers improved. The authors' framing — biomarker engagement without demonstrated clinical benefit, possibly a matter of timing or CNS exposure — is a fair reading of the results, and the open questions they list are the right ones.
Molecular biology reportsn=——Aug 10, 2026 - Study · SemaglutideMixed
Perioperative management of GLP-1 receptor agonists: a structured narrative review with considerations relevant to neurosurgical patients.
A practical safety review for the growing number of GLP-1 users heading into surgery, with a focus on neurosurgical settings where aspiration carries outsized consequences. The evidence is two-sided: gastric retention is reliably more common on these agents, particularly during dose escalation or active GI symptoms, yet population-level data have not shown more aspiration events. The authors are candid that neurosurgery-specific evidence is thin and frame their guidance as expert extrapolation rather than formal recommendations — a caveat worth keeping in view.
Journal of endocrinological investigationn=——Aug 10, 2026 - Study · SemaglutideSupported
Efficacy and safety of once-weekly semaglutide 2·4 mg in Chinese adults with overweight or obesity (STEP 12): a randomised, double-blind, placebo-controlled, multicentre, phase 3b trial.
STEP 12 extends the semaglutide 2.4 mg weight-loss evidence base to a Chinese population using locally defined BMI thresholds, which start lower than Western cutoffs. The result — a 9.9 percentage-point placebo-adjusted weight reduction at 44 weeks — lands squarely in line with earlier STEP trials, and the safety profile was familiar, led by gastrointestinal events. It is a Novo Nordisk-funded phase 3b trial, but the design is rigorous and the finding consistent with the wider program.
The lancet. Diabetes & endocrinologyn=—HumanAug 10, 2026 - Study · TirzepatideMixed
Changes in recorded background glucose-lowering therapy after initiation of a GLP-1 receptor agonist or dual GIP/GLP-1 receptor agonist in adults with type 2 diabetes.
This Polish EHR study tracks what happens to background diabetes medications after patients start semaglutide, tirzepatide, or older GLP-1 agents. Additional glucose-lowering substances were recorded more often than they were removed, with tirzepatide starters showing the lowest rate of added therapy at 20.4 percent versus 52.9 percent for dulaglutide. The authors are appropriately careful: these are prescription-record patterns, not proof of actual exposure or a causal difference between agents.
Diabetes research and clinical practicen=—HumanAug 10, 2026 - Study · SemaglutideMixed
AI Patient Support and 6-Month Medication Adherence in a Digital Obesity Program: A Retrospective Analysis.
Staying on semaglutide is a known weak point in commercial weight-loss programs, and this large retrospective analysis tests whether an AI support agent moves the needle. It does not: after adjustment, the AI era was actually associated with slightly higher attrition, while program cost, pauses, and very high-intensity tracking in month one were the dominant predictors of dropping off. The finding is observational and specific to one Australian program, but it is a useful caution against assuming chatbots solve GLP-1 persistence.
Diabetes, obesity & metabolismn=—HumanAug 10, 2026 - Study · SemaglutideMixed
GLP-1-Based Therapies in Pain Medicine: A Narrative Review and Expert Opinion on Obesity-Related Low Back and Knee Pain.
This is an expert-opinion narrative review, not new trial data, so it carries the weight of clinical judgment rather than fresh evidence. Still, it marks a notable shift: pain physicians are now openly debating whether to prescribe GLP-1 class drugs themselves. The authors are careful to position these agents as adjuncts to rehabilitation and standard pain care, not substitutes, and they flag possible anti-inflammatory and cartilage-related effects as promising but unproven.
Current pain and headache reportsn=——Aug 10, 2026 - Study · SemaglutideMixed
Glucagon-Like Peptide-1 Receptor Agonists and Related Incretin Therapies in Dermatology: Patient Selection and Shared Decision-Making.
A narrative review rather than new data, but useful as a window into how GLP-1 therapies are rippling into specialties far from diabetes care. The authors' framing is notably measured: the evidence in dermatology is still evolving, and they lean on shared decision-making rather than firm indications. The catalog of appearance-related effects, particularly facial volume loss and hair shedding, tracks closely with what the community has been reporting anecdotally.
Clinics in dermatologyn=——Aug 9, 2026 - Study · TirzepatideMixed
Impact of GLP-1 Analogue Therapy on Gastrointestinal Outcomes in Patients with Irritable Bowel Syndrome: A Real-World TriNetX Analysis.
The direction of this result runs against the common expectation that GLP-1 agonists worsen gut symptoms, which is what makes it worth a look. The absolute differences are small — roughly two to four percentage points — and the outcomes are diagnostic codes in health records, which capture what a clinician chose to document rather than what a patient actually experienced. Propensity matching cannot rule out that people prescribed these drugs differed in ways the data do not record, including care intensity. Regard it as a signal for a prospective study, not as evidence of benefit in IBS.
Digestive diseases and sciencesn=—HumanAug 8, 2026 - Study · SemaglutideSupported
Effect of semaglutide on kidney outcomes in the SELECT, FLOW, and SOUL trials: a prespecified pooled analysis.
This is a prespecified, participant-level pooling of three phase 3 trials, which puts it near the top of the evidence hierarchy for kidney outcomes with semaglutide. The 16% relative reduction in the primary kidney composite was consistent across a broad cardio-kidney-metabolic population, with and without diabetes, and across oral and injectable dosing. The authors note the effect may not be fully explained by glucose or weight changes, which keeps the mechanism question open. Novo Nordisk funded the analysis, a standard caveat for sponsor-led pooled work.
The lancet. Diabetes & endocrinologyn=—HumanAug 7, 2026 - Study · SemaglutideWeak / none
Initiating semaglutide therapy reduces tobacco cigarette smoking intensity among people with HIV.
This slots into the growing file on GLP-1 drugs and addictive behaviors, alongside earlier signals on alcohol and nicotine. The effect here is real but modest, and the design — a before-and-after comparison in 123 people with no control group — cannot separate the drug's effect from quitting attempts that would have happened anyway. An intriguing data point for the antiaddictive hypothesis; randomized trials now underway will carry more weight.
AIDS (London, England)n=—HumanAug 6, 2026 - Study · SemaglutideSupported
Safety of semaglutide on depressive symptoms among people with HIV in routine clinical care.
The neuropsychiatric question has followed semaglutide since regulators opened reviews into suicidality reports, and this study adds a reassuring data point from a population with a high baseline burden of depression. Within-person comparisons using a validated questionnaire found essentially no overall change, and the largest subgroup shift was an improvement among the most depressed. It is observational and modest in size, but it lands on the same side as most of the recent evidence: no mood-worsening signal.
AIDS (London, England)n=—HumanAug 6, 2026 - Study · TirzepatideSupported
Analysis of the efficacy and safety of liraglutide, semaglutide, and tirzepatide for the treatment of overweight and obesity: a systematic review and network meta-analysis.
This is the most current head-to-head-style comparison of the major weight-management incretins, and its ordering — tirzepatide first, high-dose semaglutide second — matches what the individual trials have suggested. The most practically useful finding is the tempered read on semaglutide 7.2 mg: consistently ranked above 2.4 mg, but with an average incremental benefit the authors themselves call modest, and statistically clear mainly in the diabetes subgroup. Rankings rest on indirect comparison with considerable heterogeneity, so direct head-to-head trials remain the missing piece.
Journal of endocrinological investigationn=—HumanAug 6, 2026 - Study · RetatrutideMixed
Integrating GLP-1 Receptor Agonists Into Dermatology Practice: Safety and Monitoring Strategies.
Useful consolidation of the dermatologic side-effect picture for the GLP-1 class, written for practicing dermatologists but readable as a map of what to watch for. The headline items — alopecia, eruptions, facial volume loss — are drawn from associations of varying strength, and the authors are careful to label the rarer signals as emerging rather than established. A solid reference piece as this drug class moves further into cosmetic and skin-adjacent territory.
Clinics in dermatologyn=——Aug 6, 2026 - Study · SemaglutideMixed
Cup-to-disc ratio in GLP-1 RA Associated Non-Arteritic Anterior Ischemic Optic Neuropathy.
This adds a useful anatomical dimension to the semaglutide-NAION story that has unsettled some GLP-1 users since 2024. The finding that GLP-1-exposed and unexposed NAION patients share the same crowded-disc anatomy suggests the underlying eye structure, not the drug alone, is the dominant risk factor — though the authors are explicit that this study cannot rule the drugs in or out as an independent contributor. For readers worried about the headlines, the practical takeaway is that a simple eye exam can stratify a risk that remains low in absolute terms.
Ophthalmologyn=—HumanAug 5, 2026 - Study · RetatrutideMixed
The role of GLP-1 and GIP receptor agonists in the treatment of diabetes and obesity.
A tidy reference review of incretin pharmacology from a veteran of the drug-mechanism literature. The most useful sections for our readers explain the molecular engineering behind long-acting peptides — fatty acid acylation piggybacking on albumin — and lay out the current approval map, with retatrutide still in trials. Nothing new here, but a well-organized primer on how this drug class actually works.
Pharmacological researchn=——Aug 5, 2026 - Study · SemaglutideSupported
Efficacy and Hypoglycaemia Outcomes With Once-Weekly IcoSema Versus Comparators in Individuals With Type 2 Diabetes by Kidney and Liver Function: A Post Hoc Analysis of the COMBINE 1-3 Trials.
This is a Novo Nordisk-sponsored post hoc slice of the COMBINE trials, asking whether the icodec-semaglutide combination performs consistently in patients with organ impairment — a practical question, since kidney and liver disease are common in type 2 diabetes. The answer is broadly yes, with a few scattered subgroup interactions that do not form a clear pattern. Incremental rather than headline material, but relevant context for semaglutide's expanding combination-therapy footprint.
Diabetes, obesity & metabolismn=—HumanAug 5, 2026 - Study · SemaglutideWeak / none
Impact of semaglutide introduction on the use of triptans: an interrupted-time series.
An inventive use of pharmacy records to probe the emerging semaglutide-migraine question without a trial. The nationwide scale is a strength, and the pattern — reductions concentrated in existing triptan users, women, and younger adults — is internally coherent. But triptan refills are a proxy, not a headache diary, and weight loss itself could account for some of the change. A modest, suggestive signal that strengthens the case for a proper randomized study.
The journal of headache and painn=—HumanAug 5, 2026 - Study · TirzepatideMixed
Safety and efficacy of glucagon like peptide-1 receptor agonism-based therapies in end-stage renal disease: A systematic review and meta-analysis.
End-stage renal disease is exactly the population excluded from the pivotal incretin trials, so any pooled data here fills a genuine gap. The effect sizes look smaller than in the general obesity trials and the heterogeneity at twelve months is high enough to blunt confidence in the point estimates. The authors call their own findings hypothesis-generating and ask for prospective randomised trials, which is the right reading of 388 patients drawn largely from observational reports.
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologistsn=—HumanAug 4, 2026 - Study · TirzepatideSupported
GLP-1 Receptor Agonist Therapy for Obesity Under Japan's Optimal Use Guideline: A Prospective Real-World Study of Lifestyle Pre-Treatment, Time-Limited Treatment Cap, and Post-Cessation Regain.
This is a natural experiment in what happens when a regulator forces discontinuation, and the answer is unambiguous: the weight came back fast. The six-month lifestyle prerequisite also looks counterproductive for post-surgical patients, most of whom gained weight while waiting. With 104 patients and small numbers at the later time points, the precision is limited, but the direction of the post-cessation curve is hard to argue with and speaks to obesity as a chronic condition rather than a fixed course of therapy.
Diabetes, obesity & metabolismn=—HumanAug 4, 2026 - Study · SemaglutideSupported
Resmetirom and semaglutide: next-generation therapies for metabolic-associated steatohepatitis. Opportunities, challenges and issues.
The approvals rested on histological endpoints measured over relatively short trial windows, and the reviewers are direct about what that leaves unanswered: how long therapy should continue, how response should be tracked without repeat biopsy, and whether liver histology changes translate into fewer hard outcomes. That gap between surrogate endpoint and clinical benefit is the central open question for this class in liver disease. Useful as a map of the current evidence, not as new data.
Expert review of endocrinology & metabolismn=——Aug 4, 2026 - Study · SemaglutideWeak / none
Semaglutide-associated NAION: a proposed 'two-hit' model involving buried optic disc drusen and sustained hypohydration.
The optic neuropathy question has followed semaglutide since the 2024 observational reports, and this adds a mechanistic hypothesis rather than epidemiological weight. The hydration measurement is the novel element: a documented 1.9 litre decline in total body water alongside stable fat mass gives a plausible physiological bridge between the drug and an ischaemic optic event. It remains one patient, and the authors themselves ask for prospective studies before any inference about risk.
The British journal of ophthalmologyn=—HumanAug 3, 2026 - Study · TirzepatideWeak / none
Peripheral nerve complications from medications utilised for weight loss: a systematic review.
The evidence base here is case reports, so incidence cannot be estimated and confounding by rapid glycaemic correction is impossible to separate from the drug itself. What the pattern does suggest is a rate-of-change signal rather than a drug-specific one: the median loss was more than a fifth of body weight in roughly five months. The authors recommend adequate nutritional status and avoiding ultrarapid HbA1c and weight decline, which is a reasonable precaution while prospective data are absent.
Journal of neurologyn=——Aug 3, 2026 - Study · SemaglutideMixed
Protecting Musculoskeletal Development and Physical Function in Adolescents on GLP-1 Therapy.
A commentary rather than primary data, this paper raises a plausible concern that GLP-1-associated weight loss in adolescents could attenuate peak muscle and bone accrual. The authors acknowledge longitudinal pediatric evidence is limited, so the musculoskeletal caution is precautionary rather than established. Semaglutide is central to the discussion but the piece offers guidance, not new outcome data.
Childhood obesityn=——Aug 3, 2026 - Study · SemaglutideWeak / none
Early changes in renal function do not appear to mediate cardiovascular risk with dapagliflozin plus semaglutide: a real-world observational hypothesis-generating cohort study.
This small, single-center observational study examines semaglutide combined with an SGLT2 inhibitor and reports neutral, wide-confidence-interval results that the authors label exploratory. Outcomes were not independently adjudicated and the sample is limited, so no firm conclusion can be drawn about the combination. Regard the results as hypothesis-generating pending larger prospective trials.
Expert review of cardiovascular therapyn=—HumanAug 2, 2026 - Study · SemaglutideSupported
Role of Oral Glucagon-Like Peptide-1 Receptor Agonists in Weight Management for Individuals With Overweight or Obesity Without Diabetes: A Network Meta-Analysis of Randomized Controlled Trials.
A network meta-analysis of nine placebo-controlled trials that puts high-dose oral semaglutide at or near the top of the oral GLP-1 field for weight reduction in adults without diabetes. The caveat is structural: rankings rest on indirect comparisons across trials of different lengths and populations, and certainty is graded low to moderate. Still, this is a useful consolidation of where the oral options stand as the pill race with small-molecule agents heats up.
Obesity science & practicen=—HumanAug 1, 2026 - Study · SemaglutideMixed
GLP-1 receptor agonist use and cancer risk in obese nondiabetic adults.
A target-trial-emulation cohort associating GLP-1 receptor agonist use with lower short-term obesity-associated cancer incidence in nondiabetic adults, with semaglutide and tirzepatide analyzed as a subgroup. As an observational analysis it establishes association only, and the authors call for prospective trials to address causality.
Annals of oncologyn=—HumanAug 1, 2026 - Study · SemaglutideWeak / none
Ability of Adults to Correctly Use Grey Market Peptide Semaglutide GLP-1 Receptor Agonists Acquired Without a Prescription.
This small usability study directly concerns semaglutide obtained through the grey market and the safety risks of untrained self-injection, which is squarely relevant to our readers. The sample of 20 is small and the design measures task performance rather than clinical outcomes, so it is best regarded as a cautionary signal. It reinforces the risks associated with unsupervised, non-prescription peptide use.
Public health reportsn=——Aug 1, 2026 - Study · SemaglutideSupported
Semaglutide ameliorates traumatic sepsis-induced cardiac injury by activating the March5-ACSL4 axis to suppress ferroptosis.
This is preclinical mechanistic work in rats and cultured cardiomyocytes, so its reported cardioprotective effect should not be extrapolated to humans. The mechanistic case is well-controlled, with March5 knockdown reversing the benefit and pointing to a specific ferroptosis pathway. Regard it as a promising early signal that motivates further study, not clinical evidence.
Free radical biology & medicinen=—AnimalAug 1, 2026 - Study · TirzepatideWeak / none
Atypical Anorexia Nervosa Developed in a Patient with Severe Obesity and Type 2 Diabetes Following Sleeve Gastrectomy and Postoperative Treatment with Semaglutide and Tirzepatide.
A single case cannot establish causation, and this patient also underwent sleeve gastrectomy, making the peptides' specific contribution impossible to isolate. It is a useful safety-awareness signal that rapid weight loss regimens may coincide with disordered-eating psychopathology in susceptible individuals. Regard it as hypothesis-generating rather than as evidence of a defined risk.
Internal medicine (Tokyo, Japan)n=—HumanAug 1, 2026 - Study · SemaglutideSupported
Real-World Use of Subsidised Semaglutide in Icelandic Children With Obesity: A Nationwide Retrospective Cohort Study.
This real-world cohort adds population-level evidence that semaglutide is associated with weight-trajectory reversal in adolescents with grade 2 obesity. As a retrospective observational study without a control arm, it cannot isolate the medication's contribution from other factors, and the authors note high persistence may partly reflect universal subsidisation. The findings are consistent with trial data and reasonably strong for their design.
Pediatric obesityn=—HumanAug 1, 2026 - Study · SemaglutideSupported
Evidence-informed guidance for the clinical use of oral semaglutide in obesity management.
An evidence-informed clinical guidance article on oral semaglutide for obesity management, drawing on trial data including OASIS 4 and the authors' clinical experience. It is practical and educational in orientation rather than a source of new outcome data, and readers should note it reflects expert guidance alongside trial evidence. The detailed administration requirements for the oral formulation are a useful, concrete takeaway.
Postgraduate medicinen=——Aug 1, 2026 - Study · SemaglutideMixed
Personalization of incretin therapy: can GLP-1 and GIP receptor polymorphisms influence therapy response?
A narrative review synthesizing pharmacogenomic data on how GLP1R and GIPR polymorphisms relate to variability in response to semaglutide and tirzepatide. The associations described are drawn largely from earlier genetic studies and remain hypothesis-generating; the authors note that population-specific prospective data are still limited. Useful as background on why individual responses differ, rather than as clinically actionable guidance.
Journal of the Endocrine Societyn=——Aug 1, 2026 - Study · SemaglutideMixed
Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Non-Arteritic Anterior Ischemic Optic Neuropathy: A Consensus Statement by the North American Neuro-Ophthalmology Society and the American Academy of Ophthalmology.
This consensus statement synthesizes retrospective observational studies examining whether semaglutide and other GLP-1 receptor agonists are associated with non-arteritic anterior ischemic optic neuropathy. The evidence is mixed: some studies report a small possible increase in risk while others find none, and the absolute risk is described as low. It is a useful safety-signal reference, with the authors emphasizing shared decision-making rather than a definitive causal link.
Ophthalmologyn=——Aug 1, 2026 - Study · SemaglutideMixed
Gestational Weight Gain and Pregnancy Outcomes After Semaglutide Exposure.
This propensity-matched retrospective cohort compared pregnancy-exposed users, former users, and non-users using linked medical and pharmacy data. Semaglutide exposure was associated with elevated risks across several pregnancy outcomes, with no significant difference between those who stopped before versus during pregnancy. As an observational study it cannot establish causation, and residual confounding and rebound effects after discontinuation complicate interpretation.
Obstetrics and gynecologyn=—HumanAug 1, 2026 - Study · SemaglutideMixed
Association of Glucagon-Like Peptide-1 Receptor Agonists and Suicidality: A Systematic Review.
This systematic review of adverse-event reports found semaglutide and liraglutide associated with elevated reported odds of suicidal ideation, with tirzepatide showing a nonsignificant trend. Both tracked peptides are genuine subjects and the safety topic is important. Critically, the data are disproportionality signals from spontaneous reports and the authors state no causality is apparent, so this is a hypothesis, not a confirmed risk.
Obesity reviewsn=——Aug 1, 2026 - Study · SemaglutideSupported
Beyond weight loss: multisystem benefits of obesity medications.
This narrative review of obesity medications covers semaglutide and tirzepatide among many agents, summarizing multisystem benefits reported across RCTs and meta-analyses. Both peptides are genuine subjects but sit within a broad drug-class overview rather than a focused analysis. Useful context, though weight-loss-independent effects are described as accumulating rather than settled.
The lancet. Diabetes & endocrinologyn=——Aug 1, 2026 - Study · CagrilintideSupported
Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study.
This large active-controlled phase 3 RCT directly compared cagrilintide-semaglutide against semaglutide monotherapy, giving a clean read on semaglutide as a comparator arm. The combination was statistically superior for HbA1c, though the absolute difference of 0.16 percentage points is small. Novo Nordisk-funded; the semaglutide 2.4 mg arm itself performed strongly, which is directly relevant.
The lancet. Diabetes & endocrinologyn=—HumanAug 1, 2026 - Study · SemaglutideSupported
Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study.
This placebo-controlled phase 3a RCT tested cagrilintide-semaglutide in early type 2 diabetes, showing large HbA1c and weight reductions versus placebo. Semaglutide is a core component, though effects reflect the combination rather than semaglutide alone. The trial was Novo Nordisk-funded and placebo-controlled rather than compared to semaglutide monotherapy, so the isolated semaglutide contribution is not separable here.
The lancet. Diabetes & endocrinologyn=—HumanAug 1, 2026 - Study · SemaglutideSupported
Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Outcomes in Patients With Atherosclerotic Cardiovascular Disease and Obesity Without Diabetes.
A target-trial emulation in nearly 15,000 propensity-matched patients with established atherosclerotic disease and obesity but no diabetes found GLP-1 receptor agonists associated with lower all-cause mortality, myocardial infarction, and heart-failure hospitalization, with no clear stroke effect. The results align directionally with the randomized SELECT trial, which lends credibility, but semaglutide is analyzed within a mixed GLP-1 class rather than alone, and the authors are explicit that observational data cannot establish causation. Strong complementary real-world signal.
The American journal of cardiologyn=—HumanAug 1, 2026 - Study · TirzepatideMixed
Glucagon-Like Peptide-1 Receptor Agonists and Risk of Systemic and Ocular Vascular Complications in Patients With Type 2 Diabetes and Diabetic Retinopathy.
A large propensity-matched cohort (173,216 adults with type 2 diabetes and pre-existing diabetic retinopathy — a high-risk group often excluded from trials) drawn from the TriNetX network. GLP-1 receptor agonist use, with semaglutide and tirzepatide among the six agents in the exposure definition, was associated over two years with lower risk of a broad range of vascular complications: myocardial infarction, heart-failure exacerbation, ischemic stroke, amputation, acute kidney injury and dialysis, and — notably for the retina — less progression to proliferative diabetic retinopathy, fewer retinal vein occlusions, and less neovascular glaucoma. Reassuringly for the ongoing NAION debate, this study found no association with NAION or retinal artery occlusion. Two caveats anchor the reading: semaglutide and tirzepatide are pooled within the class exposure, so agent-specific effects cannot be separated, and the observational design leaves room for confounding by indication despite matching. A meaningful data point on retinal and vascular outcomes, weighted associational.
American journal of ophthalmologyn=—HumanAug 1, 2026 - Study · SemaglutideMixed
Association Between Glucagon-Like Peptide-1 Receptor Agonists and Suicidality: A Systematic Review.
A systematic review of 43 observational studies addressing a high-stakes safety question that drew regulatory attention: whether GLP-1 receptor agonists are associated with suicidal ideation or behaviour. It is largely class-level but semaglutide is named specifically, and the topic belongs above the fold on any peptide safety page. The picture the authors draw is genuinely mixed and, importantly, not causal: some case reports suggested a temporal link to suicidal ideation, cross-sectional and case-control studies pointed toward a lower risk of suicide attempts, and pharmacovigilance and cohort data ran in both directions — some flagging a positive association of semaglutide or liraglutide with ideation, others a paradoxically protective association with attempts or completed suicide. The authors conclude the evidence does not support GLP-1RAs as a cause of suicidality, while sensibly advising baseline and ongoing mental-health assessment. The core caveat is design: these are observational studies subject to confounding by indication and channelling. Weighted as reassuring-but-unsettled.
Diabetes, obesity & metabolismn=——Aug 1, 2026 - Study · SemaglutideMixed
Real-World Effectiveness and 12-Month Persistence of a Semaglutide-Supported Digital Weight-Loss Service: A Retrospective Cohort Study in Germany.
A real-world retrospective cohort (4,535 patients) of a semaglutide-supported commercial digital weight-loss service in Germany. Semaglutide is genuinely the pharmacological anchor, but the study's real subject is adherence and persistence, not the drug's efficacy per se — and its most instructive finding is the gap between conditions. Among the 12% who stayed fully adherent, mean weight loss was 15.13%; but the whole-cohort figure was 9.47% by last-observation-carried-forward and just 2.40% under a worst-case model assuming zero loss for the 88% who dropped out. That spread is the story: real-world effectiveness is heavily conditional on persistence, and attrition was severe in this unsubsidised setting. Notable predictors included higher churn among patients with three or more comorbidities and, interestingly, among prior GLP-1 users. Caveats: retrospective, single commercial program, no control arm, and outcomes shaped by service design as much as by semaglutide. Useful for the real-world-adherence angle, weighted accordingly.
Diabetes, obesity & metabolismn=—HumanAug 1, 2026 - Study · TirzepatideMixed
Comparative Effects of Individual Glucagon-Like Peptide-1 Receptor Agonist-Based Medications on Direct Measurement of Body Composition Among Adults With Overweight or Obesity With or Without Type 2 Diabetes: A Systematic Review and Network Meta-Analysis of Randomised Controlled Trials.
A network meta-analysis of 43 randomized trials (3,379 participants) examining what GLP-1 receptor agonists do to body composition — not just scale weight, but fat versus lean tissue measured directly. It is agent-level, so both tracked peptides surface: subcutaneous semaglutide 1.0 mg weekly and tirzepatide 15 mg weekly are named, alongside liraglutide, as agents associated with statistically significant loss of lean mass from baseline (standardized mean differences roughly -0.50 to -1.09). The headline is nuanced and worth surfacing carefully: these drugs substantially reduced total body fat, fat mass, visceral and subcutaneous fat, and liver fat, but the lean-mass finding — especially at higher doses — is the clinically important caveat the muscle-preservation conversation has been circling. As meta-analytic RCT evidence this ranks well, though network meta-analyses depend on trial comparability and body-composition measurement varied across studies. A substantive, peptide-specific data point on the fat-versus-muscle question.
Diabetes, obesity & metabolismn=—HumanAug 1, 2026 - Study · SemaglutideSupported
Semaglutide Injection in Indian Patients With Type 2 Diabetes Mellitus: A Randomised, Phase III, Active-Controlled Study.
A Phase III randomized non-inferiority trial directly about semaglutide — here comparing a synthetic semaglutide injection against reference-branded Ozempic in 314 Indian adults with type 2 diabetes inadequately controlled on metformin. Over 24 weeks, both arms lowered HbA1c substantially and comparably (Test -2.04%, Reference -1.95%), with the between-group difference (-0.09%) inside the pre-specified non-inferiority margin, and similar effects on glucose, weight, and the proportion reaching HbA1c below 7%. Adverse events were predominantly mild-to-moderate gastrointestinal in both arms, and no anti-drug or neutralising antibodies were detected — a relevant immunogenicity reassurance for a synthetic version. This is a legitimately high-tier design (randomized, active-controlled, multicentre) and directly peptide-specific. The main caveats are the open-label design and the 24-week horizon, which limits inference about durability and rarer harms. The finding is essentially a biosimilar-equivalence result rather than a novel efficacy claim, but it is solid and publishable.
Diabetes, obesity & metabolismn=—HumanAug 1, 2026 - Study · SemaglutideSupported
The Impact of GLP-1-Based Therapies on Cardiovascular Outcomes in Type 2 Diabetes: A Comprehensive Systematic Review and Network Meta-Analysis.
A substantial network meta-analysis — 15 randomized trials, 97,173 participants — assessing cardiovascular outcomes of GLP-1-based therapies in type 2 diabetes. It earns its place partly because it is agent-level, not purely class-level: injectable semaglutide is singled out (alongside efpeglenatide and albiglutide) as having among the most favourable comparative profiles for major adverse cardiovascular events (MACE). Meta-analysis of randomized trials sits high on the evidence hierarchy, and the pooled placebo-controlled signal for reduced all-cause mortality, cardiovascular mortality and MACE is a genuine strength. Two honest caveats: in the network comparison, most between-agent mortality differences were not statistically significant, so ranking semaglutide 'among the best' for MACE should not be overread as a proven superiority over other agents; and network meta-analyses depend on the comparability of the trials being linked. This is credible, well-powered evidence that semaglutide sits within a cardiovascular-favourable class, with agent-level ranking held loosely.
Diabetes, obesity & metabolismn=—HumanAug 1, 2026 - Study · SemaglutideMixed
Semaglutide 25 mg Oral Versus Semaglutide 2.4 mg Injectable: An Indirect Treatment Comparison of Weight Loss Outcomes.
A tightly scoped indirect treatment comparison examining whether oral semaglutide 25 mg and injectable (subcutaneous) semaglutide 2.4 mg deliver similar weight loss — a directly semaglutide-specific question with practical relevance to patients weighing pill versus injection. Bridging the OASIS 4 and STEP 1 placebo-controlled trials via a naive Bucher comparison, the authors report comparable efficacy across weight-change endpoints and responder thresholds, with any numerical differences well below the FDA's 5% threshold for clinical relevance and safety profiles broadly similar. The caveats are the standard ITC ones, and they matter: a naive Bucher approach assumes the two trials are exchangeable, which is never fully true, and the confidence intervals here straddle zero, so 'comparable' means 'no difference detected,' not 'proven identical.' The author affiliations point to manufacturer involvement. Still, the finding is coherent given the shared active molecule and similar systemic exposure. Solid, well-hedged formulation-comparison evidence for semaglutide.
Diabetes, obesity & metabolismn=——Aug 1, 2026 - Study · SemaglutideMixed
Oral Semaglutide 25 mg Versus Orforglipron 36 mg in Obesity: A Population-Adjusted Indirect Treatment Comparison.
This is an indirect treatment comparison (ITC) pitting oral semaglutide 25 mg against the oral small-molecule GLP-1 agonist orforglipron 36 mg for weight loss, stitched together from two separate trials (OASIS 4 and ATTAIN-1) rather than a head-to-head study. The population-adjusted analysis reported greater body-weight reduction with oral semaglutide (about 3 percentage points more) and notably fewer discontinuations, especially for gastrointestinal side effects. Readers should weight ITCs cautiously: comparing across trials — even with individual-patient-data anchoring and population adjustment — assumes the trials are similar enough to bridge, and unmeasured differences in populations, endpoints, and conduct can bias the result. The wide confidence interval on GI-discontinuation odds (up to 96) signals real imprecision. This is a sponsor-relevant comparison (a semaglutide manufacturer-affiliated author set) and, importantly, not a substitute for the head-to-head trial the authors themselves say is absent. Useful directional evidence on semaglutide, appropriately hedged.
Diabetes, obesity & metabolismn=——Aug 1, 2026 - Study · SemaglutideMixed
Risk of Age-Related Ocular Diseases in Non-Diabetic Adults With Obesity Using Glucagon-Like Peptide 1 Receptor Agonists.
A large propensity-matched cohort (68,536 non-diabetic older adults with overweight or obesity) drawn from the TriNetX network, comparing users of GLP-1 receptor agonists — the exposure arm was liraglutide or semaglutide — against users of other weight-loss drugs. Across a five-year horizon, GLP-1RA use was associated with markedly lower incidence of cataract, age-related macular degeneration, ocular hypertension, open-angle glaucoma and dry eye. The relative risks are striking (many around 0.33–0.50), but three cautions matter. First, this is observational: propensity matching reduces but cannot eliminate confounding, and healthier-user or surveillance effects are plausible given who gets prescribed these drugs. Second, semaglutide is pooled with liraglutide, so its individual contribution is not isolated. Third, note the tension with the NAION pharmacovigilance literature — a reminder that different eye endpoints and different methods can point in different directions. A useful signal for the metabolic-eye-health story, weighted as associational.
Diabetes, obesity & metabolismn=—HumanAug 1, 2026 - Study · TirzepatideMixed
Optic Ischaemic Neuropathy in Incretin-Based Therapy: A Comparative Analysis of Real-World Safety Data.
This is a pharmacovigilance study of a live safety question — the reported association between semaglutide and non-arteritic anterior ischemic optic neuropathy (NAION), an eye condition serious enough to have prompted European Medicines Agency review. Using the FDA Adverse Event Reporting System, the authors found a very strong disproportionality signal for semaglutide (355 reports; reporting odds ratio around 94) and smaller but significant signals for tirzepatide and liraglutide, while dulaglutide, exenatide and lixisenatide showed none — arguing against a uniform class effect. The central caveat is fundamental to the method: FAERS is a spontaneous-reporting database, so disproportionality signals reflect reporting patterns, not incidence, and cannot establish causation or absolute risk. Media attention and regulatory notoriety can inflate reporting for a drug like semaglutide. The authors say as much, calling for prospective, ophthalmologist-confirmed studies. Because side effects and risks belong above the fold on our peptide pages, this is worth surfacing — with disproportionality framed carefully as a hypothesis-generating signal.
Diabetes, obesity & metabolismn=——Aug 1, 2026 - Study · TirzepatideMixed
GLP-1 receptor agonist adjunct therapy stabilises Ramadan dysglycaemia in insulin-treated diabetes: a CGM-based study.
A small, focused observational study with a genuinely peptide-specific question: whether adding semaglutide (a GLP-1 receptor agonist) or tirzepatide (a GLP-1/GIP dual agonist) to insulin helps stabilize blood sugar during Ramadan fasting. Using continuous glucose monitoring, researchers compared matched groups of insulin-treated type 2 diabetes patients with and without the add-on peptides. The reported signal is sizeable — time in range 74.4% versus 36.8%, and roughly a 61% reduction in the post-iftar glucose excursion — with no increase in hypoglycemia and no discontinuations. Two important caveats temper the finding: the study is small (18 per arm, 54 total) and observational rather than randomized, so matching on age, HbA1c and BMI cannot fully rule out confounding, and it collapses two distinct drugs into one 'add-on' arm, so we cannot separate semaglutide's contribution from tirzepatide's. The finding is promising and mechanistically coherent, but the evidence weight is modest.
Diabetes research and clinical practicen=—HumanAug 1, 2026 - Study · SemaglutideWeak / none
18 F-FDG PET/CT Five Days Post First Administration of Semaglutide : Side Effects in One Shot.
This case report describes a 60-year-old woman with metastatic breast cancer whose 18F-FDG PET/CT, performed five days after her first semaglutide dose, showed abnormal gastric retention plus gallbladder, colonic and renal uptake patterns interpreted as semaglutide-associated gastroparesis, cholecystitis, colitis and possible dehydration-related acute kidney injury; symptoms resolved with supportive care after withholding the drug. As a single case, causation is inferred from timing and imaging rather than established, and the oncology context complicates attribution. Its real contribution is educational for imaging specialists: GLP-1 agonist side effects can produce striking, potentially misleading uptake patterns on PET/CT. Read it as a clinically instructive image-based observation, not as evidence about the frequency or severity of these effects at population level.
Clinical nuclear medicinen=—HumanAug 1, 2026 - Study · SemaglutideWeak / none
Semaglutide treatment reverses HFD induced hippocampal microglia activation and improves cognitive dysfunction.
In mice fed a long-term high-fat diet, this study tested whether semaglutide affects diet-related brain inflammation and cognition, focusing on microglia and the IGFBPL-1 and PI3K/AKT pathways. Researchers reported that semaglutide improved cognitive performance, reduced hippocampal microglial activation, and lowered Alzheimer's-like markers (phospho-Tau, amyloid-beta), with the neuroprotective factor IGFBPL-1 identified as a key mediator; supplementing IGFBPL-1 reproduced the effects while blocking PI3K/AKT abolished them. These are preclinical findings in a rodent model, mechanistic signals, not clinical evidence, and the abstract is brief. The idea that metabolic GLP-1 agents might influence neuroinflammation is an active research thread, but nothing here speaks to human cognition or dementia. Human studies would be needed before any clinical interpretation; readers should read this as early mechanism, not a brain-health claim.
Tissue & celln=—AnimalAug 1, 2026 - Study · SemaglutideWeak / none
Glucagon-like peptide-1 receptor agonists for weight loss in end-stage heart failure patients considered for heart transplantation.
This small retrospective case series describes nine end-stage heart-failure outpatients with severe obesity who were started on semaglutide as a bridge toward heart-transplant eligibility. Researchers reported median BMI fell from 35.9 to 32.2 kg/m2 (about 5 kg median loss) over a median four months; all nine were subsequently listed and seven underwent transplantation, with no significant adverse effects reported in this series. This is nine patients, uncontrolled and retrospective, the weakest evidence tier, so it demonstrates feasibility and a plausible signal rather than establishing benefit. Selection and the pressures of transplant listing could shape outcomes. Still, it is a clinically interesting use case: weight reduction to cross a BMI listing threshold. Larger, controlled study would be needed before drawing conclusions.
JHLT openn=—HumanAug 1, 2026 - Study · SemaglutideWeak / none
Prolonged Dysesthesia After Massive Accidental Semaglutide Overdose: A Case Report.
This single case report describes a 50-year-old man who accidentally injected 9.6 mg of semaglutide (four times his weekly 2.4 mg dose) through a pen-handling error. Two days later he developed generalised burning dysesthesia and marked fatigue, without the nausea or vomiting usually seen; symptoms resolved within a week without specific treatment and labs were unremarkable. The authors note clinical-trial data hint at a possible dose-related dysesthesia signal with high-dose oral semaglutide. As a case report, this is the weakest evidence tier, one patient, no control, causation inferred from timing, but it is clinically instructive for recognising an unusual, apparently self-limited neurological presentation after supratherapeutic exposure. It should inform vigilance, not general expectations about the drug at normal doses.
Journal of the American College of Emergency Physicians openn=—HumanAug 1, 2026 - Study · SemaglutideSupported
Comparative Effectiveness and Safety of Once-Weekly Injectable Semaglutide Versus Dulaglutide in Individuals with Type 2 Diabetes Managed in UK Primary Care: A Population-Based Cohort Study.
This UK primary-care cohort (IMRD/THIN, 6,616 new users) compared once-weekly semaglutide against dulaglutide in type 2 diabetes using a new-user, active-comparator design with marginal structural models. Researchers reported semaglutide achieved greater one-year reductions in HbA1c (-0.22 percentage points) and bodyweight (-1.92 kg) than dulaglutide, with benefits preserved among the roughly 88% who would not have qualified for the SUSTAIN-7 trial. Early discontinuers had attenuated effects and higher gastrointestinal event rates. As an observational study it cannot fully exclude confounding, but its direction and magnitude echo the SUSTAIN-7 randomised trial, which strengthens confidence. For readers, it is a useful real-world confirmation that semaglutide's edge over dulaglutide extends to routine patients outside strict trial criteria, while the absolute differences are modest.
The Lancet regional health. Europen=—HumanAug 1, 2026 - Study · SemaglutideMixed
Impact of incretin therapies on biochemical and imaging outcomes in metabolic dysfunction-associated steatotic liver disease.
This meta-analysis of 24 randomised trials (2,158 adults) assessed incretin therapies, GLP-1 receptor agonists and emerging dual agonists, in metabolic dysfunction-associated steatotic liver disease. Compared with placebo, the pooled estimates showed reductions in the liver enzymes ALT and AST and in liver fat, with greater enzyme improvement versus insulin and improved non-invasive fibrosis markers. Notably, steatohepatitis resolution was greater than placebo but not insulin, and effects on histologic fibrosis remained inconclusive with wide confidence intervals for liver fat. The abstract does not name specific agents, so this reads as class-level evidence for the family that includes semaglutide and tirzepatide. Benefits appeared larger in patients with diabetes. For readers, this supports a biochemical and imaging benefit signal in fatty liver disease while leaving the harder endpoint, fibrosis reversal, unproven; the authors call for larger, longer trials.
American journal of preventive cardiologyn=—HumanAug 1, 2026 - Study · SemaglutideSupported
Semaglutide and major adverse cardiovascular events in patients with and without DM: A systematic review and meta-analysis.
A systematic review and meta-analysis of 11 randomized trials (12 comparisons; 25,067 participants) of semaglutide versus placebo or active control. Researchers reported a 32% reduction in major adverse cardiovascular events (pooled OR 0.68; 95% CI 0.52 to 0.91), with the estimate stable after removing the STEP obesity or heart-failure trials, and low heterogeneity, consistent with semaglutide's dedicated cardiovascular outcome trials. Importantly, the analysis balances this against harms: higher risk of any GI disorder (RR 1.47), gallbladder events (RR 2.37), and discontinuation for GI intolerance (RR 2.32). Caveats the authors stress: seven of 11 trials were >=75% White with no low-income-country sites, limiting generalizability, and cost-utility estimates ($180,000 to 260,000/QALY) sit above usual willingness-to-pay thresholds. Weight this as solid randomized evidence of cardiovascular risk reduction, tempered by real GI and gallbladder trade-offs, representativeness limits, and cost questions, not an unqualified benefit.
Biomedical reportsn=—HumanAug 1, 2026 - Study · SemaglutideMixed
Hypertensive disorders of pregnancy and GLP-1 receptor agonist timing: a systematic review and meta-analysis.
Semaglutide and tirzepatide are among the class members pooled here, but the analysis reports a class-level estimate rather than peptide-specific results. The pooled odds ratio was non-significant and the constituent studies conflicted, so the finding is best regarded as inconclusive. Larger prospective studies are needed before drawing conclusions about pregnancy risk.
Endocrinen=—HumanJul 31, 2026 - Study · SemaglutideSupported
Effectiveness & safety of semaglutide in weight reduction in obese nondiabetic patients: A systematic review and meta-analysis.
Pooling four randomized controlled trials, this meta-analysis provides high-quality evidence that semaglutide is associated with substantial weight reduction in non-diabetic adults. The safety picture is balanced, with clearly higher rates of nausea, vomiting, diarrhea, and constipation and more discontinuations, though serious events were uncommon. The authors appropriately note that long-term durability data are still needed.
Medicinen=—HumanJul 31, 2026 - Study · SemaglutideWeak / none
Transforming a protease inhibitor into a peptide Guardian: BBI-armed hydrogel beads for Oral delivery of active peptides.
This in-vitro formulation study repurposes the Bowman-Birk protease inhibitor (BBI), co-encapsulating it with semaglutide in hydrogel beads to protect the peptide from digestion for oral delivery. Researchers reported that BBI release inhibited trypsin and extended semaglutide's simulated intestinal residence time from 2.5 to 4 hours, with early BBI release creating a low-protease window for sustained semaglutide release. These are laboratory and simulated-digestion results only, no animals or people, so they demonstrate a delivery concept, not clinical performance or bioavailability. Oral delivery of injectable peptides is a genuinely active problem, and semaglutide is the model cargo here rather than the object of study. Weight this as early proof-of-concept chemistry; whether it translates to meaningful absorption in vivo is untested.
Food research international (Ottawa, Ont.)n=—In vitroJul 31, 2026 - Study · SemaglutideSupported
Impurities and Potential Immunogenicity Associated With Follow-on and Compounded Glucagon-like Peptide-1 Receptor Agonists.
This in vitro analysis is directly relevant to readers considering compounded or follow-on semaglutide, showing measurable impurity and immunogenicity differences versus originator products. The work characterizes laboratory potential rather than confirmed clinical immune reactions, so the real-world consequence remains to be established. It reinforces quality and sourcing concerns around compounded peptide products.
Pharmaceutical researchn=—In vitroJul 30, 2026 - Study · SemaglutideMixed
Prescription Sequence Symmetry Analysis of Glucagon-Like Peptide-1 Receptor Agonists and Neuropsychiatric Conditions.
This prescription-sequence analysis reports semaglutide as the dominant agent and finds inverse associations with later antidepressant and substance-use medication starts. The design detects temporal patterns but cannot establish causation or rule out confounding by indication. Regard the inverse associations as signals warranting dedicated study rather than evidence of a therapeutic effect.
Clinical pharmacology and therapeuticsn=—HumanJul 30, 2026 - Study · SemaglutideMixed
Oral Semaglutide for Alcohol Use Disorder: A Randomized Clinical Trial.
This is a genuine randomized controlled trial of semaglutide for alcohol use disorder, giving it real evidentiary weight for our readers. The primary craving endpoint was not met, though several secondary drinking measures improved, so the result is mixed and the small sample of 50 limits certainty. Regard it as a promising but preliminary signal supporting larger confirmatory trials.
The American journal of psychiatryn=—HumanJul 29, 2026 - Study · SemaglutideSupported
PYY3-36 potentiates Semaglutide-mediated mitochondrial modulation in MASLD.
This controlled rodent study reports that semaglutide, alone and combined with PYY3-36, is associated with reduced hepatic inflammation and improved mitochondrial measures in a MASLD model. As preclinical work, the mechanistic findings should not be extrapolated to humans without clinical confirmation. The additive effect beyond food restriction is a noteworthy early signal for combination approaches.
American journal of physiology. Endocrinology and metabolismn=—AnimalJul 29, 2026 - Study · SemaglutideSupported
Semaglutide improves MASLD and MASH in people with HIV: The SLIM LIVER study.
This phase 2b open-label trial reports that semaglutide is associated with improved MASLD severity in people with HIV, a population with limited prior data. The single-arm design without a placebo control and reliance on a metabolomic surrogate rather than biopsy temper the strength of the conclusion. Regard it as encouraging evidence in a specific population that warrants controlled confirmation.
HIV medicinen=—HumanJul 28, 2026 - Study · SemaglutideMixed
Incretin-based therapies, alcohol and tobacco use, and acute substance-related events: emerging implications for cardiovascular medicine.
This narrative review pulls together randomized and observational evidence linking semaglutide to reduced alcohol-related outcomes, with weaker signals for tobacco and other substances. As a synthesis rather than primary data, it reflects an evolving and still-uncertain evidence base, and tirzepatide-specific data are noted as preliminary. Regard the alcohol association as the most substantiated of the behaviors discussed.
Journal of cardiovascular pharmacologyn=——Jul 28, 2026 - Study · SemaglutideMixed
Dose-dependent effects of oral semaglutide on arterial stiffness and the additive role of SGLT-2 inhibitors in type 2 diabetes.
This single-centre retrospective cohort reports a dose-dependent association between oral semaglutide and improved arterial stiffness (CAVI), amplified by concomitant SGLT-2 inhibitor use. Because the design is observational and retrospective, the findings are associations rather than causal effects, and the difference in downstream cardiovascular events did not reach statistical significance. Read the results as supportive but preliminary evidence on a surrogate vascular marker.
British journal of clinical pharmacologyn=—HumanJul 28, 2026 - Study · SemaglutideMixed
Understanding Biased Signaling and Small-Molecule Binding for Treatment of Type 2 Diabetes Mellitus and Obesity at the Glucagon-Like Peptide-1 Receptor (GLP-1R) Based on Molecular Dynamics Simulations.
This is a molecular dynamics simulation study probing how semaglutide and tirzepatide, alongside small-molecule agonists, engage the GLP-1 receptor at the structural level. Its value is mechanistic insight into receptor binding and biased signaling to inform the design of orally available agonists, not any clinical or safety outcome. Readers should view it as basic pharmacology relevant to how these compounds work rather than how they perform in patients.
Medicinal chemistry researchn=—In vitroJul 27, 2026 - Study · SemaglutideMixed
The cost-effectiveness of second line diabetes medication added to standard therapy in preventing type 2 diabetes related nephropathy in Germany.
This is a Markov-microsimulation cost-effectiveness model, not a clinical trial; its outputs depend on published transition probabilities and cost inputs. It suggests semaglutide and tirzepatide are associated with modeled gains in kidney-related outcomes and survival, with semaglutide remaining cost-effective and tirzepatide constrained by its higher price. Readers should read the numbers as scenario estimates specific to the German statutory system rather than measured patient outcomes.
Cost effectiveness and resource allocationn=——Jul 27, 2026 - Study · SemaglutideMixed
Trends in publicly subsidized and private access to GLP-1 medicines indicated for type 2 diabetes in Australia, 2020-2025.
This population-level utilization study quantifies the sharp rise in semaglutide and tirzepatide use in Australia and highlights that a large share is accessed privately, outside subsidized care. It speaks to real-world demand, supply shortages, and equity of access rather than to efficacy or safety. The findings are descriptive and useful context for readers tracking market and access dynamics.
British journal of clinical pharmacologyn=—HumanJul 27, 2026 - Study · SemaglutideMixed
Semaglutide and Other GLP-1 Agonists for Antipsychotic-Associated Metabolic Dysfunction in Schizophrenia: A Systematic Review and Meta-Analysis.
A PRISMA-registered systematic review and meta-analysis pooling seven RCTs on GLP-1 receptor agonists for antipsychotic-associated metabolic dysfunction. Weight and glycemic signals reached significance, but very high heterogeneity (I-squared=99%), small samples, and low-to-moderate GRADE certainty temper the conclusions. Readers can read the results as an early, cautiously encouraging signal that calls for larger, longer trials before firmer statements are warranted.
Journal of clinical psychopharmacologyn=—HumanJul 27, 2026 - Study · CagrilintideSupported
Efficacy of CagriSema for Reaching Anthropometric Treatment Targets and Cardiometabolic Outcomes: A Secondary, Post hoc Analysis of REDEFINE 1.
A secondary, post hoc analysis of the phase 3a REDEFINE 1 trial examining anthropometric target attainment across CagriSema, its individual components, and placebo. As a post hoc analysis of a secondary endpoint, it is hypothesis-generating rather than confirmatory, but the underlying randomization and clear dose-ordered separation lend weight to the signal. Readers can read the results as support for target-based obesity management and for the combination's added anthropometric effect over its components.
Diabetes, obesity & metabolismn=—HumanJul 26, 2026 - Study · SemaglutideSupported
A Cost-Effectiveness Model of Semaglutide 2.4 mg, Resmetirom 80 mg, and Resmetirom 100 mg Versus Standard of Care for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis in the United States.
A Markov cost-effectiveness model comparing semaglutide 2.4 mg and resmetirom against standard of care for MASH from a US payer perspective. It is an economic simulation rather than new clinical evidence, drawing on prior trials such as ESSENCE and MAESTRO-NASH, so the findings reflect modeling assumptions rather than head-to-head outcomes. Readers can read the results as a health-economics argument for semaglutide's value, not a clinical efficacy comparison.
PharmacoEconomicsn=——Jul 26, 2026 - Study · SemaglutideSupported
Efficacy and Safety of Once-Weekly Semaglutide 2.0 mg as an Add-On to Dose-Reduced Insulin Glargine versus Dose-Titrated Insulin Glargine in People With Type 2 Diabetes and Overweight (SUSTAIN OPTIMIZE).
A phase 3b randomized trial reporting that adding once-weekly semaglutide while reducing basal insulin outperformed titrating insulin alone on glycemic control, weight, and insulin dose, with fewer severe hypoglycemia events. The open-label design is a limitation, and gastrointestinal events were notably higher in the semaglutide arm. Readers can read the results as consistent with the broader SUSTAIN evidence base for semaglutide in type 2 diabetes.
Diabetes, obesity & metabolismn=—HumanJul 26, 2026 - Study · SemaglutideSupported
Nutritional intake changes during GLP-1 receptor agonist therapy: A systematic review and meta-analysis.
This systematic review and meta-analysis pools randomized and crossover trials to quantify how GLP-1 receptor agonists, including semaglutide and tirzepatide, affect measured food intake, finding a consistent reduction in acute energy intake with no heterogeneity in the primary analysis. The signal is robust for standardized meal tests but the authors caution that habitual, real-world intake is underreported and that adding an exploratory phase 1 trial introduced substantial heterogeneity. Read the results as strong evidence on short-term appetite suppression rather than long-term dietary behavior.
Diabetes & metabolic syndromen=—HumanJul 25, 2026 - Study · SemaglutideSupported
Effects of glucagon-like peptide-1 receptor agonists on metabolic outcomes in antipsychotic-treated patients with schizophrenia: A systematic review and meta-analysis.
A PROSPERO-registered meta-analysis of eight randomized trials covering the GLP-1 receptor agonist class, with semaglutide as one of several agents rather than the sole focus. Semaglutide was reported to show the largest weight reduction in exploratory subgroup analysis, though the class as a whole drove the pooled anthropometric and glycemic improvements. Gastrointestinal adverse events were more frequent, and no significant effects were seen on fasting insulin, lipids, or blood pressure.
Schizophrenia researchn=—HumanJul 24, 2026 - Study · SemaglutideSupported
Therapeutic role of semaglutide in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: A systematic review and meta-analysis of placebo-controlled trials with GRADE evidence assessment.
A meta-analysis of placebo-controlled randomized trials, using Cochrane RoB 2 and GRADE, so the evidence base is relatively strong. Semaglutide was associated with lower liver enzymes and roughly double the odds of NASH resolution, alongside weight and HbA1c improvements. The effect on fibrosis stage was not statistically significant, and gastrointestinal adverse events were more common, so read the results as promising but not settled.
Medicinen=—HumanJul 24, 2026 - Study · SemaglutideMixed
Advances in proteomics research related to semaglutide: evidence from humans and animals.
This is a narrative review synthesizing proteomic studies rather than new primary data, and it is descriptive rather than outcome-focused. It offers a useful molecular framework for the biological responses associated with semaglutide, but the authors emphasize small sample sizes and platform heterogeneity as major limitations. The recurring pathway signals are worth noting while remaining preliminary.
Journal of endocrinological investigationn=——Jul 23, 2026 - Study · SemaglutideMixed
Impact of semaglutide on cognitive function in patients with type 2 diabetes and mild cognitive impairment: a 24-month observational study.
This is a prospective observational cohort, not a randomized trial, so unmeasured differences between the semaglutide and control groups could account for part of the association. The reported cognitive improvements and lower rate of progression to dementia are notable signals, but the authors themselves call for randomized trials to confirm them. Read the results as hypothesis-generating for semaglutide's studied neurocognitive effects.
Internal and emergency medicinen=—HumanJul 23, 2026 - Study · SemaglutideMixed
Cost-Effectiveness of Endoscopic Bariatric Therapies Compared with Laparoscopic Sleeve Gastrectomy and Semaglutide.
A health-economic modeling study evaluating obesity interventions from a UK National Health Service perspective, with semaglutide serving as the pharmacotherapy comparator. The findings concern cost-effectiveness rather than clinical efficacy or safety, and depend heavily on modeling assumptions about long-term weight regain. Useful context on how semaglutide compares economically with procedural options, but not a source of new clinical evidence.
Obesity surgeryn=——Jul 22, 2026 - Study · SemaglutideMixed
Therapeutic Potential of Incretin-Based Therapies for Alcohol Use Disorder - A narrative review of available clinical evidence.
A narrative review synthesizing randomized, observational, and preclinical evidence on GLP-1 receptor agonists and alcohol use disorder. Only three randomized trials exist so far, and while observational data consistently point in the same direction, the authors are clear that larger long-term trials are still needed. Semaglutide is named as a leading candidate, though much of the evidence spans the drug class rather than one agent.
Biological psychiatryn=——Jul 22, 2026 - Study · SemaglutideWeak / none
Negative effects of semaglutide on bone in obese mice.
A preclinical study reporting that semaglutide was associated with reduced bone mass and strength in obese male mice, beyond what caloric restriction alone produced, with reversal after discontinuation. As a rodent study confined to male mice, it cannot be extrapolated to people, and the authors explicitly call for clinical investigation. It raises a specific, testable question about skeletal effects that complements the more commonly reported lean-mass concerns.
Cell reports. Medicinen=—AnimalJul 21, 2026 - Study · SemaglutideSupported
Oral Semaglutide and CV Benefits in the SOUL Trial: How Do Baseline or Changes in HbA1c or BMI Affect Clinical Outcomes?
A post hoc analysis of the large, double-blind SOUL cardiovascular outcomes trial of oral semaglutide in high-risk type 2 diabetes. The cardiovascular benefit was more pronounced at higher baseline HbA1c and with greater HbA1c reduction, yet consistent across BMI, suggesting the effect is not simply weight-mediated. As a post hoc subgroup analysis, the interaction findings are hypothesis-generating despite the trial's strong randomized design.
The Journal of clinical endocrinology and metabolismn=—HumanJul 21, 2026 - Study · SemaglutideSupported
Respiratory Adverse Events of Weight-Loss Drugs: A Systematic Review and Meta-Analysis.
A systematic review and meta-analysis of 123 studies assessing respiratory adverse events of weight-loss medications, including semaglutide and tirzepatide. The pooled randomized-trial data, judged at low risk of bias, showed no signal of increased respiratory harm versus placebo, though evidence specific to people with asthma was sparse. This is a reassuring, well-conducted synthesis on a focused safety question.
Annals of the American Thoracic Societyn=—HumanJul 21, 2026 - Study · SemaglutideMixed
GLP-1 Receptor Agonists as a Candidate Treatment for Opioid Use Disorder: From rats to humans.
A review spanning preclinical and clinical evidence on GLP-1 receptor agonists for opioid use disorder, covering semaglutide and tirzepatide among other agents. The animal data are relatively consistent, but human evidence rests on one small liraglutide trial plus observational database analyses, with dedicated semaglutide and tirzepatide trials still ongoing. The authors are appropriately cautious that confirmatory clinical trials are needed.
Biological psychiatryn=——Jul 21, 2026 - Study · SemaglutideSupported
From FLOW to translational positioning in chronic kidney disease: mechanistic complementarity of SGLT2 inhibitors and GLP-1 receptor agonists.
A translational review positioning GLP-1 receptor agonists and SGLT2 inhibitors as mechanistically complementary in chronic kidney disease, anchored on the FLOW trial's kidney-outcome data for semaglutide. The piece is conceptual, synthesizing mechanism rather than reporting new data, and it flags as unresolved whether semaglutide's renal benefit extends to the whole GLP-1 class. Useful for readers interested in the biological rationale behind combination strategies.
Translational research : the journal of laboratory and clinical medicinen=——Jul 21, 2026 - Study · SemaglutideSupported
Association between GLP-1 receptor agonists and alcohol-related hospitalisations among adults with alcohol use disorder: multi-target trial emulation study.
A large retrospective target-trial-emulation study using US electronic health records, reporting that initiation of semaglutide or tirzepatide was associated with lower rates of alcohol-related hospitalization across four emulated trials. The use of active comparators, propensity-score methods, and a negative-control outcome strengthens the analysis, but as an observational study it establishes association rather than causation and remains subject to residual confounding. The consistency of the effect across diabetes and obesity subgroups is notable.
BMJ openn=—HumanJul 21, 2026 - Study · SemaglutideMixed
Safety Signals of GLP-1 Receptor Agonists: A Multi-Method Pharmacovigilance Analysis of FAERS (2018-2025) With Sensitivity-Stratified Prioritisation, Notoriety-Bias Assessment, and Cross-Database Validation.
A rigorous multi-method pharmacovigilance analysis of FAERS data, with semaglutide featuring prominently among the class-level and drug-specific safety signals. Disproportionality analyses of spontaneous reports can flag potential associations but cannot establish incidence, relative risk, or causation, as the authors explicitly note. The reproducibility across a second database (JADER) strengthens the signal detection, but findings should be read as pointers for further study rather than confirmed risks.
Diabetes, obesity & metabolismn=——Jul 21, 2026 - Study · SemaglutideSupported
Pharmacologic Treatments for MASLD: A Review of Efficacy and Safety Considerations.
A narrative review of pharmacologic options for MASLD/MASH in which semaglutide is highlighted, alongside resmetirom, as having among the most consistent evidence for histologic improvement including fibrosis reduction. As a narrative review of eighteen sources, it summarizes rather than pools existing trial data. It offers a useful positioning of semaglutide within the broader metabolic liver disease treatment landscape.
The Journal of pharmacy technology : jPTn=——Jul 20, 2026 - Study · SemaglutideWeak / none
Semaglutide promotes angiogenesis and blood-brain barrier repair after traumatic brain injury via PDGF-BB/PDGFRβ/Ang1/Tie2/VEGF signaling pathway.
This is a single mechanistic study in a mouse controlled-cortical-impact model, so the evidence is preliminary and animal-only. It reports that semaglutide is associated with upregulated PDGF-BB signaling and improved vascular and barrier markers after injury. Human relevance remains undetermined, and the results should be read as hypothesis-generating rather than clinically actionable.
Scientific reportsn=—AnimalJul 18, 2026 - Study · SemaglutideWeak / none
N-terminally modified GLP1R agonists drive G protein bias via extracellular loop 3 displacement.
This is a structural and mechanistic study combining cryo-EM, cell signaling assays, and diet-induced obese mice, not a clinical investigation. Semaglutide appears mainly as an acetylated variant used to probe biased GLP-1 receptor signaling, so the relevance is molecular rather than protocol-level. The findings are associated with a clearer picture of how modifications change receptor signaling and trafficking. Of interest to readers following the mechanistic and next-generation-molecule angle rather than human outcomes.
Cell reportsn=—In vitroJul 17, 2026 - Study · SemaglutideMixed
Glucagon-like peptide-1 receptor agonists in the aging population of people with HIV: emerging evidence and clinical implications.
A narrative review focused on how GLP-1 receptor agonists such as semaglutide are being studied in people with HIV, a population with high cardiometabolic burden. Reported benefits include reductions in weight, glycemia, and visceral and hepatic fat, though the authors caution that HIV-specific and older-population data are sparse and often used lower doses. Concerns around lean-mass loss and bone health are described as limited but generally reassuring. Useful as a signal of an emerging use-context, with the caveat that it is opinion-review rather than trial evidence.
Current opinion in HIV and AIDSn=——Jul 17, 2026 - Study · SemaglutideWeak / none
Effect of semaglutide on hidradenitis suppurativa disease control and quality of life: A case series.
Semaglutide is the direct subject here, studied for its association with hidradenitis suppurativa outcomes. As an uncontrolled case series with no abstract detail available, the evidence is weak and hypothesis-generating. Worth noting as an emerging off-label signal, but not a basis for firm conclusions.
Journal of the European Academy of Dermatology and Venereology : JEADVn=—HumanJul 17, 2026 - Study · SemaglutideSupported
Management of patients with cardiovascular disease and overweight/obesity: expert opinion on semaglutide use.
This is an expert-opinion consensus paper rather than new primary data, so it reflects panel judgment layered on existing evidence such as the SELECT trial. Semaglutide is discussed as a disease-modifying option associated with cardiovascular risk reduction largely independent of weight loss. Readers should note the guidance is Italy-specific in its care-model and reimbursement framing. Useful as context on how specialists are integrating semaglutide into secondary prevention.
Nutrition, metabolism, and cardiovascular diseases : NMCDn=——Jul 16, 2026 - Study · SemaglutideSupported
Semaglutide vs. liraglutide and incidence of diabetes and cardiovascular disease: A target trial emulation using real-world data.
This target-trial emulation matched over 57,000 GLP-1 users and is directly relevant to semaglutide's metabolic profile. The lower diabetes incidence versus liraglutide is a meaningful signal, though the effect emerged only after the first six months and the cardiovascular comparison was underpowered. Observational design means residual confounding cannot be ruled out.
British journal of clinical pharmacologyn=—HumanJul 16, 2026 - Study · SemaglutideMixed
Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial.
A large, well-controlled phase 2 RCT in which semaglutide is a core study arm, not an incidental mention. The combination with zalfermin failed to beat placebo on the fibrosis endpoint, but semaglutide 2.4 mg alone was associated with a nominally significant improvement, prompting the authors to flag it for further study in the F4c cirrhosis population. Gastrointestinal adverse events were common, consistent with the known profile.
The lancet. Gastroenterology & hepatologyn=—HumanJul 15, 2026 - Study · SemaglutideWeak / none
Vutiglabridin overcomes the GLP-1 RA-associated weight-loss plateau to achieve normal body weight.
This is a mouse study whose primary subject is vutiglabridin, a novel oral compound, with semaglutide serving as the comparator and combination partner. The reported signal is that adding vutiglabridin was associated with overcoming the weight-loss plateau seen with semaglutide alone. As preclinical animal work, it offers mechanistic direction only and does not speak to outcomes in people.
International journal of obesity (2005)n=—AnimalJul 15, 2026 - Study · SemaglutideMixed
Semaglutide and Exercise Synergy in Obesity: Preserving Muscle Mass and Uncovering Organ Crosstalk.
This mouse study found semaglutide reduced both fat and lean mass, and that adding exercise partially preserved muscle while improving metabolic and vascular outcomes. Semaglutide is a genuine subject and the lean-mass finding is a relevant caveat for the drug class. Evidence is preclinical, so conclusions should not be extrapolated directly to people.
Diabetes & metabolism journaln=—AnimalJul 15, 2026 - Study · SemaglutideMixed
Semaglutide and Resmetirom in Patients With Metabolic Dysfunction-Associated Steatohepatitis and Fibrosis: An Exploratory Indirect Comparison.
This is an indirect, cross-trial comparison of semaglutide and resmetirom for MASH with fibrosis, not a head-to-head trial. Indirect comparisons carry substantial methodological caveats and cannot establish superiority. Semaglutide is a genuine subject, so it carries moderate signal, but conclusions should be read cautiously given no abstract detail and the exploratory design.
Diabetes, obesity & metabolismn=——Jul 15, 2026 - Study · SemaglutideWeak / none
Thermosensitive Hydrogels for Sustained Semaglutide Release: Overcoming Weight Loss Plateau in Diet-Induced Obese Rats.
This is a drug-delivery formulation study using a thermosensitive hydrogel to extend semaglutide release in obese rats. Semaglutide is genuinely the subject, but the work is about the delivery system rather than the drug's efficacy, and results are preclinical. Weight for the peptide itself is modest.
Pharmaceutical development and technologyn=—AnimalJul 15, 2026 - Study · SemaglutideWeak / none
Incretin-Based Therapies in Doxorubicin-Induced Cardiotoxicity: A Systematic Review of GLP-1 and Dual GIP/GLP-1 Agonists.
This review pools thirteen small rodent studies and reports incretin therapies were associated with better left ventricular function during doxorubicin exposure. Semaglutide and tirzepatide each appear in only a handful of animal studies, and the authors rate certainty as low-to-very-low. Findings are explicitly hypothesis-generating with no human data, so weight is limited.
Cardiovascular toxicologyn=——Jul 15, 2026 - Study · SemaglutideSupported
Cancer risk of glucagon-like peptide-1 receptor agonists for obesity: comparison with bariatric surgery and other weight-loss drugs.
This large TriNetX cohort compared semaglutide and tirzepatide users against bariatric surgery and other weight-loss drugs, finding therapeutic-dose use associated with lower colorectal and pancreatic cancer incidence and no increased cancer risk. Both tracked peptides are genuine subjects. As a retrospective, propensity-matched study it supports safety reassurance but cannot prove causation, and any-dose effects were not significant.
Journal of gastrointestinal surgeryn=—HumanJul 14, 2026 - Study · SemaglutideContradicted
Comparative Effectiveness of Glucagon-like Peptide-1 Receptor Agonists Versus Oral Agents for Insulin Discontinuation in Type 2 Diabetes: A Target Trial Emulation.
A well-designed target-trial emulation finding no advantage for GLP-1RAs over SGLT-2i or DPP-4i for insulin discontinuation in type 2 diabetes. Semaglutide made up most of the GLP-1RA arm but was not analyzed separately, and the cohort was overwhelmingly older male veterans, limiting generalizability. This tempers expectations that GLP-1RAs help patients come off insulin, a useful counterweight to the enthusiasm around this class.
Annals of internal medicinen=—HumanJul 14, 2026 - Study · SemaglutideWeak / none
Semaglutide and Risk of Adult-Onset Seizure: A Target Trial Emulation.
Using a research database, investigators emulated a target trial comparing semaglutide against SGLT2 inhibitors and other glucose-lowering drugs for the risk of adult-onset seizure in type 2 diabetes. Researchers reported semaglutide initiation was associated with lower seizure risk (weighted HR 0.44 vs other GLDs; 0.48 vs SGLT2i), with 4-year risk differences around 1.5-1.8% and NNT values (number needed for one to benefit) of 70 and 131; mediation through HbA1c and BMI was minimal. This is an observational emulation, graded Class II, and the authors are candid about low event counts, short follow-up and residual confounding, any of which could move the estimate. Read it as a hypothesis-generating association rather than proof of a neuroprotective effect. It is an intriguing addition to the pleiotropic-effects literature, best confirmed by prospective study.
Neurologyn=—HumanJul 14, 2026 - Study · SemaglutideMixed
GLP-1 Receptor Agonists and Fertility: What Is Known So Far?
A narrative review of GLP-1 receptor agonists in fertility and PCOS care, where most of the reproductive-outcome evidence comes from liraglutide and exenatide rather than the peptides we track. Semaglutide and tirzepatide appear mainly around safety and washout guidance, and narrative reviews carry selection risk. The pregnancy-contraindication and washout points are the most durable takeaways for our readers.
JBRA assisted reproductionn=——Jul 13, 2026 - Study · SemaglutideMixed
Treatment Patterns and Experienced Effects of Semaglutide for Weight Management Among Adult Users in Denmark: A Community Pharmacy-Based Cross-Sectional Survey.
A cross-sectional pharmacy survey documenting real-world semaglutide dosing patterns and self-reported outcomes for weight management. Weight-loss figures are self-reported and the design is observational, so they describe association and user experience rather than controlled efficacy. The finding that many stay at 1 mg with comparable reported results is a useful, if hypothesis-generating, signal on individualized dosing.
Diabetes, obesity & metabolismn=—HumanJul 13, 2026 - Study · SemaglutideWeak / none
Revision Medialization Thyroplasty for Glottic Insufficiency Amid Rapid Weight Loss on Semaglutide.
A single case report linking rapid semaglutide-associated weight loss to vocal fold atrophy and glottic insufficiency, resolved with revision thyroplasty. It adds an unusual soft-tissue observation to the growing catalog of downstream effects of fast weight loss, but with one patient and an obvious confounder (prior thyroplasty nine years earlier) the causal thread is loose. A minor safety curiosity rather than a substantive finding.
The Laryngoscopen=—HumanJul 13, 2026 - Study · SemaglutideWeak / none
Sustained metabolic control in latent autoimmune diabetes in adults (LADA) with semaglutide therapy in a patient with multiple autoimmune comorbidities: a case report and literature review.
A single-patient case report describing durable glycemic control, weight loss, and preserved beta-cell function over five years on semaglutide in latent autoimmune diabetes (LADA). The authors' own literature review turned up only two comparable case reports, so this is genuinely novel but carries the weight any single anecdote does: no control, no causal claim. Useful color on an under-studied indication, but readers should not generalize from one patient.
Acta diabetologican=—HumanJul 13, 2026 - Study · SemaglutideMixed
How Low Could Semaglutide Prices Fall? An Analysis of Production Cost and Implications for Global Access.
A cost-plus pricing analysis projecting that generic semaglutide could reach $28-$140 per person-year for injectables once patents lapse in 2026, with access potentially opening in 162 countries. This is a market and access study, not a clinical one, so no efficacy question is at stake, but it is highly relevant to anyone tracking the peptide market's economics. The estimates rest on Indian API shipment data and modeling assumptions, and device costs and secondary patents are flagged as real limits on the rosy access picture.
Obesity (Silver Spring, Md.)n=——Jul 12, 2026 - Study · SemaglutideWeak / none
Semaglutide alters behaviour and nucleus accumbens oscillatory activity in healthy mice.
A mechanistic mouse study showing semaglutide shifts behavior and nucleus accumbens oscillations even in healthy, non-diseased animals. As a single small animal study it is early-stage and does not translate directly to humans, but it is genuinely about semaglutide and adds to the growing interest in its central-nervous-system effects. Frame it as preclinical signal, not clinical evidence.
Molecular brainn=—AnimalJul 11, 2026 - Study · TirzepatideSupported
Tirzepatide compared with semaglutide in obesity disease: a subpopulation analysis applying Japan Society for the Study of Obesity criteria in the global SURMOUNT-5 trial.
A prespecified subpopulation analysis of the randomized SURMOUNT-5 trial, applying Japanese obesity criteria, found tirzepatide produced markedly greater weight loss than semaglutide (roughly 20% versus 13% at 72 weeks) with a comparable, mostly gastrointestinal safety profile. As a head-to-head RCT-derived comparison this carries real weight, though it is a subgroup of 383 and industry-sponsored, so the headline gap should be read as consistent with rather than independent confirmation of the main trial. Strong signal on relative efficacy for peptide readers.
Current medical research and opinionn=—HumanJul 11, 2026 - Study · TirzepatideSupported
Lower fall and femoral fracture risks with semaglutide and tirzepatide compared with DPP-4 inhibitors in older adults with type 2 diabetes.
A large retrospective cohort using TriNetX and propensity-score matching found semaglutide and tirzepatide associated with roughly halved femoral fracture risk and about a third lower fall risk versus DPP-4 inhibitors in older adults with type 2 diabetes. The effect sizes are consistent across both drugs and several subgroups, which strengthens the signal, but this is observational and residual confounding remains possible. Solid hypothesis-generating evidence for a musculoskeletal benefit beyond glucose control, not proof of causation.
Osteoporosis internationaln=—HumanJul 11, 2026 - Study · SemaglutideSupported
Semaglutide cardiovascular outcomes align more closely with attained dose than achieved weight loss.
A retrospective analysis of nearly 47,000 patients found semaglutide's cardiovascular benefit tracked more closely with attained dose than with achieved weight loss, supported by transcriptomic evidence of GLP1R expression in cardiac tissue. The dissociation from weight loss is an intriguing mechanistic argument for a direct cardiac effect, but the design is observational, dose and adherence are entangled with healthier-patient confounders, and the near-perfect dose-weight correlation complicates attribution. Noteworthy and hypothesis-generating, best read as a signal rather than settled causation.
NPJ cardiovascular healthn=—HumanJul 10, 2026 - Study · SemaglutideWeak / none
Partially reversible bilateral non-arteritic anterior ischemic optic neuropathy and branch retinal artery occlusion following semaglutide use. a case report.
A single case report describing bilateral non-arteritic anterior ischemic optic neuropathy with branch retinal artery occlusion emerging after eleven months of semaglutide and partly recovering after discontinuation. It adds to an active safety conversation about GLP-1 agonists and NA-AION, and the temporal dechallenge pattern is suggestive, but one patient cannot establish causation. A relevant safety data point that belongs alongside the larger pharmacovigilance signal rather than standing on its own.
BMC ophthalmologyn=—HumanJul 10, 2026 - Study · TirzepatideWeak / none
Influence without medical expertise: a social network analysis of Mounjaro discussions on twitter (X).
This is a social-media discourse study, not clinical research: an observational social-network and sentiment analysis of 5,566 tweets about Mounjaro (tirzepatide) collected over roughly six weeks in early 2025. It is genuinely about a tracked peptide, but it measures conversation, not the drug's effects. The findings are sociologically useful and squarely on-brand for a property covering community synthesis: the most influential voices were non-medical — public figures and patients sharing personal experiences — sentiment ran positive (62.6% favorable), and discussion clustered around weight loss, brand comparisons (Ozempic, Wegovy), and diabetes. The authors' own point is the important one: non-experts dominate online tirzepatide discourse, underscoring the need for evidence-based communication. Caveats: a single platform, a short window, automated sentiment tools that miss nuance and sarcasm, and no clinical outcomes at all. Read this as a snapshot of the information environment around tirzepatide, not as evidence about the medication itself.
Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Societyn=——Jul 10, 2026 - Study · SemaglutideMixed
Pharmacological Therapy for Metabolic Dysfunction-Associated Steatotic Liver Disease in a New Era for Obesity and Metabolic Medicine: A State-of-the-Art Review.
This state-of-the-art narrative review maps the drug landscape for metabolic dysfunction-associated steatotic liver disease (MASLD) and its inflammatory form, MASH. Semaglutide is genuinely foregrounded: the authors note it has received conditional approval for MASH alongside resmetirom, and they position incretin-based therapies as a potential backbone of complication-centric obesity management. That gives the peptide real standing in the piece. But as a review it summarizes rather than tests, and it is candid that pharmacological therapy for MASH-related cirrhosis remains an unmet need — the approvals apply to earlier disease, not advanced fibrosis. For readers, the value is context: semaglutide's role in liver disease is now regulatory reality, not just trial signal, but it sits within a crowded and evolving field (FGF-21 analogues, resmetirom, other incretins) and is not a stand-alone answer. Weight this as a credible orientation to where semaglutide fits in MASH care, not as new efficacy data.
Journal of obesity & metabolic syndromen=——Jul 9, 2026 - Study · TirzepatideMixed
Special Considerations When Using GLP-1 Receptor Agonists in the Treatment of Obesity and Diabetes Mellitus Type 2 in Older Adults.
This is a narrative review on using GLP-1 receptor agonists — semaglutide and tirzepatide named among them — in older adults with obesity or type 2 diabetes. As a review it synthesizes rather than generates evidence, so its role for readers is orientation, not new data. Its most useful contribution is framing the trade-offs specific to older patients: the authors flag sarcopenia (age-related muscle loss) as a real concern when pursuing weight loss in this group, alongside polypharmacy and cumulative side-effect burden. They note that while large trials support these drugs for lowering HbA1c and body weight and for renal and cardiovascular benefit, direct evidence in older adults specifically remains limited. That gap is the honest headline. Both tracked peptides appear, but only as class exemplars — the review does not isolate their individual geriatric profiles. Weight this as a balanced clinician-facing overview of cautions, not as a peptide-specific evidence update.
Advances in therapyn=——Jul 9, 2026 - Study · TirzepatideMixed
Patterns of Use for GLP-1 Receptor Agonists in a Weight Management Cohort: A Military Health System Database Analysis of Active Duty Service Members From 2021 to 2025.
This retrospective cohort tracks how long people actually stay on weight-management injectables — a real-world adherence question that matters as much as trial efficacy. Among 10,649 active-duty service members starting liraglutide (Saxenda), semaglutide (Wegovy), or tirzepatide (Zepbound) between 2021 and 2025, tirzepatide showed the highest one-year persistence (81.9%) and adherence, semaglutide was intermediate (70.7%), and liraglutide trailed badly (34.2%). Adjusted models put tirzepatide's discontinuation hazard 33% below semaglutide's. Both tracked peptides are central here. Caveats: this is observational, so persistence differences may reflect dosing schedule (weekly vs daily), supply and formulary dynamics, tolerability, and patient selection rather than any intrinsic superiority — and the cohort is a specific, relatively young and health-screened military population, which limits generalizability. It measures whether people keep taking the drug, not how much weight they lost. Read it as useful real-world adherence signal favoring the weekly agents, not as comparative efficacy evidence.
Military medicinen=—HumanJul 9, 2026 - Study · TirzepatideWeak / none
Association of Glucagon-Like Peptide-1 Receptor Agonists With Menstrual Events in Reproductive-Aged Patients.
This pharmacovigilance analysis is directly about both tracked peptides. Using FDA adverse-event reports through March 2026, researchers ran disproportionality and Bayesian analyses in women aged 12–55 and found that semaglutide had the broadest signal — disproportionate reporting of heavy menstrual bleeding, intermenstrual bleeding, clots, oligomenorrhea, and anovulatory cycles — while tirzepatide showed narrower signals (intermenstrual bleeding, clots) and liraglutide showed none. The critical caveat is the data source: FAERS is a spontaneous-reporting system, so it can flag a possible association but cannot establish incidence, causation, or whether the drug or the underlying weight/metabolic change drives the pattern. Reporting is subject to notoriety and stimulated-reporting bias — heavily publicized drugs generate more reports. So this is a signal-generation study, not confirmatory. Its practical value is that it supports raising menstrual health in counseling for reproductive-aged patients on these agents. Weight it as a hypothesis worth prospective study, not as established risk.
Obstetrics and gynecologyn=—HumanJul 9, 2026 - Study · SemaglutideWeak / none
GLP-1 regulates osteo-adipogenic fate of BMSCs via HIF-2-AKT signaling and supports trabecular bone in glucocorticoid-induced osteoporosis.
This is a mechanistic study combining cell-culture work with a mouse model, and semaglutide is used directly as the in-vivo probe — so it is genuinely about the peptide, not a passing class-mention. Researchers report that GLP-1 shifted bone marrow stem cells away from becoming fat cells and toward becoming bone cells, acting through the PI3K-AKT and HIF-2α pathways. In mice with steroid-induced bone loss, semaglutide was associated with improved trabecular bone mass, and that association largely disappeared when the HIF-2α gene was knocked out — a clean mechanistic link. The important caveat is altitude: these are preclinical findings in cells and rodents, not clinical evidence in people. Semaglutide's human evidence base sits in metabolic and weight endpoints; skeletal effects in humans are not established, and lean/bone-mass loss during rapid weight loss is a live clinical question that this mouse work does not resolve. Read this as a hypothesis about mechanism, not as guidance on bone health. Human data are needed before any clinical conclusion.
Stem cell reportsn=—AnimalJul 9, 2026 - Study · SemaglutideSupported
Pharmacological Interventions for Weight Reduction in Patients With Schizophrenia Treated With Antipsychotics: A Systematic Review and Network Meta-Analysis.
Published in JAMA Psychiatry, this systematic review and network meta-analysis (95 studies, 39 interventions, pooled N=5,898) ranks drugs for antipsychotic-induced weight gain in schizophrenia-spectrum disorders — a clinically important, cardiometabolically high-risk problem. Semaglutide is directly evaluated and topped the list, associated with the largest weight reduction (−10.98 kg; 95% CI −13.33 to −8.62) at moderate certainty, and among the few agents reaching a clinically meaningful ≥5% change. That is a strong relative signal from a high-quality synthesis using CINeMA certainty grading. The load-bearing caveat is sparse direct data: the semaglutide estimate rests on just three trials (k=3), so the wide confidence interval reflects genuine uncertainty despite the moderate rating, and the population is specific. Reassuringly, the review reported no major excess of gastrointestinal dropout across interventions. Read this as credible, appropriately-hedged evidence that semaglutide is a leading option for weight in this population, grounded in few trials that warrant confirmation.
JAMA psychiatryn=—HumanJul 8, 2026 - Study · SemaglutideWeak / none
GLP-1R and GIPR crosstalk modulates insulinotropic signaling pathways.
This is molecular pharmacology, and semaglutide is used directly as a probe — so it is genuinely about the peptide at the mechanistic level. Working in human pancreatic islets and cell systems with phosphoproteomics and molecular dynamics, researchers report that GLP-1 and semaglutide, but not exendin-4, drive the GLP-1 receptor and the GIP receptor to physically pair up (heterodimerize) via specific transmembrane contacts, and that dimerizing versus non-dimerizing agonists switch on different downstream signaling. They also note semaglutide and exenatide show distinct patterns in FDA-reported safety data. The value here is explanatory: it offers a receptor-level rationale for why incretin drugs differ and informs next-generation dual-agonist design. The essential caveat is altitude — this is in-vitro and computational work on receptors and cells, not a clinical study. It explains mechanism; it does not measure patient outcomes. Read it as a molecular insight into how semaglutide engages receptor crosstalk, with human clinical relevance still to be established.
Cell chemical biologyn=—In vitroJul 8, 2026 - Study · RetatrutideSupported
Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis.
This is a major, GRADE-rated network meta-analysis — 262 RCTs, 99,791 participants, 19 drugs — and it puts both tracked peptides at the center of the obesity-pharmacotherapy map. With moderate-to-high certainty, tirzepatide showed the largest one-year weight loss (−14.9% vs lifestyle), with subcutaneous and oral semaglutide also substantial (−9.8% and −10.9%). Crucially, subcutaneous semaglutide was the only drug associated with reduced all-cause mortality and myocardial infarction, and both semaglutide and tirzepatide were associated with lower heart-failure risk — though the mortality/MI estimates are driven by cardiovascular-outcome trials in high-risk populations, an important scoping caveat. The analysis is admirably balanced on harms: larger weight loss generally came with more discontinuation and gastrointestinal events, and tirzepatide, while cutting fat mass most (−25.7%), also cut lean mass most (−8.3%) — a real signal on muscle loss. No drug meaningfully improved quality of life. This is high-quality synthesis and among the most useful single references for weighting these peptides. Read the benefit and harm columns together.
BMJ (Clinical research ed.)n=—HumanJul 8, 2026 - Study · SemaglutideMixed
Glucagon-like peptide-1 receptor agonists for weight management in mental illness: a network meta-analysis.
This network meta-analysis of nine RCTs (595 participants, mostly schizophrenia-spectrum) examines GLP-1 receptor agonists for weight in people with serious mental illness — a group at high cardiometabolic risk, often from antipsychotic-related weight gain. Semaglutide is directly evaluated and posts the largest weight effect versus control (standardized mean difference −2.10), with associated reductions in BMI, waist circumference, fasting glucose, and HbA1c, alongside the expected higher gastrointestinal side effects (nausea, vomiting, constipation). Both semaglutide and liraglutide beat control on weight. The authors are appropriately restrained: they call semaglutide's top ranking uncertain because the networks are sparse, heterogeneity is substantial, and evidence is largely indirect. With only 595 participants across nine trials, confidence intervals are wide and the semaglutide arm rests on limited data. Read this as an encouraging but preliminary signal that semaglutide can address weight in a high-need psychiatric population, not as settled comparative evidence. Larger dedicated trials are needed.
Translational psychiatryn=—HumanJul 8, 2026 - Study · SemaglutideMixed
Real-World Use of Semaglutide for Weight Management: Dose Titration, Discontinuation Patterns and Weight Changes.
This small real-world cohort is squarely about semaglutide for weight management and usefully documents how everyday practice diverges from the trial protocol. In one Danish general practice, 206 adults (76% women, mean weight 105 kg) were prescribed semaglutide between 2022 and 2024. By 12 months, 38% had permanently stopped and another 15% had paused — only about half remained on treatment — and among continuers many stayed on lower-than-labeled maintenance doses (40% at ≤1.0 mg/week). Yet those who stayed on lost a substantial 13.6% of body weight, close to trial-level results. The honest tension: real-world titration is slower and doses lower than the label, and discontinuation is common, but persisters still did well. Caveats are significant — a single-practice sample of 206 is small, the weight-change figure covers only continuers with paired measurements (survivor bias), and there's no comparator. Weight it as an instructive snapshot of real-world semaglutide use, not as generalizable effectiveness data.
Diabetes, obesity & metabolismn=—HumanJul 8, 2026 - Study · TirzepatideSupported
Neuropsychiatric Outcomes With Tirzepatide, Semaglutide, and Other GLP-1 Receptor Agonists.
This large real-world cohort speaks directly to a well-publicized worry: whether semaglutide and tirzepatide carry neuropsychiatric risk, including depression and suicidal ideation. Drawing on a federated network of over 192 million patients with propensity-matched, new-user designs (85,546 pairs for tirzepatide vs semaglutide; 80,115 for semaglutide vs other GLP-1 RAs), researchers found the two tracked peptides had comparable psychiatric risk over two years, with only a small, cautiously-flagged Year-2 anxiety signal for tirzepatide. Semaglutide was associated with lower rates of depression, anxiety, and suicidal ideation than earlier-generation GLP-1 RAs. Both peptides are central. The caveats are real: this is observational, so residual confounding by indication and channeling (who gets prescribed what) can bias comparisons; coded diagnoses undercount psychiatric events; and the tirzepatide-vs-other-GLP-1 comparison isn't shown. Reassuring as a signal against a heightened neuropsychiatric hazard, but not a substitute for randomized safety adjudication. Weight it as supportive real-world evidence, appropriately hedged.
Diabetes, obesity & metabolismn=—HumanJul 8, 2026 - Study · TirzepatideContradicted
Preventative semaglutide and tirzepatide treatment does not alter disease progression in the 5xFAD mouse model of Alzheimer's disease.
This is a directly peptide-specific preclinical study, and notably a negative one — worth surfacing precisely because the field's momentum runs the other way. Working in the 5xFAD mouse model of Alzheimer's, researchers tested semaglutide (a GLP-1 receptor agonist) and tirzepatide (a GLP-1/GIP co-agonist) as preventive treatments. Both did what these peptides reliably do — lowered body weight and improved glucose tolerance — but the authors report no measurable effect on memory or learning tasks, amyloid-beta plaque burden, or glial activation, even when treatment began before overt pathology and continued for months. A companion inflammation challenge showed no change in microglial activation. These are preclinical findings in a genetically engineered mouse model; human data would be needed before any clinical conclusion. Still, the result is a useful counterweight to enthusiasm about incretin therapies as Alzheimer's disease-modifiers, and it comes from a well-designed, temporally staged experiment.
Cell reports. Medicinen=—AnimalJul 7, 2026 - Study · SemaglutideWeak / none
Sirtuin 1 deficiency mediates chronic kidney disease-induced inflammaging cardiovascular calcification.
This mechanistic study of chronic kidney disease-associated aortic valve calcification integrates human data (UK Biobank associations, single-cell sequencing, Mendelian randomisation) with cell and animal experiments, centring on the SIRT1-NF-kB-NLRP3 pathway. Semaglutide enters late: a screen of anti-diabetic compounds identified it as a modulator that, in vitro and in vivo, restored SIRT1/NLRP3 balance and attenuated calcification. That is a preclinical mechanistic signal, not clinical evidence; human trials would be needed before drawing conclusions about valve disease. Semaglutide is one finding within a broader pathway paper rather than its main subject, so weight this modestly: it hints at a possible cardiovascular mechanism beyond glucose and weight, consistent with the field's interest in pleiotropic GLP-1 effects, but it is early and indirect.
Molecular biomedicinen=—AnimalJul 7, 2026 - Study · SemaglutideSupported
Semaglutide Injection Once-Weekly for Weight Management in Adults: Results From A Randomized Phase III, Active-Controlled Study.
A 24-week randomised Phase III non-inferiority trial (270 adults with obesity or overweight plus a comorbidity, 21 Indian centres) compared a synthetic 'test' semaglutide against reference Wegovy for weight management. Researchers reported mean weight change of -13.8% (test) versus -14.1% (reference), a difference of 0.26% with a confidence interval well inside the non-inferiority margin, meaning the two performed comparably. Proportions reaching at least 5% and 10% loss were similar, as were BMI, waist, quality-of-life and glycaemic changes. Gastrointestinal events were the most common adverse events in both arms. This is solid randomised evidence for biosimilar-style equivalence rather than a novel efficacy claim, and the population and 24-week horizon are its main limits. For readers, it speaks to the growing supply of semaglutide products and whether alternatives match the reference in short-term weight outcomes.
Diabetes, obesity & metabolismn=—HumanJul 6, 2026 - Study · SemaglutideMixed
GLP-1 Receptor Agonists for Weight Loss and Risk of Major Safety Outcomes: A Multicentre Cohort Study.
This multicentre cohort (13 South Korean hospitals, 2018-2025, OMOP-mapped) compared weight-management semaglutide or liraglutide initiators against propensity-matched non-initiators. Researchers reported that semaglutide initiation was associated with higher risks across several outcomes: psychiatric disorders overall (HR 2.02), anxiety (2.39), depressive disorder (3.42), gastrointestinal dysmotility or obstruction (3.91) and vision impairment (1.58). This is observational, not a trial: propensity matching cannot rule out residual confounding, and differences between people who start these agents and those who do not can inflate associations. Some signals (semaglutide-linked vision impairment) were not consistent across sensitivity analyses. Read this as a monitoring and patient-selection signal that adds to the safety conversation around GLP-1 receptor agonists, not as evidence of causation. Randomised trial data remain the stronger reference for weighing benefit against these harms.
Diabetes, obesity & metabolismn=—HumanJul 6, 2026 - Study · CagrilintideSupported
Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study.
REIMAGINE 3 is a double-blind, placebo-controlled Phase 3a trial (274 adults, six countries) testing once-weekly cagrilintide-semaglutide (CagriSema) added to basal insulin in type 2 diabetes. Researchers reported HbA1c reductions of -2.33% (2.4 mg each) and -2.10% (1.0 mg each) versus -0.66% for placebo, meeting the primary endpoint, alongside 10-12% bodyweight reductions and no additional hypoglycaemia; adverse events were mostly mild-to-moderate gastrointestinal, and one unrelated death (malignancy) occurred. Note this is a combination of cagrilintide with semaglutide, not semaglutide alone, so the effect cannot be attributed to semaglutide by itself. The design is strong (randomised, masked, active insulin background), and the result is clear and clinically meaningful over 40 weeks. Longer-term durability and the semaglutide-versus-combination contribution remain open questions. Sponsor: Novo Nordisk.
Lancet (London, England)n=—HumanJul 4, 2026 - Study · TirzepatideSupported
Time to benefit of incretin-based therapies in adiposity-related heart failure with mildly reduced or preserved ejection fraction: a systematic review and meta-analysis.
This meta-analysis reconstructed individual-participant data from four randomised trials (4,149 adults with overweight or obesity and heart failure with mildly reduced or preserved ejection fraction) to estimate how quickly incretin-based therapies, specifically semaglutide and tirzepatide, separate from placebo. Researchers reported a reduction in worsening heart-failure or cardiovascular-death events (hazard ratio 0.59) with low risk of bias and moderate-to-high certainty by GRADE, and a nominal time to first statistical significance of about four months, sustained from roughly six months onward. Because this pools two distinct agents in a specific obesity-related HFpEF/HFmrEF population, the finding should be read at the class level rather than as agent-specific evidence, and the reconstructed-IPD method carries assumptions. Still, the consistency and event reduction make this among the stronger signals for semaglutide and tirzepatide in this cardiac population.
Journal of cardiac failuren=—HumanJul 4, 2026 - Study · SemaglutideMixed
Effect of GLP-1RA on blood eosinophil levels in adults: a real-world study.
This single-centre retrospective study in Shanghai looked at whether semaglutide, a GLP-1 receptor agonist widely used for glycaemic control and weight management, is associated with changes in blood eosinophils, a white-cell type relevant to allergic and asthmatic inflammation. Among 371 patients, researchers reported that median eosinophil counts fell from 160 to 110 cells/uL after treatment, with a larger percentage drop in non-obese participants; baseline eosinophil count was the only independent predictor of the reduction. As an uncontrolled before-after chart review, this design cannot separate the drug's effect from weight loss, regression to the mean, or other factors, and there was no placebo group. The eosinophil signal is hypothesis-generating and aligns with growing interest in GLP-1 agonists and inflammation, but it should be read as an association within one clinic, not evidence of a clinical asthma benefit.
BMC pulmonary medicinen=—HumanJul 4, 2026 - Study · SemaglutideMixed
Effect of Semaglutide on Measured vs Estimated Glomerular Filtration Rate.
This is a post hoc analysis of a randomized, double-blind, placebo-controlled trial in 48 adults with type 2 diabetes and albuminuria, all on empagliflozin, comparing semaglutide 1 mg weekly with placebo over 26 weeks. The precise question is measurement, not outcome: does semaglutide shift the blood markers used to estimate kidney function? Researchers reported that semaglutide was associated with small but statistically significant rises in creatinine and beta-trace protein, no change in cystatin C or beta-2 microglobulin, and — importantly — no significant change in directly measured GFR (via 99mTc-DTPA clearance). The practical takeaway is a nuanced one: a creatinine-based eGFR could suggest apparent kidney-function change that measured GFR does not confirm, and a combined creatinine-plus-cystatin equation tracked true GFR best. Caveats are the tiny sample (n=48), post hoc framing, and a specific population. A careful, clinician-facing measurement finding rather than an efficacy result.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Associationn=—HumanJul 3, 2026 - Study · TirzepatideWeak / none
Current Concepts in Perioperative Guidance and Outcomes in Hand Surgery Patients Taking Glucagon-Like Peptide-1 Receptor Agonists.
This is a narrative concepts review for hand surgeons on managing patients taking GLP-1 receptor agonists, naming semaglutide and tirzepatide specifically. The clinical hinge is delayed gastric emptying and the theoretical aspiration risk around anesthesia, which has driven evolving perioperative guidance. The authors report that the existing hand and orthopedic literature is limited, but that multiple studies to date describe no notable increase in postoperative complications, and they raise open questions about bone and wound healing during rapid weight loss and anesthesia-related risk. As a narrative review it pools no data and grades no evidence; its value is orientation and unresolved-question framing rather than a quantified risk estimate. Useful context on how these peptides intersect with surgical care, appropriately hedged.
The Journal of hand surgeryn=——Jul 3, 2026 - Study · SemaglutideWeak / none
GLP-1 receptor agonists in ADPKD: from metabolic rationale to phenotype-enriched translational testing.
This is a translational review arguing that GLP-1 receptor agonists — with semaglutide named specifically, citing recent data in Pkd1 mouse models — deserve exploration as metabolic candidates in autosomal dominant polycystic kidney disease (ADPKD), a condition currently anchored to the vasopressin antagonist tolvaptan. The authors are deliberately cautious: they frame GLP-1 agents as plausible modifiers of adiposity- and metabolic-stress pathways in disease progression, not as replacements for tolvaptan, and they state explicitly that GLP-1 therapy should not currently be considered a treatment for ADPKD. As a narrative synthesis at an early translational stage, this carries no trial outcomes; the semaglutide-specific evidence cited is preclinical. Read it as rationale and study-design thinking for future early-phase trials, not as clinical evidence in kidney disease.
Translational research : the journal of laboratory and clinical medicinen=——Jul 3, 2026 - Study · SemaglutideMixed
Rebooting blood vessel repair: implications of the SEMA-VR CardioLink-15 trial.
This is a mechanistic review built around one recent randomized translational trial, SEMA-VR CardioLink-15, that tested semaglutide versus usual care over six months. The hypothesis is that GLP-1 receptor agonists blunt cardiovascular events partly by reversing 'vascular regenerative cell exhaustion' — a depletion of bone-marrow progenitor cells that repair blood vessels. Researchers reported that semaglutide was associated with a 34.8% increase in vascular-regenerative myeloid progenitors and a 66.2% expansion of endothelial precursor cells, alongside reduced circulating granulocytes and lower TNF and interleukin cytokines. These are intermediate, cellular biomarkers, not clinical outcomes: the review proposes they may help explain the early event-curve separation seen in outcome trials, which is a plausible but unproven bridge. The trial appears small and translational, and the piece is a narrative review interpreting it. Interesting mechanistic candidate for semaglutide's cardiovascular signal; not itself outcome evidence.
Current opinion in cardiologyn=——Jul 2, 2026 - Study · SemaglutideWeak / none
Females Are Completely Resistant to Semaglutide-Induced Muscle Loss in ob/ob Mice.
This is a preclinical mouse study addressing a live clinical question — muscle loss during GLP-1-driven weight loss — in a controlled model. Using leptin-deficient (ob/ob) mice of both sexes, researchers reported that semaglutide had minimal effects on skeletal-muscle mass and strength overall, and that females were 'completely resistant' to muscle-mass loss, framing this as a sex-specific, protective effect. The finding is mechanistically interesting because concern about lean-mass loss accompanies real-world semaglutide use, but the caveats are substantial: this is a rodent model with a specific genetic obesity background, the abstract gives no group sizes or effect magnitudes, and mouse body-composition responses do not map directly onto humans. These are preclinical, hypothesis-generating findings; human data are needed before any clinical conclusions about sex differences in muscle preservation can be drawn.
Diabetesn=—AnimalJul 2, 2026 - Study · SemaglutideWeak / none
Enhanced Stability and Transdermal Delivery of Semaglutide Using an L-Arginine Based Dissolving Microneedle System.
This is a pharmaceutical formulation study — laboratory and ex-vivo, not clinical — developing a dissolving-microneedle (DMN) skin patch to deliver semaglutide without an injection or the oral bioavailability problem. The notable technical claim is using L-arginine as an excipient to stabilize the peptide, which the authors describe as a first. They characterized the arrays for mechanical strength, insertion into synthetic film and ex-vivo porcine skin, 12-hour release, and dye penetration by imaging. Crucially, this is a delivery-and-stability proof-of-concept: the work demonstrates that the patch can be made and can deposit material into skin, and the authors themselves acknowledge persisting challenges around loss of therapeutic activity and peptide stability. There is no measurement of drug absorption, blood levels, glucose or weight effects in any living subject. These are preclinical device findings; human data would be needed before any clinical conclusions about a semaglutide patch.
AAPS PharmSciTechn=—In vitroJul 2, 2026 - Study · TirzepatideWeak / none
Hypersensitivity Reaction to Tirzepatide With Demonstrated Tolerance to Semaglutide: A Case Report.
A single case report describing tirzepatide-specific hypersensitivity in a 25-year-old woman who later tolerated semaglutide after supervised testing. As an individual case, it cannot establish how common such reactions are, but it illustrates that hypersensitivity to one GLP-1-based agent does not necessarily extend to others in the class. The main value is in documenting a diagnostic approach using intradermal testing and supervised challenge.
Clinical case reportsn=—HumanJul 1, 2026 - Study · SemaglutideWeak / none
Severe Perioperative Lactic Acidosis and Hyperglycemia Responsive to Thiamine in a Patient With Prior Semaglutide Use and Restrictive Dieting: A Case Report.
A single case report flagging that GLP-1-driven appetite reduction plus restrictive dieting may unmask thiamine deficiency, which surfaced here as severe perioperative lactic acidosis that reversed rapidly with intravenous thiamine. Semaglutide is one contributing factor among several rather than the study's focus, and causality in a single patient is speculative. The safety signal is worth logging for readers on GLP-1 agonists with limited nutritional intake, but the evidence weight is minimal.
A&A practicen=—HumanJul 1, 2026 - Study · TirzepatideSupported
Approved weight loss drugs for obesity with a thorough emphasis on GLP-1 agonist medications: A systematic review.
A PRISMA-based systematic review of 15 studies on approved anti-obesity pharmacotherapies, with a focus on GLP-1 and dual incretin agents. For tracked peptides it reports dose-dependent weight loss, semaglutide 2.4 mg around -15%, tirzepatide roughly -15% to -18.5%, alongside glycemic and cardiometabolic improvements (HbA1c, blood pressure, LDL) and predominantly mild gastrointestinal adverse events, with serious events, pancreatitis and gallbladder complications described as rare and discontinuation generally under 15%. As a qualitative systematic review it synthesizes rather than pools data, so it lacks the quantitative rigor of a meta-analysis, and the 15-study base spans heterogeneous populations. The findings are consistent with the broader trial record for semaglutide and tirzepatide. Read as a solid orienting summary of where these agents stand on weight and cardiometabolic measures, with the usual caveat that review-level synthesis is only as strong as its included studies.
Disease-a-month : DMn=——Jul 1, 2026 - Study · TirzepatideMixed
Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and Obesity.
An indirect comparison using multilevel network meta-regression to weigh injectable tirzepatide against daily oral semaglutide 50 mg for weight management, anchoring on the SURMOUNT-1 and OASIS 1 trials and adjusting for population differences. Tirzepatide 10 and 15 mg were associated with statistically greater weight and waist-circumference reductions and higher odds of hitting >=5–20% weight-loss thresholds than oral semaglutide, with cardiometabolic and safety profiles described as improved or comparable. The ranking is consistent with the broader record on these two agents. The central caveat is in the method: this is an indirect, cross-trial comparison, not a head-to-head trial; the two pivotal studies differed in design and duration, and adjustment can reduce but not remove that mismatch. Read as a reasonable model-based estimate favoring higher-dose tirzepatide on weight, pending direct comparative data, which does not yet exist.
Diabetes, obesity & metabolismn=—HumanJul 1, 2026 - Study · TirzepatideWeak / none
Clinical Characteristics of Users of Weight Loss Drugs: Population-Based Case-Control Study.
A nationwide Norwegian nested case-control study describing who starts weight-loss drugs, using dispensing and diagnosis registries; each user was matched to five population controls. Among agents, semaglutide (Wegovy) dominated by volume (150,036 initiators) with tirzepatide far smaller (3,596). Users carried heavier comorbidity burdens than controls, more hypertension, hyperlipidemia, sleep apnea, back pain, and more antidepressant and opioid use. This is descriptive epidemiology, not an efficacy or safety study: it characterizes the treated population and prescribing patterns, not outcomes. Its editorial value is market-and-access intelligence, showing real-world uptake skewed toward semaglutide and toward patients with complex needs, plus an equity note on education level. Caveats: registry data reflect what is dispensed and coded, not why, and the design cannot speak to how well any drug works. A useful population snapshot, weak as clinical evidence.
Diabetes, obesity & metabolismn=——Jul 1, 2026 - Study · TirzepatideWeak / none
Incretin-Based Anti-obesity Medications in Polycystic Ovary Syndrome: The Evidence Map.
A narrative, drug-by-drug 'evidence map' of incretin anti-obesity medications in polycystic ovary syndrome. The key takeaways for tracked peptides: semaglutide has sparse but mechanistically interesting PCOS data with early signals around weight and conception, while tirzepatide has no PCOS-specific evidence at all; the authors are explicit that its use here rests only on extrapolation from obesity and diabetes trials and should not be extended to PCOS on that basis. Liraglutide (not tracked) has the densest evidence. As a narrative review this maps gaps rather than generating data, and the authors stress that reproductive, pregnancy-safety, adolescent and long-term outcomes remain major unknowns. Editorially valuable precisely for calibrating expectations: it documents how thin the peptide-specific PCOS evidence is. Read as an honest gap analysis, not support for use in PCOS.
Drugsn=——Jul 1, 2026 - Study · CagrilintideSupported
Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta-Analysis of Randomized Clinical Trials.
A network meta-analysis pooling 25 randomized trials and 12 interventions to compare advanced anti-obesity agents. Tirzepatide 15 mg produced the greatest percent weight reduction (mean difference -17.97%), with CagriSema close behind (-17.84%) and semaglutide 7.2 mg at -14.66%; at the >=20% weight-loss threshold CagriSema and tirzepatide 15 mg led. Gastrointestinal adverse events rose with all treatments, while serious adverse events were comparable to placebo. As a meta-analysis of RCTs this sits near the top of the evidence hierarchy, and the ranking of tirzepatide and semaglutide is consistent with the broader trial record. The main caveats are inherent to network meta-analysis: it mixes indirect comparisons across trials with differing populations and durations, so the precise numeric ordering (especially tirzepatide vs CagriSema) carries uncertainty. The authors note no direct head-to-head data exist and call for them. Strong, well-grounded synthesis.
Endocrinology, diabetes & metabolismn=—HumanJul 1, 2026 - Study · TirzepatideMixed
Dulaglutide in the era of tirzepatide and semaglutide: reaffirming its role in contemporary cardiometabolic care.
A narrative review arguing that dulaglutide retains a place alongside newer agents. For our tracked peptides, the useful content is comparative: the authors note that tirzepatide and semaglutide deliver larger reductions in HbA1c and body weight than dulaglutide, while framing dulaglutide's distinct strength as its cardiovascular outcome data (REWIND) and accessibility. They cite SURPASS-CVOT, which established tirzepatide's non-inferiority to dulaglutide for cardiovascular outcomes. As a narrative review this is synthesis and argument, not new data, and it is explicitly written to defend dulaglutide's role, so read the framing with that intent in mind. It is a reasonable orientation to where tirzepatide and semaglutide sit on efficacy versus an older comparator, but it should not be read as a systematic or quantitative comparison. Weight it as context, not evidence.
Diabetology internationaln=——Jul 1, 2026 - Study · SemaglutideWeak / none
Semaglutide alleviates osteoarthritis independent of weight loss via GLP-1R-mediated activation of autophagy through AKT/mTOR inhibition.
This is a multi-model preclinical study (zebrafish cartilage-injury screen, a surgical osteoarthritis mouse model via medial-meniscus destabilization, plus cultured chondrocytes and receptor/autophagy inhibitors) investigating whether semaglutide protects joint cartilage. Researchers reported that in mice, semaglutide was associated with improved gait and pain-related behavior and reduced cartilage destruction, synovitis and bone changes — notably without significant weight change, arguing for a direct joint effect. Mechanistically, they place the action at chondrocyte GLP-1R, inhibiting AKT/mTOR and restoring autophagy; blocking the receptor or autophagy abolished the benefit, which strengthens the causal claim within the model. Still, this is entirely animal and cell work; the 'disease-modifying' framing is preclinical. Human osteoarthritis differs, and no clinical outcomes are shown here. These are mechanistic signals worth watching for the semaglutide-repurposing hypothesis, not evidence in patients — human trials would be needed before any clinical conclusion.
Journal of orthopaedic translationn=—AnimalJul 1, 2026 - Study · TirzepatideMixed
Weight loss and cardiovascular outcomes with incretin-based therapies after metabolic and bariatric surgery: a nationwide US cohort study.
This is a large nationwide retrospective cohort (208,155 post-bariatric-surgery patients, 39,750 on incretin therapy) examining semaglutide and tirzepatide as add-on treatment after metabolic and bariatric surgery. Among those on therapy at least a year, tirzepatide was associated with greater additional weight loss than semaglutide (17.2% vs 12.0% total weight loss; adjusted difference ~5.2 points) in a dose-dependent way, and later post-surgical initiation was associated with more weight loss than earlier. Notably, in matched landmark analyses, pooled incretin therapy was not associated with a reduction in major adverse cardiovascular events (HR 0.91, CI 0.80–1.05) — a null result the authors present honestly. Standard observational caveats apply: confounding by indication, adherence, and the fact that patients starting later may differ systematically. The authors explicitly call for prospective work to establish causality and cardiovascular benefit. Solid comparative signal on weight, appropriately cautious on hard outcomes.
EClinicalMedicinen=—HumanJul 1, 2026 - Study · SemaglutideMixed
Efficacy and Safety of Intensifying Once-Weekly Insulin Icodec Treatment With Once-Weekly Semaglutide in Adults With Type 2 Diabetes: A Single-Arm, Open-Label, Treat-to-Target, Phase 3b Trial (ONWARDS 8).
This is a Phase 3b interventional trial (ONWARDS 8), but it is single-arm and open-label — there is no control group and no randomization, so results cannot be attributed to semaglutide against a comparator. In 148 adults with type 2 diabetes on weekly insulin icodec, 94 added weekly semaglutide (up to 1.0 mg) for a 26-week intensification phase. Researchers reported HbA1c fell by an estimated 1.23 percentage points (from 7.88% to 6.66%) from week 26 to 52, with improvements in self-measured and post-meal glucose, a 3.85 kg weight reduction, a 24% reduction in weekly insulin dose, and a low rate of clinically significant or severe hypoglycemia (0.24 events per person-year). The magnitude is meaningful and consistent with semaglutide's known glucose and weight effects, but the single-arm design, open-label knowledge, modest size and estimated endpoints limit inference. Read as supportive feasibility data for combining semaglutide with weekly insulin, not a controlled efficacy result.
Diabetes, obesity & metabolismn=——Jul 1, 2026 - Study · SemaglutideMixed
Reassessing the risk-modifying effects of novel antidiabetic agents on asthma-COPD overlap syndrome: a dose-stratified network meta-analysis of 316,832 adults from 128 randomised trials.
A dose-stratified network meta-analysis pooling 128 randomised trials (about 316,800 adults) that examined whether newer glucose-lowering drugs are linked to asthma-COPD overlap (ACOS) and related respiratory events. Injectable semaglutide was associated with lower ACOS risk (RR 0.64) and lower COPD risk, alongside several SGLT2 inhibitors; saxagliptin, a different drug class, was associated with higher asthma risk. As evidence tiers go, a meta-analysis of randomised trials sits high, and the authors reported no major heterogeneity or small-study bias. But the important caveat is that respiratory events were not the primary purpose of the pooled trials; they were captured incidentally, which invites detection and reporting inconsistencies across studies. The findings are associations, agent-specific and dose-suggestive, and the authors frame them as grounds for prospective evaluation rather than practice change. For semaglutide readers, this adds a plausible respiratory signal to a drug already well-supported for glycaemic and weight outcomes, hypothesis-generating, not an established respiratory use.
EClinicalMedicinen=—HumanJul 1, 2026 - Study · SemaglutideMixed
Assessing the risk of diabetic retinopathy progression with GLP-1 receptor agonists: a systematic review and meta-analysis.
This is a systematic review and meta-analysis (11 studies, RCTs and retrospective cohorts, samples from 137 to 9,463) of whether GLP-1 receptor agonists are associated with progression of diabetic retinopathy — a long-standing safety question for the class, and semaglutide in particular. The pooled result found no statistically significant association overall (RR 1.07, 95% CI 0.90–1.28), with low assessed risk of bias and no detected publication bias. The nuance worth flagging: semaglutide showed the highest point estimates for retinopathy progression in two individual studies (RR 1.76, CI 1.11–2.79; and RR 6.41, CI 0.67–61.46 — the latter's enormous confidence interval signals a tiny, imprecise dataset), contrasting with the null overall. This is a class-level reassurance tempered by an unresolved, compound-specific signal for semaglutide that the authors explicitly say warrants further investigation. Meta-analyses inherit the limits of their inputs — here, heterogeneity is the key caveat.
BMC ophthalmologyn=—HumanJun 30, 2026 - Study · SemaglutideWeak / none
BMI response to dapagliflozin with or without semaglutide across obesity classes: a real-world observational study conducted in Saudi Arabia.
This is a small retrospective observational cohort (328 patients, single Saudi hospital) examining BMI change with dapagliflozin, with or without weekly semaglutide, across WHO obesity classes over up to a year. Semaglutide is the secondary player here — the primary agent is the SGLT2 inhibitor dapagliflozin — and the analysis is exploratory. Researchers reported the greatest absolute BMI drop in the most severe obesity class, but proportional (percentage) change was uniform across classes, which they interpret as reflecting higher starting BMI rather than any class-specific drug advantage. The semaglutide add-on showed only a 'directional trend' toward greater benefit in one class, not a significant effect. Key limits: no control group, individual semaglutide doses were unavailable, small subgroups, and single-center scope. Read this as hypothesis-generating monitoring guidance, not evidence of semaglutide's incremental effect.
Current medical research and opinionn=—HumanJun 30, 2026 - Study · TirzepatideMixed
Real-World Comparative Effectiveness of Tirzepatide and Semaglutide for Obesity: A Multicentered Study.
This is a retrospective, multicenter real-world cohort (511 US adults) directly comparing tirzepatide and semaglutide for obesity — a head-to-head question that matters because the two are so often weighed against each other. Researchers reported greater 12-month total body weight loss with tirzepatide than semaglutide (16.6% vs 13.4%), with more tirzepatide users reaching ≥15% and ≥20% loss, and a larger gap among people without diabetes. Prior obesity-medication use was associated with less weight loss in both groups, and semaglutide users reported more gastrointestinal side effects (50.7% vs 28.5%). The design caveats are important: this is observational, not randomized, so channeling by clinician or patient preference, differing dose titration, and adherence can bias a head-to-head comparison; the cohort was predominantly White and female. Directionally consistent with randomized trial data favoring tirzepatide on weight, but read the magnitude cautiously given the observational design.
Mayo Clinic proceedingsn=—HumanJun 30, 2026 - Study · SemaglutideSupported
Weekly and Biweekly Treatment With Bofanglutide Versus Semaglutide in Chinese Patients With Type 2 Diabetes : A Phase 2b Randomized Clinical Trial.
A Phase 2b, randomised, open-label, active-controlled trial (n=272, 37 Chinese sites, 24 weeks) in which semaglutide 1 mg weekly served as the reference arm against a novel GLP-1 receptor agonist, bofanglutide, at several doses and schedules. At 24 weeks, bofanglutide lowered HbA1c by 1.87–2.32%, and the higher-dose arms (18 mg every two weeks and 24 mg weekly) showed statistically greater reductions than semaglutide 1 mg (differences about −0.68% and −0.72%). Importantly, the comparator was semaglutide 1 mg, not its higher 2 mg dose, so this does not establish superiority over maximal semaglutide. Gastrointestinal adverse events were more common with bofanglutide (82–87%) than semaglutide (52%), though mostly grade 1–2; no severe hypoglycaemia occurred. Limits the authors note: open-label design, short 24-week duration, and a Chinese-only population. A solid early-phase signal for bofanglutide; semaglutide's own large Phase 3 evidence base is unaffected by its role as comparator here.
Annals of internal medicinen=—HumanJun 30, 2026 - Study · SemaglutideWeak / none
[Insulin intoxications caused by falsified semaglutide].
This two-case report speaks directly to peptide-market safety: two people without diabetes or obesity injected semaglutide obtained without a prescription and presented in a coma with severe hypoglycemia, low potassium and hypothermia — caused, on investigation, not by semaglutide but by synthetic insulin contaminating or substituting the product. The authors underscore the clinical logic: semaglutide monotherapy is not associated with significant hypoglycemia in healthy people, so the profound low blood sugar (requiring up to two days of continuous glucose infusion) pointed to a falsified product. This is a vivid illustration of the risk of buying peptides outside regulated supply chains, where quality controls are absent. As a case report it establishes occurrence, not frequency. The actionable point is provenance: falsified 'semaglutide' can contain dangerous undeclared drugs, and regulators should be notified promptly.
Nederlands tijdschrift voor geneeskunden=—HumanJun 29, 2026 - Study · SemaglutideMixed
Weight loss and gut microbial changes associated with semaglutide among people living with schizophrenia receiving clozapine or olanzapine: An open-label 24-week semaglutide intervention and 76-week trial.
A small, open-label, single-arm intervention (n=26; 17 completers) in a real-world mental-health setting — a design with no control group, so results cannot be separated from other influences. Over 24 weeks of nurse-administered semaglutide, adults with schizophrenia on clozapine or olanzapine lost a mean 9.8% of body weight (about 10 kg), with reduced waist circumference and a non-significant HbA1c change; gut microbial diversity fell over time. At 76 weeks — one year after stopping — mean weight loss had attenuated to 5.1%, consistent with the regain seen when GLP-1 agonists are discontinued. This addresses a genuinely important, under-served population where antipsychotic-associated weight gain is a major problem, and the weight findings align with semaglutide's large Phase 3 record. But the absence of a control arm, the small sample and notable dropout limit confidence, and the microbiome findings are exploratory. These are reported associations, not proof of benefit specific to this group; a controlled trial would be needed to confirm them.
Schizophrenia researchn=——Jun 29, 2026 - Study · SemaglutideWeak / none
Engineered circular RNA compatible with complete nucleoside modification and rolling circle translation through a Cap-independent translation enhancer.
Semaglutide appears here as a benchmark, not the subject of study. This is a bioengineering paper introducing a nucleoside-modified circular-RNA platform that uses a viral cap-independent translation enhancer to drive protein production. Among several demonstrations, a circRNA encoding GLP-1 peptides reduced blood glucose in obese mice ‘with efficacy comparable to’ commercial semaglutide and lessened liver damage. That comparison is a preclinical yardstick for the RNA technology; it is not an efficacy study of semaglutide itself, whose own evidence rests on large human Phase 3 trials. The genuinely novel contribution is the circRNA/translation platform and its lower immunogenicity, shown across tumour, metabolic and autoimmune mouse models. All findings are in mice or cells. These are preclinical results; human data would be needed before any therapeutic conclusions could be drawn about the RNA approach.
Nature biomedical engineeringn=—AnimalJun 29, 2026 - Study · TirzepatideMixed
Neuropsychiatric association of tirzepatide and semaglutide in obesity with and without type 2 diabetes.
A large US electronic-health-record cohort study using a new-user, active-comparator design with 1:1 matching — a rigorous observational approach, but still observational. Over 24 months, both semaglutide and tirzepatide were associated with lower hazards of incident anxiety and depression versus naltrexone-bupropion, across patients with and without type 2 diabetes (hazard ratios roughly 0.5–0.8). Head-to-head, tirzepatide versus semaglutide was associated with modestly higher hazards of anxiety (HR 1.12) and insomnia (HR 1.13) in people without diabetes. These signals are reassuring against earlier concerns of psychiatric harm from these agents, and the effect sizes for depression are sizeable. The authors themselves flag residual confounding and diagnosis misclassification as key limits: people prescribed these drugs differ systematically from comparators, and record-based diagnoses are imperfect. Associations here cannot establish causation. Useful for monitoring and shared decision-making, not for concluding that either drug lowers mood-disorder risk.
Communications medicinen=—HumanJun 29, 2026 - Study · SemaglutideWeak / none
GLP-1 Receptor Agonists in Adolescents: Emerging Endocrine, Reproductive, and Psychosocial Concerns.
This is a commentary/review rather than new data, and it is deliberately cautionary. It maps concerns specific to using GLP-1 agonists in adolescents, a period of peak bone-mass acquisition and reproductive development that the efficacy trials were not designed to probe. The authors note that adolescent trials of liraglutide and semaglutide reported significant weight reduction without short-term effects on growth or puberty, but they emphasize what is unknown: rapid pharmacologic weight loss may theoretically impair bone-mineral accrual (extrapolated from adult data showing modest BMD reductions with weight loss), no data exist on reproductive outcomes after adolescent exposure, and potent appetite suppression raises eating-disorder concerns in a body-image-vulnerable group. These are framed as hypotheses and expert concerns, not demonstrated harms. Read it as an agenda-setting risk inventory that should temper enthusiasm and prompt monitoring, not as evidence that harm has occurred. The abstract also notes these agents are not advised in pregnancy.
Journal of pediatric and adolescent gynecologyn=——Jun 28, 2026 - Study · SemaglutideSupported
GLP-1 receptor agonists in pediatric obesity and diabetes: a systematic review of efficacy, metabolic effects, and safety.
This is a systematic review with meta-analytic components spanning seven pivotal RCTs and six meta-analyses, roughly 901 participants aged 6 to under 18, so among the study types here it sits near the top of the evidence hierarchy for pediatric GLP-1 use. The finding is clear and consistent: semaglutide 2.4 mg weekly produced the largest BMI reduction in adolescents with obesity, with liraglutide next; in youth-onset type 2 diabetes, liraglutide and dulaglutide improved HbA1c versus placebo. Gastrointestinal events (nausea, vomiting) were the most frequent, generally transient and dose-dependent, and no significant effect on linear growth or puberty was reported. The important caveat is duration and scope: the authors themselves flag that longer-term cardiovascular, bone-health, and growth outcomes remain unstudied, and 901 pooled participants is modest for a pediatric safety question. Weight this as reasonably strong short-term evidence in adolescents, with the long-term safety picture explicitly unresolved.
Diabetes research and clinical practicen=—HumanJun 28, 2026 - Study · SemaglutideMixed
Real-World Evidence of the Effectiveness and Safety of Biosynthetic Semaglutide in Type 2 Diabetes: A Multicentre Study From Pakistan.
A 30-week prospective, non-interventional cohort of 217 adults with type 2 diabetes in Pakistan, examining a locally produced biosynthetic semaglutide in routine care. The reported results are substantial and directionally consistent with the registration trials: mean HbA1c fell from 9.27% to 7.41% (a 1.86-point drop), mean weight fell 7.84 kg, and roughly three-quarters achieved at least 5% weight loss. Adverse events were mostly non-serious and gastrointestinal, with no severe hypoglycemia reported. The value here is real-world, cost-constrained context, a population and setting under-represented in the SUSTAIN program. But the design limits interpretation: single-arm and non-interventional means no comparator, so regression to the mean, concurrent care changes, and the high baseline HbA1c (leaving more room to fall) all inflate apparent effect. It is also observational, not randomized. This is supportive real-world evidence that a biosynthetic preparation behaved consistently with established semaglutide over 30 weeks, not proof of equivalence.
Diabetes, obesity & metabolismn=—HumanJun 28, 2026 - Study · SemaglutideWeak / none
GLP-1 Receptor Agonists and the Ocular Surface: A Narrative Review of Restoration, Remodeling, and Clinical Implications.
A narrative review, so it synthesizes existing work rather than generating new data, and its weight depends entirely on the studies it summarizes. Those are uneven. The strongest thread is preclinical: liraglutide work in animals reported reduced lacrimal gland inflammation and better tear secretion, corneal epithelial migration, and nerve regeneration, and a semaglutide study in aged mice suggested structural rescue of the lacrimal gland. These are mechanistic signals in animals; human data are needed before clinical conclusions can be drawn. Human evidence here is limited and largely observational, retrospective diabetic cohorts reporting lower rates of dry eye, plus one small study on tear measures, designs that cannot establish cause. The review also raises a countervailing point: rapid weight loss may cause periocular volume loss and altered lid mechanics. The authors are candid that their clinical suggestions are expert extrapolation, not guideline-grade evidence. Read this as a well-framed hypothesis map for the ocular surface, not as established effect.
Ophthalmology and therapyn=——Jun 28, 2026 - Study · SemaglutideWeak / none
Chronic semaglutide alters ingestive behavior without impairing taste function in mice.
A mechanistic mouse study addressing a specific clinical question: do GLP-1 agonists blunt food intake by dulling taste? Working in diet-induced obese mice with brief-access gustometer tests, the researchers found chronic semaglutide produced robust weight loss but did not change lick responses to sweet, bitter, sour, salty, or fatty tastants, and sweet-taste sensitivity (EC50 across sucrose concentrations) was unchanged. Taste-cell subtypes and taste-signaling gene expression were likewise unaffected. If anything, semaglutide modestly increased engagement with sucrose. The clean interpretation, that reduced intake operates through motivational or central pathways rather than peripheral taste, is well supported within the model. These are preclinical findings; human data are needed before clinical conclusions can be drawn, and prior human taste studies have been conflicting. The contribution is negative and clarifying: it argues against a peripheral-taste explanation for appetite suppression, narrowing where the real mechanism lies.
Molecular metabolismn=—AnimalJun 27, 2026 - Study · SemaglutideWeak / none
From dual to quintuple agonism for next-generation pharmacology to treat obesity and type 2 diabetes: synergistic incretin and nuclear receptor signaling.
This is a preclinical mouse study of an experimental conjugate (GLP-1-GIP-lanifibranor), not of semaglutide itself; semaglutide appears here only as a comparator. In obese mouse models researchers reported the conjugate produced greater reductions in body weight, adiposity, food intake and hyperglycemia than semaglutide, GLP-1-GIP co-agonism, or lanifibranor alone, and improved insulin sensitivity. Mechanistic work pointed to PPARdelta signaling as a mediator of glycemic improvement independent of weight loss, and the conjugate avoided some adverse effects (anemia, fluid retention, renal dysfunction) seen with systemic PPAR agonism. Weight it as an early platform signal: rodent efficacy against a benchmark drug is interesting, but the authors themselves flag substantial translational uncertainty. These are preclinical findings; human data are needed before clinical conclusions can be drawn. Semaglutide's own weight and glycemic effects rest on large Phase 3 trials, whereas this conjugate has none.
Cardiovascular diabetology. Endocrinology reportsn=—AnimalJun 26, 2026 - Study · SemaglutideWeak / none
From evidence to practice: Identifying candidates for semaglutide in chronic atherosclerotic disease.
This is not an efficacy study but an eligibility-mapping exercise, and reading it correctly matters. The underlying evidence, that semaglutide reduced atherothrombotic events and cardiovascular mortality in coronary patients with and without diabetes, comes from the SELECT and SOUL randomized trials and is genuinely strong. What this paper adds is a real-world denominator: applying regulatory eligibility criteria to 12,430 patients in two Italian cardiology registries, the authors estimate that 54.3% (6,748) would potentially qualify for semaglutide, including 42.5% of non-diabetic patients (SELECT-like) and 97.9% of diabetic patients (SOUL-like). The finding is about scale of the eligible population, not about whether giving them the drug yields benefit, that inference rests on the trials. Caveats: registry populations reflect specific catchments and prescribing eras, eligibility is not the same as appropriateness or access, and cost/sustainability, which the authors flag, is left open. Useful for health-system planning; it says nothing new about how well the drug works.
International journal of cardiologyn=——Jun 26, 2026 - Study · TirzepatideMixed
Real-World Effectiveness of Semaglutide and Tirzepatide Compared With Bariatric Surgery.
A large retrospective real-world cohort (44,025 adults, BMI >=35, two urban health systems, 2018 to 2024) comparing weight loss on injectable semaglutide or tirzepatide against sleeve gastrectomy and gastric bypass, using inverse-probability weighting to balance groups. Researchers found bariatric surgery was associated with substantially greater total weight loss at 1 to 3 years: for example roughly 22 to 28% with surgery versus about 7 to 9% (semaglutide) and 11 to 12% (tirzepatide) in the per-protocol analysis. Tirzepatide outperformed semaglutide. Key caveats: this is observational, so residual confounding by indication remains despite weighting; medication adherence is imperfect (intention-to-treat numbers ran below per-protocol); and real-world dosing and persistence differ from trials. Weight it as a useful real-world magnitude comparison, not a randomized head-to-head. It reflects effectiveness as actually used, which for the drugs runs below the results seen in controlled trials.
Obesity (Silver Spring, Md.)n=—HumanJun 25, 2026 - Study · TirzepatideWeak / none
Cost-Effectiveness of Pharmacologic Therapies for Metabolic Dysfunction-Associated Steatohepatitis With Significant Fibrosis in the United States.
This is a health-economic modeling study, not a clinical trial; it asks whether drugs are cost-effective for MASH with F2 to F3 fibrosis at U.S. prices, using a Markov model fed by a Bayesian network meta-analysis. Researchers reported both semaglutide (ICER ~$80,076/QALY) and tirzepatide (~$42,705/QALY) fell below the $100,000/QALY threshold, while resmetirom did not. The output is only as good as its inputs: efficacy estimates came from an indirect network comparison, drugs were each compared to standard of care rather than head-to-head, and drug price was the dominant driver in sensitivity analysis. The authors explicitly caution that tirzepatide is not FDA-approved for MASH and its estimate rests on a Phase 2 trial via network meta-analysis. Weight this as a pricing/value argument for payers, not as evidence of clinical efficacy in MASH; neither peptide's fibrosis benefit is established here, only modeled.
Diabetes, obesity & metabolismn=——Jun 25, 2026 - Study · SemaglutideWeak / none
The risk of retinal vascular events in patients using semaglutide: a scoping review.
This scoping review pooled reporting of retinal vascular events across 13 mostly double-blind, placebo-controlled semaglutide trials (17,478 semaglutide vs 17,334 placebo participants). Researchers found 15 retinal vascular events in semaglutide arms versus 4 in placebo, and a similar numerical excess for ischemic optic neuropathy (6 vs 1). This aligns with an active safety discussion around GLP-1 agents and eye outcomes. Important caveats: absolute rates were very low (0 to 0.33 vs 0 to 0.05 per 1,000 person-years in the large long-term trials), a scoping review tallies reported events rather than formally adjudicating or statistically testing them, and it cannot establish causation or account for confounders such as rapid glycemic change. The authors frame this as a signal warranting large registry studies, not a settled risk. Weight it as a hypothesis to watch against semaglutide's substantial cardiovascular and metabolic benefit base, not as demonstrated harm.
Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunden=——Jun 25, 2026 - Study · SemaglutideWeak / none
Hydrophobic ion pairing formed semaglutide designed for oral self-microemulsifying delivery in diabetes treatment.
This is a pharmaceutical formulation study, not a clinical efficacy trial. Researchers built an oral delivery system (a hydrophobic ion pair of semaglutide with docusate, carried in a self-emulsifying system) to improve absorption of an otherwise poorly-absorbed peptide. In lab (Caco-2/HT-29 cell) models the formulation improved permeability and reduced efflux; in a diabetic rat model it lowered blood glucose and improved lipid markers with no observable toxicity. Read this as proof-of-concept for a delivery technology, not evidence about semaglutide's therapeutic value, which for injectable and existing oral (Rybelsus) forms rests on large Phase 3 trials. The animal and in-vitro nature is central: these are preclinical, mechanistic signals, and human pharmacokinetic and safety data would be needed before any clinical conclusion. "No observable toxicity" in rats is not a safety claim for people.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.Vn=—AnimalJun 25, 2026 - Study · SemaglutideWeak / none
Papillary thyroid carcinoma discovered in a patient on semaglutide therapy for metabolic syndrome: a case presentation and review of current evidence.
A single case report describes a 40-year-old man with metabolic syndrome and obesity, treated with semaglutide for several years, in whom papillary thyroid carcinoma was found incidentally on a CT scan done for an unrelated hernia. As the authors themselves emphasize, concurrence is not causation: a case report cannot establish that semaglutide contributed to the cancer, and the lesion was discovered by chance. GLP-1 thyroid concerns have historically centered on medullary (not papillary) carcinoma and derive largely from rodent data; the authors note current human evidence remains inconclusive and that, in their reading, the overall human data have not established an increased thyroid-cancer risk. Weight this as a hypothesis-flagging anecdote, not evidence of risk. It is a useful reminder that surveillance and large epidemiological studies are still warranted, but it should not shift a risk picture that rests on the large Phase 3 trial base.
Hormones (Athens, Greece)n=—HumanJun 25, 2026 - Study · SemaglutideWeak / none
The systems medicine view of semaglutide: from clinical trials to molecular mechanisms.
A narrative "systems medicine" review connecting semaglutide's established clinical trial results to molecular findings from proteomic and metabolomic studies. It is primarily a mechanistic synthesis: the authors trace how semaglutide's effects may work through mediators such as adiponectin, FGF21, ApoC-III, ceramides and extracellular-matrix-remodeling proteins, linking these to improved insulin sensitivity and reduced adipose inflammation, and they discuss using AI/ML to tie omics biomarkers to outcomes. This is useful context rather than new evidence: as a narrative review it selects and interprets, the omics biomarkers are described as needing longitudinal validation, and mechanistic plausibility does not by itself establish clinical benefit (which for semaglutide rests separately on large Phase 3 trials). Weight it as a readable map of proposed mechanisms and a research direction toward precision care, not as a source of effect sizes or as validated biomarker-guided practice.
Expert review of clinical pharmacologyn=——Jun 24, 2026 - Study · SemaglutideSupported
Semaglutide for the Silent Phenotype: A Translational Signal in Obesity-Driven HFpEF.
A systematic review and meta-analysis of six randomized trials (n=4,216) of semaglutide versus placebo in adults with obesity-related HFpEF. Researchers reported semaglutide was associated with lower NT-proBNP (mean difference -119.7 pg/mL), improved symptom scores (KCCQ +8.27 points), and lower odds of heart-failure hospitalization (OR 0.81). Between-study heterogeneity was low and sensitivity analyses were reported as robust, which strengthens confidence. Caveats: the pooled population is modest and dominated by a small number of trials, hard-outcome and mortality data are limited, and much of the benefit may flow through weight loss and its downstream effects rather than a direct cardiac mechanism. The KCCQ improvement is meaningful to patients; NT-proBNP is a surrogate. Weight this as consistent, moderate-strength randomized evidence for symptomatic and biomarker benefit in this specific phenotype, aligning with semaglutide's broader cardiometabolic record, while noting the benefit is associational and long-term outcome data remain thinner.
The American journal of cardiologyn=—HumanJun 24, 2026 - Study · SemaglutideWeak / none
Erratum.
This item is an erratum correcting the results section of a previously published conference abstract on GLP-1 receptor agonist use in children and young people with severe obesity across 35 English specialist clinics; the original abstract was based on a preliminary dataset, and this correction reports updated figures. As corrected, 406 young people (mean age 15.3) on semaglutide were matched to 787 comparators, and %BMIp95 was lower in the semaglutide group by 13.8, 19.0 and 22.9 percentage points at 6, 12 and 18 months (relative reductions of roughly 9 to 14%). Treat this with real caution: it is a corrected conference abstract, not a peer-reviewed full paper, in a matched (non-randomized) pediatric cohort with a high burden of comorbidity, so confounding and adherence are unaddressed here. Weight it as an early, real-world observational signal in an especially vulnerable population where evidence is thin, pending full peer-reviewed publication.
Obesity factsn=—HumanJun 23, 2026 - Study · SemaglutideWeak / none
The Impact of Missed Doses on Pharmacokinetic Concentrations for Oral Semaglutide in Comparison to Other Glucagon-Like Peptide-1-Based Therapies.
No abstract was available for this item, so this note is based on the title alone and the study's findings cannot be assessed. The title indicates a pharmacokinetic analysis of how missed doses affect drug concentrations for oral semaglutide compared with other GLP-1-based therapies, an adherence-relevant question given that oral semaglutide requires strict daily, fasting administration and achieves lower, more variable levels than the injectable form. Without the abstract, the design, dataset (likely PK modeling or simulation), the magnitude of any concentration drop, and the conclusions are unknown. Weight it only as a pointer to a clinically relevant topic, missed-dose forgiveness across formulations, and not as a source of findings. The full text would be needed before drawing any conclusion about how forgiving oral versus longer-acting GLP-1 therapies are to missed doses.
Diabetes, obesity & metabolismn=——Jun 23, 2026 - Study · SemaglutideSupported
Efficacy and Safety of GLP-1 Receptor Agonists on Combined Cardiovascular and Renal Outcomes in Patients With Chronic Kidney Disease: A Systematic Review and Meta-Analysis.
A large systematic review and network meta-analysis of 13 RCTs (97,428 participants; 31,846 with confirmed CKD) evaluating GLP-1 receptor agonists for cardiorenal outcomes, anchored by the landmark FLOW trial. Researchers reported the class reduced MACE by 16% (HR 0.84) and a composite kidney endpoint by 21% (HR 0.79), both graded high certainty by GRADE, with kidney-failure risk down 28% and albuminuria down 26%; benefits were consistent regardless of SGLT2-inhibitor background, and no excess acute kidney injury was seen. Semaglutide ranked highest in the network (SUCRA 78.4%). Two caveats worth holding: cross-trial network rankings are indirect and can be fragile, so the SUCRA ordering is weaker than the direct pooled estimates; and class-level evidence is driven by specific agents. Weight this as strong, high-certainty randomized evidence for cardiorenal protection in CKD, with the head-to-head "best agent" claim carrying more uncertainty than the class-level benefit.
Diabetes, obesity & metabolismn=—HumanJun 23, 2026 - Study · SemaglutideWeak / none
Dual Glucagon and GLP-1 Receptor Agonist Survodutide Improves Biomarkers of Beta-Cell Function and Insulin Sensitivity in People With Type 2 Diabetes or Living With Overweight/Obesity.
This is a post hoc analysis of two Phase 2 trials of survodutide, a dual glucagon/GLP-1 receptor agonist; semaglutide appears only as an active comparator in one arm, not as the study's focus. Researchers reported that in participants with type 2 diabetes (n=413, 16 weeks) survodutide was associated with rapid increases in a beta-cell function index (HOMA-beta) and decreases in insulin resistance (HOMA-IR), glucagon and fasting glucose, while in a normoglycemic overweight/obesity trial (n=387, 46 weeks) it reduced HOMA-IR, glucagon, C-peptide and fasting insulin and raised adiponectin. Notably, weight change explained the largest share of variability in insulin/HOMA-IR but not the other markers, suggesting effects partly independent of weight loss. Caveats: post hoc analyses are hypothesis-generating, HOMA indices are surrogates, durability after stopping is unknown, and this is survodutide, not semaglutide, evidence. Weight it as an early mechanistic signal for a different investigational agent.
Diabetes, obesity & metabolismn=—HumanJun 22, 2026 - Study · SemaglutideMixed
Therapeutic Effects of Glucagon-like Peptide-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: A Systematic Review.
A systematic review (PROSPERO-registered) of GLP-1 agonists in NAFLD/MASLD and MASH, synthesizing 12 studies narratively because of heterogeneity in populations and outcomes. Its conclusions are appropriately graded. The most consistent finding across semaglutide, liraglutide, dulaglutide, and beinaglutide was reduction in hepatic fat. Liver-enzyme improvements (notably ALT) were less consistent and, as the authors note, should be read as supportive rather than definitive of histological change. Histological benefit was strongest for steatohepatitis resolution in non-cirrhotic MASH; fibrosis results were mixed, with the greatest benefit in intermediate F2-F3 disease and little in established cirrhosis. Tolerability was generally acceptable with gastrointestinal effects most common. This aligns with the broader picture, GLP-1 agonists reliably reduce liver fat and can resolve steatohepatitis in earlier-stage disease, but their effect on advanced fibrosis and hard long-term outcomes remains unproven. A narrative synthesis cannot quantify pooled effect, and the studies are heterogeneous. Weight as moderate, encouraging evidence with clear boundaries at advanced disease.
International journal of molecular sciencesn=——Jun 22, 2026 - Study · TirzepatideWeak / none
Long-term effects of weight-reducing drugs in people with hypertension.
This is a Cochrane systematic review — the highest methodological tier — updating evidence on long-term weight-management drugs in people with essential hypertension (8 RCTs, ~13,000 participants). Its central finding is a gap: for the newest agents, semaglutide and tirzepatide, no results were reported for the review's critical outcomes (mortality, cardiovascular morbidity, serious adverse events) in hypertensive patients specifically. Older drugs showed mixed signals — orlistat probably increased serious adverse events; several agents increased overall adverse events — mostly at low or very low GRADE certainty. The honest conclusion is that evidence remains insufficient to judge whether pharmacological weight loss reduces death or cardiovascular events in people with hypertension. For tirzepatide this is a useful corrective: despite strong weight data, trial reporting has not isolated hypertensive subgroups for hard outcomes. Weigh it as a rigorous map of what we still don't know, and a call for disaggregated trial reporting.
The Cochrane database of systematic reviewsn=—HumanJun 19, 2026 - Study · SemaglutideMixed
Glucagon-like Peptide-1 Receptor Agonists and Alcohol Use Outcomes: A Systematic Review of Clinical Evidence.
A PRISMA-guided systematic review of whether GLP-1 agonists influence alcohol use, an area of intense interest given the drugs' action on reward pathways. It pooled five studies (n=49,892), three RCT-based analyses and one large cohort, with formal risk-of-bias assessment. The finding is measured: semaglutide and dulaglutide were associated with modest reductions in alcohol consumption and craving, with significant improvements on selected behavioral outcomes, while exenatide showed no overall effect (only subgroup signals), and the cohort study found small but significant AUDIT-C reductions after initiation. That heterogeneity of agent and outcome is the key caveat, alongside the fact that most included data are secondary analyses of trials designed for other endpoints, not purpose-built alcohol-use trials. Objective biomarkers (PEth, breath alcohol) were reported in only a few studies. The authors are appropriately restrained: the signal is real but preliminary, and adequately powered dedicated RCTs are needed before any role in alcohol use disorder can be defined.
Journal of clinical medicinen=—HumanJun 19, 2026 - Study · TirzepatideMixed
Cardiovascular outcomes of semaglutide and tirzepatide in type 2 diabetes mellitus and obesity: a systematic review and meta-analysis.
This large systematic review and meta-analysis (47 RCTs, 59,352 participants) compares cardiovascular signals for semaglutide and tirzepatide. Researchers reported that semaglutide was associated with reduced major adverse cardiovascular events (RR 0.71), cardiovascular death, myocardial infarction, and heart failure, but not stroke. For tirzepatide, only a lower myocardial-infarction risk reached significance (RR 0.63), while the MACE reduction did not (RR 0.79, CI crossing 1). The crucial caveat, which the authors stress, is that most data came from separate drug-versus-control trials rather than head-to-head comparisons — so this cannot be read as evidence that one agent is cardiovascularly superior. The asymmetry more likely reflects tirzepatide's younger, thinner cardiovascular-outcomes evidence base (its dedicated CVOT is ongoing) than a true difference. Weigh semaglutide's signal as reasonably consistent and tirzepatide's as still limited and uncertain — an evidence-maturity gap, not a verdict.
Diabetology & metabolic syndromen=—HumanJun 18, 2026 - Study · TirzepatideWeak / none
Psychiatric Safety Signals of GLP-1 Receptor Agonists: A FAERS-Based Pharmacovigilance Study with Explainable Machine Learning.
A disproportionality (pharmacovigilance) study of FDA adverse-event reports enhanced with machine learning, and its design dictates cautious reading. Spontaneous reporting databases like FAERS can flag potential signals but cannot establish causation, incidence, or risk, they are shaped by reporting biases, media attention, and prescribing volume. Across 211,195 cases, sixteen psychiatric preferred terms met signal criteria, with suicidal ideation most frequently reported (ROR 2.95), and signal magnitudes were consistently higher for semaglutide than tirzepatide. An explainable-ML model (AUROC 0.816) identified semaglutide use and younger age (19-44) as positively associated with psychiatric-event reporting, and age 65+ as negatively associated. These are associations within reporting patterns, not clinical risk estimates, and the authors themselves call for prospective study. Notably, regulators including EMA and FDA have previously reviewed GLP-1 suicidality signals without establishing a causal link. Weight this as hypothesis-generating surveillance that flags subgroups for scrutiny, not as evidence that semaglutide causes psychiatric harm.
Pharmaceuticals (Basel, Switzerland)n=——Jun 18, 2026 - Study · TirzepatideMixed
1-year outcomes of semaglutide, tirzepatide, and sleeve gastrectomy in obesity in type 2 diabetes: a retrospective cohort study.
This large real-world retrospective cohort (Epic Cosmos; 45,093 analysed) compares one-year outcomes of semaglutide, tirzepatide, and sleeve gastrectomy in adults with obesity and type 2 diabetes. The demanding composite endpoint — at least 20% weight loss plus HbA1c below 5.7% — was reached by an adjusted 3.0% on semaglutide, 13.2% on tirzepatide, and 24.0% after surgery, placing tirzepatide between the two. Emergency-department visits and new reflux/nausea prescriptions were more frequent after surgery. The scale is a strength, but the authors are candid about limitations: the groups differed at baseline (the surgical cohort was younger, heavier, with lower HbA1c), and residual confounding plus a narrow safety scope constrain interpretation. This is not a randomised comparison, and one-year data cannot speak to durability. Consistent with tirzepatide outperforming semaglutide on weight while surgery remains most potent, weigh it as informative real-world benchmarking — hypothesis-refining, not a definitive ranking.
The lancet. Diabetes & endocrinologyn=—HumanJun 17, 2026 - Study · TirzepatideWeak / none
Adjunctive GLP1 Receptor Agonists in Patients with Inflammatory Bowel Diseases and Obesity and/or Diabetes: A Target Trial Emulation.
This is a target-trial-emulation cohort study using administrative claims to test whether adding semaglutide or tirzepatide changes outcomes in patients with stable inflammatory bowel disease plus obesity and/or diabetes. Across two cohorts (2,028 and 346 matched pairs), researchers found no significant difference in one-year IBD relapse or safety outcomes between GLP-1RA initiators and non-initiators; notably, roughly a third of patients discontinued the drug within a year. Target-trial emulation is a rigorous approach to observational data, strengthening causal interpretation, but it remains non-randomised — residual confounding, claims-based outcome definitions, and high discontinuation all temper conclusions. The finding is essentially null, and null results are informative here: they push back on the idea that incretin therapy meaningfully modifies IBD activity in already-stable patients. Weigh it as reassuring evidence of no clear relapse signal in either direction, not as evidence of an IBD-specific benefit.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Associationn=—HumanJun 17, 2026 - Study · TirzepatideSupported
Pharmacologic Treatments With Lifestyle Modifications in Nonpregnant Adults With Overweight or Obesity in Outpatient Settings: A Living Clinical Guideline From the American College of Physicians (April 2026).
This is a clinical guideline from the American College of Physicians (April 2026), built on the accompanying systematic reviews, rather than a primary study. Guidelines synthesise evidence into practice guidance, and this one uses GRADE and issues only conditional recommendations, signalling genuine uncertainty and a strong role for patient preference. For adults with obesity (BMI 30 or higher), ACP positions semaglutide and tirzepatide as first-line options, both on moderate-certainty evidence, with phentermine-topiramate, liraglutide and naltrexone-bupropion as later lines on low-certainty evidence. The guidance is careful about harms and access: it foregrounds contraindications and warnings (cardiovascular contraindication and monthly pregnancy testing for phentermine-topiramate, suicidal ideation with naltrexone-bupropion) and directs clinicians and patients to weigh benefits, harms, cost, availability, comorbidities and values together. For readers, the takeaway is that the two peptide agents here now sit at the top of a mainstream professional-society algorithm, but as conditional suggestions paired with shared decision-making, not directives.
Annals of internal medicinen=——Jun 16, 2026 - Study · RetatrutideSupported
Benefits and Harms of Pharmacologic Treatments in Adults With Overweight or Obesity: A Living Systematic Review and Network Meta-analysis for the American College of Physicians.
A living systematic review and network meta-analysis for the American College of Physicians, and one of the strongest evidence syntheses in this batch: 69 randomised controlled trials, 112,511 participants, with 37 trials at low risk of bias. Network meta-analysis lets researchers rank treatments partly through indirect comparison, useful when head-to-head trials are scarce, but indirect estimates carry more uncertainty than direct ones. Researchers reported that nearly all drugs beat placebo or lifestyle intervention for weight loss while causing more adverse-event discontinuations; that semaglutide probably reduced mortality and major cardiovascular events; and that semaglutide and tirzepatide produced the greatest weight loss in both pairwise and network analyses. Crucially, the authors flagged that evidence for mortality, cardiovascular events and serious adverse events was limited and direct head-to-head data sparse, so the weight-loss ranking is far more certain than the hard-outcome claims. Weight this as high-quality comparative evidence for weight change, and more cautiously for survival and cardiovascular benefit.
Annals of internal medicinen=—HumanJun 16, 2026 - Study · TirzepatideWeak / none
Cost-Effectiveness of Pharmacologic Treatments in Adults With Overweight or Obesity: A Systematic Review for the American College of Physicians.
A systematic review of cost-effectiveness, not clinical efficacy, prepared for the American College of Physicians. It asks whether weight-management drugs deliver value for money in a US setting, using incremental cost-effectiveness ratios and GRADE certainty. The headline finding is about the weakness of the evidence: across nine included studies and 42 pairwise comparisons, none reached high certainty, and all were model-based rather than trial-based. Within six moderate-certainty studies, researchers reported that tirzepatide (and phentermine-topiramate) showed high value versus lifestyle modification, while liraglutide showed low value; semaglutide showed low value against naltrexone-bupropion and phentermine-topiramate but high value against liraglutide. These are economic-model outputs, highly sensitive to drug-price assumptions, willingness-to-pay thresholds and modelled horizons, so conclusions shift as prices move. The reviewers were explicit that poor study quality limits firm conclusions. Read this as a map of where the economic evidence is thin, not as a durable value ranking, and separate cost-effectiveness entirely from questions of clinical benefit or safety.
Annals of internal medicinen=——Jun 16, 2026 - Study · TirzepatideSupported
Comparative Effects of Antidiabetic Drugs on Body Composition: A Systematic Review and Network Meta-Analysis.
This systematic review and network meta-analysis (41 RCTs, 2,906 participants) compares antidiabetic drugs' effects on body composition — fat mass and lean body mass. Among incretin therapies, tirzepatide showed the greatest fat-mass reduction versus placebo (MD −10.70 kg), ahead of semaglutide and liraglutide; but it was also associated with the largest lean-mass reduction (MD −4.40 kg). That dual finding is the substantive contribution: the potent fat loss from GIP/GLP-1 agonism comes with meaningful lean-mass loss, and the review notes exercise mitigated liraglutide-related lean-mass loss. Network meta-analyses allow indirect comparisons across trials but rest on assumptions of transitivity and consistency, and the total sample is modest with likely heterogeneity in how body composition was measured. Consistent with growing attention to muscle preservation during rapid weight loss, weigh this as useful comparative evidence on composition — while remembering that lean-mass change is not equivalent to functional or clinical outcomes, which the analysis does not assess.
Diabetes, obesity & metabolismn=—HumanJun 16, 2026 - Study · SemaglutideWeak / none
Prioritizing Antidiabetic Drugs for Inflammatory Bowel Disease Through Inverse Signal Detection: A FAERS Pharmacovigilance Study.
This is a drug-repurposing signal-detection exercise, and semaglutide appears only as one of ten antidiabetic candidates flagged, not as a study subject in its own right. The method, inverse signal detection in FAERS, looks for drugs reported less often than expected alongside inflammatory bowel disease, then filters for plausibility. Semaglutide showed the weakest inverse signal of the GLP-1/antidiabetic agents listed (ROR 0.622, 95% CI 0.507-0.764), well behind dulaglutide, the insulins, and metformin. Crucially, an inverse disproportionality signal is a hypothesis-generating artifact of a spontaneous-reporting database; it cannot demonstrate benefit, protection, or any therapeutic effect, and is highly vulnerable to confounding by indication and reporting bias. The authors are explicit that interventional evidence is largely lacking and that these are testable hypotheses only. Weight this as a research-prioritization prompt, essentially a way to rank which drugs merit a proper IBD trial, and not as evidence that semaglutide does anything for inflammatory bowel disease.
Journal of clinical medicinen=——Jun 16, 2026 - Study · SemaglutideWeak / none
Personalized Combination of a Ketogenic Diet and Low-Dose Semaglutide for Cardiometabolic Health: A Retrospective Case Series.
A small, uncontrolled retrospective case series (seven adults, six women) describing a clinician-supervised 6-month program pairing a whole-food ketogenic diet with low-dose semaglutide (<=1.0 mg/week). Researchers reported mean total weight loss of 21.9 kg, of which about 92% was attributed to fat mass by bioimpedance, with skeletal muscle largely preserved, plus falls in fasting insulin and visceral fat and broadly favorable lipid and inflammation markers. The interest here is the lean-mass-preservation question surrounding GLP-1 weight loss. But the design is weak: no control group, only seven patients, bioimpedance (BIA) rather than DXA/imaging for body composition, and an individualized protocol that confounds diet with drug. The authors themselves call these findings hypothesis-generating. Weight it accordingly, as a signal to test in controlled trials, not as evidence that the combination outperforms either component.
Journal of personalized medicinen=—HumanJun 12, 2026 - Study · SemaglutideWeak / none
Semaglutide Selectively Improves Metabolic and Cognitive Function in 5xFAD Mice.
A preclinical study in the 5xFAD transgenic mouse model of Alzheimer's disease, testing semaglutide over 13 weeks across diet and genotype conditions. The headline is context-dependence, and the nuance matters. In metabolically challenged 5xFAD mice on a high-fat diet, semaglutide was associated with reduced weight, improved glucose tolerance, normalized cholesterol, lower Abeta40/42, restored GLP-1 receptor expression, higher synaptic markers, and better spatial memory, plus coordinated anti-inflammatory effects in brain and adipose tissue. Notably, metabolically normal wild-type mice showed minimal benefit and a modest decline in one memory test, a signal the authors read as possible disruption of neuronal homeostasis when metabolism is already normal. This is a genuine efficacy-style mechanistic study, not a mere mention, but these are preclinical findings; human data are needed before clinical conclusions can be drawn. The bidirectional result, benefit under metabolic dysfunction, possible harm without it, is a useful caution against assuming universal neuroprotection. GLP-1 Alzheimer's trials in humans (e.g. evoke) remain the arbiter.
International journal of molecular sciencesn=—AnimalJun 11, 2026 - Study · SemaglutideMixed
Effects of Semaglutide on Cardiometabolic Risk in People with Obesity, With and Without Type 2 Diabetes: A Retrospective Observational Study.
A small retrospective observational cohort (70 adults with obesity, 42 with and 28 without type 2 diabetes) reporting real-world semaglutide effects on cardiometabolic markers and body composition. The associations are broad and directionally consistent with trial evidence: significant reductions in body weight (-9 kg), waist circumference (-8 cm), HbA1c (-1.1%), systolic blood pressure (-7.5 mmHg), and visceral fat area (-30.1 cm2), with skeletal muscle relatively preserved, glycemic gains larger in the diabetic subgroup, and baseline HbA1c and visceral adiposity predicting response. The body-composition detail via bioimpedance is a nice addition. But the constraints are substantial: n=70, single-arm and retrospective with no control group, so no causal or comparative claim is supportable, and bioimpedance is an approximate method for body composition. Predictor findings from a sample this size are exploratory. Read this as corroborating real-world observation, consistent with the much stronger STEP trial base, rather than as independent evidence of effect magnitude.
Journal of clinical medicinen=—HumanJun 7, 2026 - Study · SemaglutideWeak / none
Incretin-based therapies and altered myocardial metabolism in a swine model of ischemic heart disease in the setting of metabolic syndrome.
This controlled large-animal study used a swine model of coronary artery disease with metabolic syndrome to ask how incretin therapies reshape heart-muscle metabolism. Yorkshire pigs received semaglutide, the DPP-4 inhibitor linagliptin, or no drug, and ischaemic myocardium underwent proteomic and metabolomic profiling. Researchers reported that semaglutide was associated with reduced fatty-acid oxidation and increased glucose metabolism, with linagliptin showing a similar but weaker pattern. These are preclinical, mechanistic findings in pigs; human data are needed before clinical conclusions can be drawn. The study measured molecular pathways, not clinical endpoints like heart function or survival, and used small groups of eight per arm. For semaglutide readers interested in cardiac effects beyond glucose and weight, this offers a plausible metabolic mechanism to explore, not evidence of a cardioprotective outcome in people.
Surgeryn=—AnimalJun 5, 2026 - Study · SemaglutideMixed
Clinical Effectiveness and Safety of Oral Semaglutide in a Real-World Cohort of Patients with Heart Failure with Reduced Ejection Fraction, Type 2 Diabetes and Obesity: A Propensity Score-Matched Analysis.
A retrospective, propensity-score-matched cohort (162 patients per arm) examining oral semaglutide in a group under-served by trials: patients with heart failure with reduced ejection fraction plus type 2 diabetes and obesity. Over 24 months, the semaglutide arm was more likely to show a clinically meaningful improvement in heart-failure health status (KCCQ, OR 2.45) and lost substantially more weight (-8.0 vs -1.9 kg), with symptom scores correlating inversely with weight and HbA1c. The signal is directionally consistent with GLP-1 evidence and with the STEP-HFpEF findings in the preserved-EF phenotype, but note this cohort is HFrEF, where GLP-1 evidence is thinner. Key limits: propensity matching reduces but cannot eliminate confounding by indication, the sample is modest, KCCQ is a symptom questionnaire rather than a hard clinical endpoint, and this is single-cohort observational data. The authors appropriately call for further research. Read it as a promising real-world signal in HFrEF that warrants a randomized trial, not as established benefit.
Pharmaceuticals (Basel, Switzerland)n=—HumanJun 5, 2026 - Study · CagrilintideSupported
Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression.
This systematic review, meta-analysis and meta-regression pools three RCTs comparing CagriSema and cagrilintide monotherapy against semaglutide. CagriSema was associated with significantly greater weight loss, while cagrilintide alone matched semaglutide but carried a higher relative risk of serious adverse events and combination therapy increased injection-site reactions and nausea. As a synthesis of randomized data on tracked peptides it is strong evidence, with both benefits and safety signals reported as associations.
Diabetes, obesity & metabolismn=—HumanJun 1, 2026 - Study · CagrilintideSupported
Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial.
This is a well-powered phase 3a randomized active-controlled trial (REDEFINE 5) comparing fixed-dose cagrilintide-semaglutide against semaglutide alone in an east Asian population. The combination was associated with significantly greater weight loss at 68 weeks, with a comparable and predominantly gastrointestinal adverse-event profile. As a rigorous head-to-head RCT on two tracked peptides it is high-value evidence, reported as association.
The lancet. Diabetes & endocrinologyn=—HumanJun 1, 2026 - Study · SemaglutideWeak / none
Do GLP-1 Receptor Agonists Sabotage Fat Grafts? A Scoping Review of GLP-1 Receptor Agonist Effects on Adipocyte Biology and Implications for Autologous Fat Transfer.
This scoping review maps mechanistic reasons GLP-1-class drugs might interfere with autologous fat grafting, but the authors stress no clinical or preclinical studies have directly examined this outcome. The conclusions are explicitly hypothesis-generating rather than evidence-based. Retatrutide is mentioned partly in the context of off-label bodybuilding use.
Aesthetic surgery journaln=——Jun 1, 2026 - Study · SemaglutideMixed
Glucagonlike Peptide-1 (GLP-1) Receptor Agonists for Cardiometabolic Risk in Severe Mental Illness: A Narrative Review.
This narrative review evaluates GLP-1 receptor agonists as an add-on strategy for the cardiometabolic burden faced by people with severe mental illness on antipsychotics, drawing on nine studies including six randomised trials. The authors report that liraglutide and semaglutide were associated with meaningful weight reduction and improved glycaemic measures without worsening psychiatric symptoms, while the most common adverse events were mild-to-moderate gastrointestinal complaints. As a narrative review with a small underlying evidence base and short follow-up, it cannot establish long-term safety or durability in this population, and it does not pool data formally. For semaglutide readers, the useful signal is that in this vulnerable group the psychiatric-safety picture in short studies looked favourable, but the authors are explicit that larger, longer trials are needed before broad implementation.
Cureusn=——Jun 1, 2026 - Study · TirzepatideMixed
Weight-loss dynamics with tirzepatide versus semaglutide.
This large real-world retrospective cohort (10,339 matched pairs from electronic health records) compares weight-loss dynamics for tirzepatide versus semaglutide, using AI-assisted note curation for adverse events. Researchers reported greater mean weight reduction with tirzepatide (14.7% vs 10.8%), nearly double the rate of high responders (≥15% in year 1: 42.6% vs 21.6%), faster weight-loss velocity, and a lower recorded prevalence of gastrointestinal and systemic adverse events. Because both cohorts drew on routine care with 1:1 propensity matching, the comparison is more directly head-to-head than pooled trial data — a genuine strength. But confounding by indication, dosing differences, adherence, and AI-based adverse-event extraction from free text are real limitations, and demographic disparities in response (by sex and race) warrant caution about generalising. This aligns with the pattern seen in randomised comparisons like SURMOUNT-5. Weigh it as strong, direction-consistent real-world evidence that tirzepatide is associated with greater weight loss, while treating the safety comparison as exploratory.
PNAS nexusn=—HumanJun 1, 2026 - Study · SemaglutideMixed
Real-world weight loss with injectable semaglutide vs dulaglutide for diabetes.
A single-center retrospective cohort (120 adults, 60 per arm) comparing weekly injectable semaglutide with dulaglutide in an urban, predominantly African American population with type 2 diabetes, a group often underrepresented in trials, which is a notable strength. At 52 weeks, researchers reported greater weight loss with semaglutide than dulaglutide (-6.51% vs -1.14% of body weight; -15.98 vs -4.93 kg) and more patients reaching >=5% and >=10% loss, plus a larger HbA1c reduction (-2.15% vs -1.36%). The direction is consistent with head-to-head trial data (e.g., SUSTAIN 7). Caveats: small sample, single site, retrospective design with potential confounding by dosing and adherence, and wide real-world variability. Weight it as a useful real-world confirmation in an underrepresented population that semaglutide was associated with greater weight and glycemic reductions than dulaglutide, while recognizing the modest size limits precision.
The American journal of managed caren=—HumanJun 1, 2026 - Study · TirzepatideWeak / none
Glucagon-like peptide-1 receptor agonists as a metabolic optimization strategy in surgical prehabilitation: a translational perspective.
A narrative "translational perspective" proposing, but not testing, the idea of using GLP-1 receptor agonists (semaglutide, tirzepatide) as a metabolic-optimization adjunct in prehabilitation before major surgery. The authors are refreshingly candid that there is currently no direct evidence supporting this use; the piece argues biological plausibility (metabolic optimization, sarcopenic obesity, oncologic and bariatric context) while flagging a concrete perioperative safety concern, delayed gastric emptying and aspiration risk, and pointing to current anesthetic guidance. Weight this as hypothesis-generating commentary, not evidence: it maps a research agenda rather than reporting outcomes. The value is in framing the open questions and the safety trade-offs; any clinical use in this setting would require prospective trials of feasibility, safety and meaningful outcomes, which do not yet exist.
Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgeryn=——Jun 1, 2026 - Study · SemaglutideWeak / none
Impact of Semaglutide on Hippocampal Injury in a Streptozotocin-Induced Model of Alzheimer's Disease.
A preclinical study in a streptozotocin (STZ)-induced rat model of sporadic Alzheimer's disease, notable for its design question: do semaglutide's effects persist after the drug is stopped? Rats received a 5-week course, then were assessed 60 days after discontinuation. STZ animals showed the expected pathology (cognitive deficits, ventricular enlargement, raised p-tau, hippocampal neuronal loss, glial activation). Semaglutide was associated with lasting attenuation, reduced ventricular enlargement (-43.5%), lower p-tau, fewer reactive astrocytes (-68.4%), restored synaptophysin, and dampened microglial activation, alongside behavioral improvement, evidence of a durable disease-modifying-type signal in this model. Importantly, the authors are candid that it did not halt neurodegeneration and had no effect on new-neuron generation in the dentate gyrus. These are preclinical findings; human data are needed before clinical conclusions can be drawn. The persistence-after-withdrawal angle is the interesting contribution, but the sporadic-AD chemical model is an imperfect proxy, and effect sizes come from small immunohistochemical samples.
Biomedicinesn=—AnimalMay 31, 2026